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I declare that I have written this thesis myself. The studies described
represent my own ideas and approach to improving the clinical management
of soldiers who contract cutaneous leishmaniasis in Belize. I obtained
permission and funding from the Ministry of Defence to study this problem in
Edinburgh. I designed and performed the studies, analysed the results, and
prepared them for publication in this thesis and as papers.
I received technical advice and assistance with several of the studies. Dr P
Hayes, of the Department of Medicine, and Dr AF Howie, of the Department
of Clinical Biochemistry, assisted me with the technical aspects of the
hepatotoxicity study. Professor KAA Fox, and Dr J Nolan of the
Cardiovascular Research Unit and Dr JMM Neilson, of the Department of
Medical Physics and Medical Engineering assisted me with the technical
aspects of the cardiotoxicity study. Dr. L Biddlestone assisted me with the
pathological study. Dr D Evans performed the cultures and typing of the
leishmania.
I started the retrospective case-note survey described in chapter 2 whilst
working at the Cambridge Military Hospital. However most of that study and
all the other studies have been undertaken during my appointment as an
Honorary Senior Registrar in the University Department of Dermatology in
The Royal Infirmary of Edinburgh from May 199t until March 1994.
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A general review of cutaneous leishmaniasis (CL) and its management is followed by a
retrospective review of 306 cases of CL in British soldiers from Belize. The diagnosis was
confirmed by demonstration of the parasite, by histology and/or culture, in 61% of cases.
Leishmania braziliensis braziliensis (Lbb) was identified in 78 cases and Leishmania
mexicana mexicana (Lmm) in a further 29 cases. Only cases in which the parasite was
identified were analysed further. A single lesion was present in 71%, usually on the exposed
extremities. The mean diameter of the ulcers was 14.4mm and lesions had been present for
a mean of 9.9 weeks before treatment started. Those due to Lbb were larger yet they had
been present for a shorter time than those due to Lmm. There were no other distinguishing
clinical features between them. Treatment with sodium stibogluconate was effective. A 10
day course of 600-800mg od healed 48.5%, whereas a 14 day course of 600 mg bd healed
63.9%. A total of 24g of sodium stibogluconate healed the ulcers of 90% of soldiers
irrespective of the regime used. Reports of myalgia, anorexia and malaise were more
frequent in those who received the higher daily dose. A transient leucopenia and a rise in
serum aminotransferases were noted during treatment. No cases of mucocutaneous
leishmaniasis were detected.
In a prospective randomised study, the efficacy and toxicity of sodium stibogluconate
20mg/kg/day for 20 days was compared with aminosidine 14mg/kg/day (max 1g/day) for 20
days. Aminosidine healed the ulcers of 10 of 17 soldiers whereas sodium stibogluconate
healed 15 of 17. Aminosidine was safe and well tolerated. Myalgia occurred in all those
treated with sodium stibogluconate. A transient leucopenia and a fall in platelet count was
noted; in one case the platelet count fell to 59 x 10^/L. Sodium stibogluconate caused acute
hepatocellular damage shown by a rise in aminotransferases and glutathione S-transferase
levels during treatment. This was associated with a fall in the metabolic capacity of the liver
as measured by caffeine clearance.
Sodium stibogluconate therapy 20mg/kg/day for 20 days has several effects on the heart. It
is associated with a progressive fall in ECG T-wave amplitude which returns to normal after
treatment stops. There is no change in ectopic activity nor in the autonomic control of the
heart. There is no change in cardiac function, in either systole or diastole, as measured by
echocardiography. Serum creatine kinase rose in 2 of 12 patients following treatment but this
was derived from skeletal muscle.
Histological examination of biopsies from the ulcers of 34 patients showed that parasites are
usually scanty. There is a characteristic dermal infiltrate composed of lymphocytes, plasma
cells, histiocytes and giant cells, which is frequently associated with necrosis. Impression
smears contribute little to confirming the diagnosis. Histological examination and culture of a
biopsy are complimentary techniques which provide a parasitological diagnosis in most
cases. Culture is more useful than histology in assessing the response to treatment.
These studies led me to propose some management guidelines. The diagnosis should be
confirmed histologically and by culture. Sodium stibogluconate 20mg/kg/day should be
administered for 20 days. Patients should be assessed 6 weeks after the completion of
treatment both clinically - complete epithelialisation with a flat, non-indurated, scar, and by
culture of a biopsy. Treatment should be repeated if the lesion has not healed or if culture is
positive. Treatment should be carefully monitored. A full blood count, urea and creatinine,
liver function tests and creatine kinase should be measured and an ECG performed before
treatment, weekly during treatment and 6 weeks after treatment. Patients should be kept
under review for 2 years.
PGS/ABST/88 Use this side only
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ADP = Adenosine diphosphate
ALB= Albumin
ALK P= Alkaline phosphatase
ALT= Alanine aminotransferase
AST= Aspartate aminotransferase
ATP = Adenosine triphosphate
bd = twice daily
BP = Blood pressure
CCL= Caffeine clearance
CK = Creatine kinase
CK-MB= Cardiac creatine kinase
CL = Cutaneous leishmaniasis
CMI = Cell mediated immunity
dB = decibels




ELISA = Enzyme-linked immunosorbant assay
FS= Fractional shortening
G = GlucantimeR
GDP = Guanosine diphosphate
GGT = Gamma glutamyl transferase
GST= Glutathione S-transferase
GTP = Guanosine triphosphate
Hb= Haemoglobin
H&E= Haematoxylin and eosin
IFAT = Immunoflourescent antibody test
IU = International units
IVRT= Isovolumic relaxation time
Lb = Leishmania braziliensis
Lbb = Leishmania braziliensis braziliensis
LD bodies= Leishman-Donovan bodies
Lm = Leishmania mexicana
Lmm = Leishmania mexicana mexicana
Lu = Lutzomyia
LVDD= Left ventricular diastolic diameter
LVDV= Left ventricular diastolic volume
LVET= Left ventricular ejection time
LVSD= Left venticular systolic diameter
LVSV= Left ventricular systolic volume
mAb = monoclonal antibody
MBCL= Methyl benzethonium chloride




NA = Not available
NS= Not stated
od = once daily
P = Phlebotomus
P = Probability of no difference
P= PentostamR
PEP= Pre-ejection period
PKDL= Post Kala-azar dermal leishmaniasis
PT= Prothrombin time
sd = standard deviation
se = standard error of the mean
UK = United Kingdom
USA = United States of America
VL = Visceral leishmaniasis
WHO = World Health Organisation
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1.2.1 Historical overview.
1.2.2 Epidemiology.




1.3 Cutaneous leishmaniasis and the British army garrison in Belize
1.3.1 The history and role of the British garrison.
1.3.2 The cutaneous leishmaniasis problem.
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1.1 Aims of the study
My overall aim in the various components of this study has been to improve
the management of cutaneous leishmaniasis contracted by British troops
during operational tours of duty in Belize. I started this study in March 1990
whilst working in the Dermatology Department of the Cambridge Military
Hospital in Aldershot. It was interrupted for six months whilst I was on active
service in Saudi Arabia during the Gulf War, but restarted when I came to
work in the University Department of Dermatology in Edinburgh. Inevitably
knowledge of cutaneous leishmaniasis has increased, facilities have changed
and my own understanding of the problem has become greater as the study
has progressed. I have therefore explored aspects of the problem which I had
not originally considered. However, my aims during this study can be
summarised as follows:
To determine the clinical features, types and response to therapy of
cutaneous leishmaniasis from Belize.
To assess the hepatotoxicity of sodium stibogluconate in the treatment of
cutaneous leishmaniasis.
To assess the cardiotoxicity of sodium stibogluconate in the treatment of
cutaneous leishmaniasis.
To compare the efficacy and toxicity of aminosidine (paromomycin) with
sodium stibogluconate for treatment of cutaneous leishmaniasis from
Belize.
To evaluate the diagnostic pathology.
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1.2. General Review of Cutaneous Leishmaniasis
1.2.1 Historical Overview
The leishmaniases are ancient afflictions of man. In the Old World,
descriptions of Balk Sore (named after Balk a town in the north of Afghanistan
near the Russian border) date back to the first century AD. The disease has
been traced back through the mediaeval literature of the Middle East by
Elgood (1934) who speculated that it was taken from Balk to Bagdad with the
invading Mongols in 1215 AD and that it subsequently spread down to the
Persian Gulf and, later, back along the trade routes into the interior of Iran
reaching Tehran in 1840. The disease has many synonyms, mostly derived
from place names such as Delhi boil, Aleppo boil, Armenian sore, Sart sore
and the still commonly used Oriental sore (Gardiner 1977).
In the New World early records of cutaneous leishmaniasis (CL) are more
difficult to identify because other endemic conditions, such as syphilis and
blastomycosis, cause similar lesions. However mucocutaneous leishmaniasis
(espundia) can be traced back to pre-Columban times through
anthropomorphic vessels or Tiuacos' which have been found amongst the
ancient Peruvian mochica pottery obtained from Inca tombs (circa 400-900
AD). Some of these figures depict the typical facial lesions, as do terracotta
figures from Northern Equador. Shortly after the Spanish conquest historians,
such as Pizarro, noted a rare, but decimating, disease amongst the Peruvian
Indians which primarily affected the nasal cavities and occurred in the same
locations as espundia today:
'Indians are taken from the highlands to work
in the coca fields in the 'Andes of Cuzco' where
they get an infection in the nostrils which also
makes their nose trunk-like and red, from which
some die.'
1 and the Indians get sick with an incurable disease
called 'of the Andes' which is worse than syphilis it attacks
most commonly the nostrils, lips and uvula of the throat...
..others get it in the mouth, making it a sight one cannot look
at without great horror and fright at such ugliness.'
(Gade 1977)
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In addition, Spaniards who explored the high Andean valleys, where sandflies
were common, occasionally developed mutilating lesions of the nares similar
to those depicted on the huacos. The disease was known as 'anti-onccoy' or
'the disease of the Andes' but only comparatively recently has the name of the
long suspected cause - a small biting fly or 'uta' - been applied to the disease
itself (Gardiner 1977). Names for the disease in its various forms are also
profuse in the New World and include uta, espundia, mucocutaneous
leishmaniasis, ulcera des los chicleros, boton de Baura, bouba, bay sore,
forest yaws, pain bois and leishmaniose tegumentar americana.
The scientific study of leishmaniasis began with the publication in 1885 in
Scientific Memoirs by Medical Officers of the Army of India by Surgeon-Major
D.D.Cunningham (1843 - 1914) of a description of amastigotes in sections of
human skin from a patient with Dehli boil. He described some 'deeply staining
bodies in certain cells larger than lymphocytes' and attributed them to the
spores of a slime mould. These observations were confirmed six years later
by Firth (1891).
In 1898 Borovsky, a Russian military surgeon studying Sart sore in Tashkent,
described 'small spherical, oval or fungal-form corpuscles' measuring 1.5-2.0
urn diameter with a nucleus and a 'process running to the periphery'. Unlike
Cunningham, he realised they were protozoa and the cause of the disease.
Unfortunately his observations were published in an obscure Russian journal
'Voenno-Medicinskij-ZurnaP and the significance of his discovery was not
recognised for many years (Gardiner 1977).
In 1903 the pace of discovery quickened, Leishman (1865-1926) a British
army pathologist (figure 1.1), reported the similarity of degenerating
trypanosomes from the spleen of a laboratory rat, which had died after an
experimental infection with African trypanosomes 48 hours earlier, and bodies
he had observed 3 years previously during a post-mortem examination of the
splenic pulp of a soldier 36 hours after death from a tropical cachexia. The
soldier had contracted this illness during service at Dum-Dum 7 miles from
Calcutta (Leishman 1903). Leishman concluded that these organisms had
been degenerating trypanosomes which, although incorrect, this was the first
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Figure 1.1: Lieutenant-General Sir William Boog Leishman (1865-1926).
description of the aetiological agent of visceral leishmaniasis. Subsequently
Donovan, a Captain in the Indian Medical Service at Madras, described
similar organisms in a fresh splenic biopsy thereby demonstrating it was a
distinct organism rather than a degenerate trypanosome (Donovan 1903).
Later the same year Wright, whilst working in Boston, USA, and using a
greatly improved Romanowsky stain, first accurately described and
photographed the cutaneous Old World parasite which he obtained from the
cheek of a nine year old girl who had developed the lesion 2 or 3 months
earlier whilst in Armenia (Wright 1903).
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In 1904 Rogers successfully cultured the visceral parasite by incubating
cultures at 22°C and in 1908 Nicolle cultured the cutaneous organism using a
modification of the rabbit blood nutrient agar medium of Novy and McNeal
known as NNN medium (Gardiner 1977).
The first report of the New World organism was made by Lindenburg in 1909.
He had been examining ulcers on the face and forearms of railway workers in
Sao Paulo. Two years later, the clinical features of mucocutaneous
leishmaniasis (espundia) were described by Carini whilst working at the
Pasteur Institute in Sao Paulo. In the same year Vianna described parasites
he had observed in ulcers contracted in Minas Gerias, Brazil - he was able to
discern a nucleus, kinetoplast and a 'rudimentary flagellum' and proposed the
name Leishmania braziliensis to distinguish it as the cause of espundia
(Vianna 1911). In 1913 an expedition from Harvard investigated and
succeeded in discovering, independently, the aetiology of 'uta' in Peruvian
mountain towns. They described and illustrated the parasites together with
the clinical features including erosion of the palate. They were also able to
culture the organism on blood agar and believed that it was transmitted by the
genus Phlebotomus (Gardiner 1977).
The sandfly has been implicated as the vector of cutaneous leishmaniasis as
far back as 1764 (Herrer and Christensen 1975). However the cycle of
infection was not worked out until this century. In 1904 Rogers observed the
conversion of amastigotes to promastigotes in culture (Rogers 1904) and then
promastigotes were found in sandflies (Alder and Theodor 1925). In 1921 a
volunteer developed a cutaneous lesion following inoculation with a
suspension of caught phlebotomus (Sergent et al 1921) but not until 1941
was L.tropica transmitted to volunteers by the bite of experimentally infected
Phlebotomus papatasii thus confirming the cycle (Alder and Ber 1941).
The taxonomy of leishmania has been, and remains, a vexed subject. Early
workers assumed that leishmania in geographically widely separated foci,
causing different patterns of disease, were due to different species and gave
them different names. It then became possible to separate them on the basis
of their morphology and differences in their behaviour in the natural sandfly
host, the vertebral host and in vitro culture media. In recent years more
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precise identification has become possible through isoenzyme electrophoresis
and DNA analysis. In 1961 Pessoa thought that all forms of visceral
leishmaniasis were due to a single species, L.donovani. He applied the name
L.tropica to the parasite of the Old World and gave leishmania of the New
World the names L.braziliensis braziliensis and L.braziliensis mexicana. In
the 1970's Lainson and Shaw divided the parasites of the New World into two
main groups, the L.mexicana complex and L.braziliensis complex on the basis
of their developmental patterns in sandfly vectors, laboratory hamsters, blood
agar culture media and buoyant density values for nuclear and kinetoplast
DNA. Then, in 1974, Lumsden combined the L.mexicana complex and
L.braziliensis complex groups of Lainson and Shaw for the New World
organisms with those of the L.tropica complex proposed by Pessoa for the
Old World and placed parasites normally associated with human visceral
leishmaniasis into an L.donovani complex (Gardiner 1977).
Leishmaniasis was first successfully treated in 1912 by Vianna in Brazil who
used the toxic antimony compound potassium antimonyl tartrate ('tartar
emetic') for cases of CL and mucocutaneous leishmaniasis (MCL) (Vianna
1912, Vianna 1914). The medicinal use of antimony dates back to the
teachings of Paracelsus in the early 16th century who observed that white
wine, which was allowed to stand in antimony goblets, acquired emetic
properties because the tartaric acid in the wine interacted with the metal to
form tartar emetic. Although popular for a time it was subsequently
abandoned because of its toxicity and lack of specific medicinal properties.
The discovery of its anti-parasitic properties, initially against trypanosomiasis,
led to its reintroduction during the early part of this century. It was mainly used
for kala-azar but its efficacy remained controversial and its toxicity a major
problem as described by Cole:
'Tartar emetic is not a pleasant drug; it produces cough,
chest pain, and great depression, just after injection, so
that patients have often refused to continue with it it is
a definite poison with action on the heart, for one case died
of sudden heart failure within an hour of injection, and others
appeared to be hastened towards heart failure by it'
after 12 of 27 patients treated for kala-azar died he concluded that:
(tartar emetic was) 'not much better than....no treatment at all'.
(Cole 1944)
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Although some aspects of toxicity could be overcome by administering it
intravenously the search for better tolerated derivatives continued and in the
1920's the first pentavalent antimonials, such as urea stibamine and stibosan,
became available. Sodium stibogluconate (Pentostam) was first
manufactured and used between 1935 and 1945 (Berman, 1988). Since that
time many other pharmacological and physical treatments for cutaneous
leishmaniasis have been proposed but pentavalent antimonials remain the
mainstay of therapy for New World cutaneous and visceral disease.
1.2..2 Epidemiology
It has become apparent during the past decade that the leishmaniases - both
visceral and cutaneous - are much more prevalent than had been
appreciated. In 1990 the World Health Organisation (WHO) estimated that 12
million people were affected in over 80 countries and that 350 million people
were at risk of infection (WHO 1990). More specifically it has been estimated
that approximately 300,000 cases of cutaneous disease occur each year in 61
countries and that 185 million people are at risk; of those 59,300 occur in the
Americas and the population at risk there is 39 million (Ashford et al 1992).
The true incidence of cutaneous leishmaniasis tends to be substantially
underestimated because of inadequate reporting (Copeland et al 1990), but
there is good evidence for a dramatic increase in the incidence of cases in the
New World (Vieira et al 1990). The geographical distribution of cutaneous
leishmaniasis is shown in figure 1.1 and the epidemiology is summarised in
table 1.1. It is important to appreciate, however, that more than half the cases
occur in just 8 countries: Afghanistan, Algeria, Brazil, Iran, Iraq, Saudi Arabia,
Sudan and Syria (Ashford et al 1992).
The cycle of infection The leishmaniases are complex protozoal infections
transmitted by the bite of an infected female sandfly. In most cases these
infections exist as zoonoses amongst wild animals and man is only infected
as an incidental host (figure 1.2). However such infections are by no means
uncommon - in endemic areas up to 9% of the healthy population may have a
positive leishmanin skin test indicative of an earlier, often asymptomatic,
Figure 1.1: Geographic distribution of CL.
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Figure 1.2: The cycle of infection.
Man (usually accidental host)
Reservoir host
(j) Sandfly vector
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infection (Weigle et al 1991). The vector species, reservoir hosts and
environmental requirements tend to be very specific for each leishmanial
species and consequently the disease is often localised to small areas ('hot
spots') where all three factors exist together.
Vector Biology. Sandflies are extremely small, measuring less than 3.5mm,
they are covered with a sandy yellow or brown coat of hair and have very dark
eyes. The male has prominent terminal organs for grasping the female. They
live in dark, damp places and make characteristic little hops when disturbed.
They are able to fly reasonably well, and although their usual radius is only 50
metres from their breeding sites, ranges of up to 1-2km have been recorded
(Lewis & Ward 1987). Only the females are blood sucking - blood is essential
for egg development. They bite at dusk, their approach is silent, in contrast to
that of most mosquitoes, and the exposed parts are usually attacked. Their
minute eggs are laid in cracks and crevices in dark, moist sites. They hatch
after 9 to 12 days and go through 4 larval stages followed by a pupal stage
before finally developing into a fly. Under favourable conditions the life cycle
takes about one month but it may be considerably prolonged under adverse
circumstances (Burgess 1981). Temperature is the only factor that correlates
well with sandfly distribution throughout the world. Although they are able to
survive cold in diapause (a period of suspended development accompanied
by greatly reduced metabolism), larval development and adult activity are
greatly reduced at temperatures below 20° C. Therefore, the distribution of
sandflies is largely confined to areas which have at least one month with a
mean temperature of 20° C (WHO 1984).
Leishmaniasis is transmitted by sandflies of the genus Phlebotomus in the
Old World and Lutzomyia or Psychodopygus in the New World. They lacerate
the skin of an infected host to feed upon a pool of serosanguinous exudate
containing amastigotes. The amastigotes develop into promastigotes in the
sandfly gut before migrating to the salivary glands from which they can be
regurgitated via the proboscis during the next blood meal. Development in
the sandfly takes 7-10 days. During feeding saliva is introduced into the host
and it has been shown that lysates of the salivary gland of Lutzomyia
longipalpis greatly enhance the infectivity of L.major in mice. A sandfly injects
about 10-100 parasites during a blood meal. However, if a mouse is
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inoculated with this number none survive unless sandfly saliva is also injected
- approximately 105 - 106 parasites are needed to establish such a laboratory
infection (Lerner 1993). In addition salivary gland lysate promotes faster
development and growth of lesions - the combination produces a 5-10 fold
increase in the size of lesions in murine foot pads and a 5000 fold increase in
parasite numbers compared with injected parasites alone (Ribeiro et al 1989).
These lysates have been analysed and a very potent vasodilator 'maxadilan',
which resembles the mammalian neuropeptide calcitonin gene related peptide
(CGRP), has been isolated. This is able to inhibit the production of hydrogen
peroxide by macrophages in response to interferon gamma - the mechanism
by which hosts destroy intracellular parasites (Theodos/1991).
Reservoir Hosts. Leishmania are maintained indefinitely within an ecological
system consisting of one or a small number of sandfly vectors and one, or a
few, vertebrate reservoir hosts. There is usually one primary reservoir host
for a given species of leishmania within a particular focus, but other animals in
the same area may become infected forming secondary hosts (from which
leishmania can be transmitted to other mammals) or incidental hosts (from
which leishmania are not passed on). These infections are often subclinical
with very few amastigotes in the skin or viscera associated with a minimal
host immune response. By contrast in dogs, which form the natural reservoir
for visceral leishmaniasis, the parasites are abundant in both viscera and skin
(from which they are readily picked up by sandfly vectors) and the infection is
ultimately fatal. The site of leishmania in the host does not necessarily
correspond to the site of the disease in man - for example L.b.guyanensis
infects the internal organs of the reservoir sloth with minimal skin involvement,
but it produces cutaneous disease in man (WHO 1990).
The leishmaniases can be crudely separated into two groups according to
their reservoir hosts. The zoonotic leishmaniases such as L.mexicana
mexicana (Lmm) and L. major in which the reservoir hosts are wild animals
(e.g. foxes or jackals), commensals (e.g. rodents) or domestic animals (e.g.
dogs); and the anthropophilic leishmaniases, such as L. tropica, in which man
is the reservoir. However such distinctions are not absolute - L.tropica
infection may derive from rodents or dogs and man may constitute a
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secondary reservoir for L.major. The principle reservoir hosts are shown in
table 1.1.
Factors Influencing Infection Frequency. Ecological factors are paramount
in determining the transmission of leishmaniasis and therefore there is great
variation from place to place. Clearly man must be exposed to the bite of an
infected sandfly for infection to occur. In the New World where leishmaniasis
is primarily zoonotic, maintained by forest rodents, the disease is often an
occupational one occurring more often in men, for example, during
construction projects, hunting or forestry (Garnham & Lewis 1959, Lainson &
Stangeways-Dixon 1963, Weigle et al 1993a, Weigle et al 1993b, WHO
1990). In each of these activities workers enter the forests where they
encounter infected sandflies at the same time as man-made changes upset
the pre-existing zoonotic cycle. The chance of any individual becoming
infected is largely due to the length of time he has been exposed - for
example during the construction of the trans-Amazonian highway the
prevalence of positive leishmanin skin tests amongst workers increased
progressively with longer exposure times. Entering the forests at night is a
particular risk factor. In addition mini-epidemics may occur if workers enter a
'hot-spot' i.e. a well-delimited microfocus where transmission is high as a
result of favourable environmental conditions associated with high densities of
both reservoirs and sandflies.
Cutaneous leishmaniasis is also predominantly a disease of the poor who
have primitive housing and sanitation. The organic debris associated with
piles of bricks and stones constitute potential breeding and resting sites for
sandflies. These people frequently live at the edge of towns close to the
natural sylvatic cycle. A large number of people sleeping in one room further
attracts peridomestic anthropophilic sandflies (WHO 1990).
Periodic fluctuations in the number of cases is well recorded. Although
sandflies are present all year round in the tropics, each species tends to have
an annual cycle and transmission is greatest towards the end of that cycle
when the maximum number of parous sandflies are present. There are also
marked year-to-year variations - in a prospective study in Tres Bragos, Brazil
a peak occurred every 8-10 years (Jones et al 1987).
26
Cutaneous leishmaniasis is increasingly seen in travellers returning to non-
endemic areas, particularly those who have engaged in field work in forested
areas (Herwaldt et al 1993). It is a major problem for the military who, by the
nature of their task, bring in large numbers of non-immune individuals to
endemic areas, where they often live under primitive conditions. The British
garrison in Belize has reported 306 cases between 1978 and mid-1990 and
the Walter Reed Army Medical centre in Washington treated 70 cases from
Panama between 1977 and 1984 (Ballou at al 1987). In both cases the
soldiers had been training in the jungle. It is currently a major problem for the
Colombian army who are involved in operations against anti-government
guerillas and drug barons; they have 2000 new cases of CL each year (Lt Col
Soto, personal communication). During the war between the Islamic Republic
of Iran and Iraq thousands of cases occurred amongst soldiers of both sides
It was the most common cause of casualty evacuation of Iranian soldiers
during the early years of that war (Dowlati, personal communication).
1.2.3 Pathogenesis, Pathology and Immunology
Inoculated promastigotes (bearing surface antigens of 116 kdaltons) bind C3b
receptors on the macrophage and are phagocytosed, whilst immature
promastigotes are destroyed by complement-mediated cytotoxicity (Kubba &
Al-Gindan 1989). Once inside the macrophage, the promastigotes lose their
flagellae and become amastigotes which multiply repeatedly by binary fission.
Infected macrophages then burst, releasing their amastigotes which in turn
infect other macrophages (figure 1.3). The subsequent fate of the
amastigotes depends upon parasite and host factors which are poorly
understood. Viscerotrophic species, such as L.donovani, tend to migrate
throughout the reticuloendothelial system, whereas dermotrophic species,
such as L.major, usually remain close to the inoculation site. Any spread of
dermotrophic species tends to be late and only to adjacent skin (producing
satellite lesions) or to lymphatics and regional lymph nodes. It is possible that
dermotrophic species migrate as far as viscerotrophic species but are unable
to survive in the internal milieu - for example L.donovani amastigotes are able
to tolerate higher temperatures and resist complement-mediated cytotoxicity.
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Figure 1.3: The life cycle of leishmania























These phenotypic distinctions are not absolute. L.braziliensis braziliensis
(Lbb) is able to migrate to the oropharyngeal mucosa where it may remain
dormant for many years before reactivating to cause the destructive
mucocutaneous form of the disease 'espundia'; there are reports of L.tropica
causing visceral leishmaniasis, and in post-kala-azar dermal leishmaniasis
(PKDL) the viscerotrophic parasite becomes dermotrophic as a consequence
of treatment (Kubba & Al-Gindan 1989, Magill et al 1993).
The interaction between the cell mediated immune response (CMI) of the
infected subject and the amastigote is complex and results in a range of
clinical and pathological changes. In all forms of leishmaniasis, however, the
presence of amastigotes within the cells of the mononuclear phagocytic
system remains the hallmark of the disease, although at times they may be
difficult to detect. Infected macrophages measure 20-30 urn in diameter
whereas amastigotes (known as Leishman-Donovan bodies) are round to
oval structures measuring only 2-5um (figure 1.4). They are surrounded by a
plasma membrane and contain both a relatively large, deeply basophilic,
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nucleus and a smaller, densely staining, rod-shaped kinetoplast of extra-
nuclear DNA (from the base of the flagellum which is lost in the conversion
from promastigote to amastigote). Although haematoxylin and eosin (H&E)
will demonstrate amastigotes, a Giemsa stain is preferred by many - it stains
the flagellum bright red (Kalter 1989, Lever 1990).
Figure 1.4: A skin biopsy from Old World CL showing LD bodies.
In early cutaneous lesions, the dermal infiltrate consists predominantly of
macrophages filled with amastigotes. There are relatively few lymphocytes
and plasma cells. As the lesions develop more lymphocytes and plasma cells
appear and the superficial dermis becomes oedematous. The overlying
epidermis becomes hyperkeratotic and subsequently breaks down to form an
ulcer covered with a coagulum of hyperkeratotic debris, dried exudate, dead
cells and a mixture of live and dead organisms. Over the following months,
there is a gradual decrease in the number of amastigotes and macrophages,
leaving a granulomatous infiltrate consisting of lymphocytes, epithelioid cells
and multinucleate giant cells. At this stage it may be difficult or impossible to
detect organisms in H&E or Giemsa stained sections. Parasite elimination
usually follows destruction of the macrophages, either at the centre of the
circumscribed clusters in the dermis, with the release of amastigotes, or in the
29
subepidermal zone causing liquefaction of the basal layer and ulceration.
Polymorphs are present in the necrotic zone and lymphocytes are numerous
at the periphery. Ultimately, either the patient's immune response is able to
eliminate the infection and effect a spontaneous cure, or it fails and a chronic
form of cutaneous leishmaniasis develops. Resolution occurs by fibrosis
(WHO 1990, Kubba & Al-Gindan 1989, Kalter 1989).
There are two special non-healing forms of CL which, although rare, are
important because they represent two extremes of host cell-mediated immune
response to infection with leishmania and have given insights into the
pathogenesis of this disease. Leishmaniasis recidivans (or lupoid) is
characterised by healing with fibrosis in the centre of the lesion, but failure to
heal peripherally where there is a granulomatous infiltrate composed of
epithelioid cells, multinucleate giant cells, a variable number of plasma cells
but relatively few lymphocytes. Amastigotes are very scanty. The
appearances are reminiscent of lupus vulgaris both histologically (although
there is no caseation) and clinically (even apple jelly nodules are seen). The
lesions usually occur on the face and develop from an acute lesion after an
interval of 12-18 months. There is a central fibrotic scar surrounded by an
active edge consisting of papules and nodules. In this type the parasite
persists indefinitely despite an exaggerated host CMI response. It is found
mainly in Iran and Iraq. The other extreme is represented by diffuse
cutaneous leishmaniasis (DCL) in which there is a specific defect in the host
CMI response to leishmania. Lesions contain many macrophages full of
amastigotes but lymphocytes are scarce. Clinically, the initial lesion spreads
locally and then the disease disseminates to other areas of the body. There
are numerous discrete papules and nodules which coalesce to form plaques
scattered over the whole skin surface but they are particularly numerous on
the face and the outer aspects of the limbs (figure 1.5). DCL is associated
with L.aethiopica in the Old World and L.mexicana complex in the New World
- there is an unusual focus in the Dominican Republic where all cases of CL
are manifest as DCL. It is very resistant to treatment (Lever 1990, Ridley
1987, Kubba & Al Gindan 1989, Griffiths 1987, Bryceson 1992, WHO 1990).
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A histological spectrum has been identified, rather analogous to that seen in
leprosy, ranging from anergic forms of infection with heavily parasitized
macrophages to hypersensitive forms with scanty organisms and a
Figure 1.5: Diffuse cutaneous leishmaniasis.
31
tuberculoid response. This spectrum has been divided up into 5, broadly
distinct, groups by Ridley (table 1.2).
Table 1.2
Ridley's Classification of the histopathological response in cutaneous
leishmaniasis
GROUP 1 Diffuse macrophage granuloma formation. Macrophages are full
of amastigotes but do not show signs of activation. Occasional
lymphocytes and plasma cells, but no giant cells. Ulceration is
rare.
GROUP 2 Focal macrophage granuloma formation, with central necrosis,
surrounded by lymphocytes and plasma cells. Initially moderate
numbers of organisms are present in surviving macrophages but
latter these disappear. Ulceration may occur independently of
the necrotic granuloma.
GROUP 3 The most non-specific group. A mixed inflammatory response
consisting mainly of lymphocytes and plasma cells but with a
few macrophages. Amastigotes scanty but are best seen in the
sub-epidermal zone.
GROUP 4 Giant cells of foreign body and Langhans types are present
together with a heavy lymphocytic infiltrate. Scanty or absent
amastigotes.
GROUP 5 Tuberculoid response. Epithelioid cell granulomas with many
giant cells but small numbers of lymphocytes and plasma cells.
No necrosis. No amastigotes.
(adapted from Ridley 1987)
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The 5 groups are arranged in order of decreasing parasite load and include
the whole spectrum of CL: DCL represents an extreme of group 1 anergy and
recidivans an extreme of group 5 hypersensitivity. These are analogous to
lepromatous and tuberculoid leprosy respectively. However, whereas in
leprosy there is a straight-line spectrum from anergy to hypersenstivity, in
individual cases of CL there are aberrations in which the parasite load is out
of step with the host cell response.
Immunology. The development of long-standing resistance to re-infection is
the principal immunological feature of classical leishmaniasis. Re-infection
amongst residents in regions endemic for L.tropica is uncommon and
experimental infections in human volunteers confirm that resistance develops
after recovery provided the initial infection runs its full course. However,
immunity is not always complete: there are reports of re-infection occurring
five or more years after an initial cure or as the result of steroid therapy. In
one case re-infection by the same L.major type followed spontaneous healing
of the original lesion although there were fewer parasites and the lesion
healed more rapidly than the primary infection (Mauel & Behin 1987).
It is the CMI response that provides resistance to infection with leishmania
(Liew 1989). Although specific antibodies can be detected in the majority of
patients with CL they do not appear to have a role in either the clearance of
the intracellular organisms or in the establishment of immunity to re-infection
even when present in high titre (Kalter 1989, Locksley & Louis 1992). The
CMI response can be demonstrated clinically by a delayed hypersensitivity
test known as the leishmanin skin test (see diagnosis) which usually becomes
positive within a few weeks of infection and then remains so for decades. The
significance of this long-lasting skin reactivity is not clear. It may represent
genuinely long-lived immunological memory or it may be explained by the
existence of an occult infection in recovered individuals. It does not, however,
represent a measure of resistance to re-infection. Whereas the reaction
generally becomes positive early in the course of the disease, the lesion heals
many months later. Re-infection of an individual with both an active sore and
a positive skin test leads to the development of a typical ulcer that develops to
the same stage as the original sore and they then heal together (Mauel &
Behin 1987).
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This sole dependence upon CMI for resolution has led to the intensive study
of leishmanial infection. Most experiments have utilized in-bred strains of
mice infected with L.major. T-helper (CD4+) cells are thought to be important
in mediating the spectrum of disease seen pathologically and clinically.
Functional subsets of T-helper cells, Th-1 and Th-2 cells, have been identified
on the basis of their cytokine secretion profiles: Th-1 cells are thought to
mediate the CMI response, they secrete interferon (IFN)-gamma and IL-2 and
are associated with resistance to infection. Th-2 cells in contrast mediate
specific antibody production, they secrete IL-4 and IL-10 and are associated
with susceptibility to infection (Miller & Scott 1989, Locksley & Louis 1992).
These observations have been followed up by blocking IFN-gamma and IL-4
with monoclonal antibodies (mAbs) in infected mice: strains of mice
genetically resistant to infection with leishmania treated with anti-IFN-gamma
mAb developed progressive infections. Treatment of susceptible strains with
anti-IL-4 mAb resulted in attenuated disease and resolution of the lesions in
85% with the establishment of protective immunity. These findings led to
clinical trials of immunotherapy using human recombinant cytokines. In a
controlled study, intralesional treatment with recombinant-IFN-gamma
produced a reduction in size of 12 out of 13 lesions due to L.b.gyanensis after
3 weeks and some lesions were free of parasites. Similarly 9 out of 13
lesions due to L.tropica resolved completely following 4-8 weeks treatment.
Resolution was associated with increased numbers of IL-2+ T-cells indicating
that therapy with recombinant-IFN-gamma promoted healing of CL by
enhancing the CMI response (Gran & Modlin 1991, Harms et al 1989).
There are, however, few T cells in the dermal infiltrate in early lesions so
infected macrophages, expressing parasite antigens, are unlikely to meet T
cells with the corresponding specificity required to trigger the CMI response.
Epidermal Langerhans cells express receptors for C3b which opsonizes
leishmania parasites for macrophages. It has been suggested that epidermal
Langerhans cells migrate from the epidermis to the dermis and, like
macrophages, take up parasites following which they express parasite
antigens in association with MHC class II molecules on the cell surface. A
proportion of Langerhans cells may transport parasites from the infected skin
to the draining lymph node for presentation to antigen-specific resting T cells.
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As a result, activated T cells migrate via the blood into the lesion where
infected macrophages and Langerhans cells that remain in the dermis
regulate their effector activity by several mechanisms including cytokine
secretion (Moll 1993).
1.2.4 Clinical Features
The clinical features of CL differ between different regions of the world,
reflecting differences in the species of the parasite, the sandfly vector and the
genetic, immunological and cultural background of the patients (WHO 1990).
The principle cutaneous manifestations are summarised in table 1.3. The
lesions develop where the infected sandfly bites and are therefore usually on
the exposed parts of the body. A cluster of lesions may occur and this has
been attributed to repeated probings by the sandfly which has difficulty
aspirating blood through its promastigote-laden proboscis. The incubation
period is 1-12 weeks, tending to be shorter with a larger inoculum (Kalter
1989). Although each parasite is classically associated with a distinctive
clinical picture, the features overlap and they cannot be reliably distinguished
on clinical grounds alone.
Table 1.3
Cutaneous manifestations of leishmaniasis
Acute disease Chronic disease Miscellaneous
Old World CL non-healing acute sore Leishmanioma
wet/rural sore mucocutaneous leishmaniasis Post Kala-Azar
dry/urban sore leishmaniasis recidivans leishmaniasis
New World acute sore diffuse cutaneous leishmaniasis
Old World acute CL (oriental sore). The lesion starts as an erythematous
papule, rather like an insect bite with which it is frequently confused. It
35
persists and enlarges to form a painless nodule with a surface crust
resembling a volcano. In some cases there is a larger subcutaneous
component which has given rise to the term 'iceberg nodule'. In most cases
the crust separates to expose an ulcer (Kubba et al 1987a) (figure 1.6).
Painless sporotricoid lymphatic spread is common and organisms can be
found in the regional lymph nodes (Al-Gindan et al 1989, Kubba et al 1987b).
Lesions heal by fibrosis leaving a sharply demarcated, irregular, cribriform
scar which in coloured races is often hyperpigmented and disfiguring.
Lesions, particularly in cases due to L.major, are often multiple and
occasionally over 100 lesions occur in a single patient (Kalter 1989).
Figure 1.6: Old World cutaneous leishmaniasis.
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Oriental sores are traditionally divided into wet and dry types. The wet, rural
or zoonotic, sore is a more inflammatory lesion which is classically associated
with L.major. It is usually acquired in rural areas where the infecting
organisms are primarily rodent parasites and are, therefore, poorly adapted to
man. After an incubation period of less than two months, an erythematous
papule develops and two weeks later a central crust appears which usually
falls off revealing a bright red base consisting of slough alternating with
papules of proliferating granulation tissue. The ulcer enlarges over the
following two to three months reaching a diameter of 3 - 6cm. Multiple
satellite papules which measure 2 - 5mm and do not contain parasites are
much more common in the wet than in the dry type. The lesion heals in 1.5-
8 months (mean 3 months).
The dry, urban or anthroponetic, sore is a more quiescent but indolent lesion.
It is classically associated with L.tropica and it is more commonly found in
urban areas where the parasite is better adapted to man. The lesion starts as
a brown nodule which enlarges to form a plaque measuring 1-2cm in diameter
in about six months. It then ulcerates in the centre and has a closely
adherent crust. Healing generally takes 5-14 months (mean 10 months) but
may take up to two years (Bryceson 1987, Griffiths 1987).
Lesions due to L.aethiopica are usually single and most commonly occur on
the central part of the face. Satellite papules amalgamate into a large
spreading nodule. Ulceration or crusting is not always a feature. There is
relatively little inflammation and healing takes 2 - 5 years. It may progress to
DCL. L.infantum (which generally causes visceral leishmaniasis in children)
usually gives rise to a self-healing sore in adults. Its appearance and
evolution are slow compared to lesions caused by L.major (WHO 1990,
Kubba et al 1987£ Griffiths 1987, Bryceson 1992).
New World acute CL. A typical lesion starts as an inflammatory papule
which rapidly evolves to a deep, well circumscribed, ulcer with raised
violaceous borders and a friable granulomatous base which may be covered
by an eschar (figure 1.7). It can reach several centimetres in size within a
month and heals with a characteristic scar (Jones et al 1987, Walton 1987).
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In an epidemiological study from Tres Bragos, an area of Brazil endemic for
L.braziliensis, 369 patients were detected (64 with active disease
Figure 1.7: New World CL from Belize.
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and the remainder with a typical scar indicating previous infection). A single
lesion was present in 74%, two lesions were present simultaneously in 17%,
three in 5.6% and four or more in 3.4%. The leg was the most common site
(73% of lesions) but lesions were also present on the arms (11%), trunk
(10%) and on the head and neck (6%). The mean size of the lesions was 33
mm (range: 5 to >100 mm) but it was not clear whether this referred to the
size of the ulcer or to the diameter of the whole lesion. All ages were
affected, but it was most prevalent in the 10-15 year age group, there was a
male predominance (1.46 : 1). A second lesion at a different site was
observed 1 to 20 years after the primary infection had healed in 11% of
patients (Jones et al 1987). Spread and localisation by trauma has also been
observed (Walton 1987). Involvement of the lymphatics is common in
infections caused by L.b.panamensis and L.b.guyanensis - pea-sized
subcutaneous nodules or chords ascend the lymphatics (Berger et al 1985).
The ulcers are painless unless there is significant secondary bacterial
infection (as distinct from colonization which is common).
The natural history of New World ulcers has been thought to be one of
gradual healing over months or years (Berman 1988). However, two recent
reports cast doubt on this belief, suggesting that spontaneous healing may
occur within a few months particularly in cases caused by L.mexicana
complex. In a placebo controlled study of sodium stibogluconate versus
allopurinol from Equador, involving patients with both Lmm and Lbb,
spontaneous healing (defined as 80% re-epithelialization after 6 weeks
observation) was observed in 9 out of 12 untreated patients (Guderian et al
1991). A subsequent prospective study of 48 patients from Guatemala
showed that out of a total of 57 lesions (32 due to Lbb and 25 due to Lmm)
which had been present for a mean of 4.5 weeks, spontaneous healing
(defined as complete re-epithelialization, absence of inflammation and
remaining healed during at least 6 months observation) occurred in 68% of
those due to Lmm but in only 6% of those due to Lbb. In those that did heal,
the median healing time was 14 weeks for Lmm and 13 weeks for Lbb
(Herwaldt et al 1992). The natural history of New World CL merits further
study.
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Chronic Cutaneous Leishmaniasis. Lesions that have been present for
over one year are considered chronic. The most common form of chronic CL
is an acute sore that has failed to heal. Leishmaniasis recidivans and diffuse
cutaneous leishmaniasis have already been described (see pathogenesis).
Mucocutaneous leishmaniasis (MCL) - 'espundia' - is most often observed in
the New World (figure 1.8). Although mucous membrane disease can occur
Figure 1.8: Mucocutaneous leishmaniasis.
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in the Old World, due to contiguous spread of facial infections with
L.aethiopica, and oropharyngeal granulomata of L.donovani are seen in the
Sudan, neither of these closely resemble espundia clinically. Lbb is the most
common cause of MCL but L.b.panamensis and L.m.amazonensis have
occasionally been isolated from the lesions (Kalter 1989). The disease
usually starts in the nasal mucosa with septal perforation, and it then
progresses to destroy the remainder of the nose, upper lip, pharynx and
larynx. The rate of progress and the amount of destruction varies from patient
to patient. A history of nasal blockage, epistaxis, discharge or nasal ulcers is
often obtained but, unlike leprosy or syphilis, which erode the proximal nasal
cartilage, MCL has a predilection for the distal cartilaginous portion causing
the characteristic 'tapir nose'. The nose and surrounding face may become
very swollen. Laryngeal involvement causes hoarseness, stridor and a
brassy cough followed by problems with swallowing and respiration. Death
usually results from secondary infection, starvation or laryngeal obstruction.
Dissemination is thought to be via the blood stream (Kalter 1989). MCL
occurred in 2.7% of individuals infected with Lbb in Brazil. It was more
common in males (2.3 : 1), in those in whom the primary skin lesions had
been either large or multiple, in those whose skin lesions had persisted for
over a year and in those who had recovered after inadequate therapy for the
primary lesion. The median time from the onset of the primary skin lesion to
the recognition of mucosal disease was 6 years (range: 0 - 16 years) (Jones
et al 1987). It is often difficult to isolate the organisms from the mucosal
lesions (Kalter 1989).
1.2.5 Diagnosis
The diagnosis of leishmaniasis is often made on the basis of the appearance
of the lesion in conjunction with an appropriate history of exposure to the
infection. However, because the differential diagnosis is extensive (table 1.4),
pathological confirmation should always be obtained (preferably by observing
the organism in tissue and/or culturing it). Unfortunately this is not always
possible in practice. In a study of 475 cases due to L.major in Saudi Arabia
the parasite was demonstrated by smear in 50-80% (depending on the
investigator and the technique used), by skin biopsy in 70% and by culture in
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only 50%. If all 3 methods were combined the parasite was still not detected
in 10-20% of cases (Kubba et al 1987a). A similar study from Colombia
compared 7 diagnostic methods in a group of 177 patients in whom a clinical
diagnosis of CL (165 patients) or MCL (12 patients) had been made. The
combined overall detection rate of all 7 methods was 67% to which each
individual method contributed: histopathology 14%, impression smear 19%,
dermal scraping 22%, aspirate & culture 58%, aspirate & hamster inoculation
38%, biopsy & culture 50% and biopsy & hamster inoculation 52%. Similar
results were obtained in a study from Guatemala (Navin et al 1990). It was
most difficult to detect parasites in older lesions whichever method was used
(Weigle et al 1987). Specimens should be taken from the active edge of the
lesion as that is where organisms are most numerous. Diagnostic methods
which have been described include:
Skin biopsy. A wedge or punch biopsy, taken under local anaesthetic, can
be used for making impression smears, parasite cultures and for routine
histological examination. The area should be thoroughly cleaned with 6%
hydrogen peroxide to reduce bacterial contamination before taking the biopsy.
Amastigotes (LD bodies) can be identified in routine H&E sections during the
early stages of the disease but they become less numerous with the passage
of time and may be impossible to find after a few months. The typical
granulomatous histology is a much less specific diagnostic pointer. At that
stage it may be possible to detect amastigotes in formalin-fixed specimens
using polyclonal antibodies in conjunction with immunoperoxidase staining
(Sells & Burton 1981). Monoclonal antibodies have been reported which,
when used in conjunction with immunofluorescent labelling, can demonstrate
as few as 50 amastigotes in both smears and biopsies; this technique can
confirm the diagnosis in as little as 1-2 hours (Anthony et al 1987). DNA
probes have also been developed for many species of leishmania which are
able to detect 100 - 200 organisms in a impression smear and are used in
some centres in the USA (Wirth 1992).
Smear preparations. Impression smears are made by gently pressing a skin
biopsy against a glass microscope slide 2 - 3 times before fixation.
Alternatively, smears can be prepared using tissue juice obtained by
aspirating the edge of the lesion with a 20 gauge needle or by using a slit-skin
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technique akin to that used in leprosy. In each case the smears should be
allowed to dry prior to fixation in 95% alcohol for 30 seconds. Amastigotes
may be detected both intracellular^ and extracellularly (Berger et al 1987).
Culture of leishmania. This is often difficult and involves both art and
science. Whilst some species, such as Lmm, grow readily others, such as
Lbb, are more fastidious. Essentially the tissue biopsy is placed in a biphasic
blood agar medium such as a modified NNN, to which antibiotics are added to
prevent bacterial overgrowth, and incubated at 22°C. Promastigotes may be
identified in as little as 7 days, although it often takes up to 21 days. The
techniques for culture (and also isoenzyme analysis) are described in a
handbook by Evans (1989). Animal inoculation is a useful alternative to in
vivo culture, particularly when the parasite load is low or if sterile conditions
are difficult to achieve. The golden hamster is generally the most suitable as
it is sensitive to most strains of leishmania, although the Balb/c mouse is best
for L.major. Homogenised tissue containing amastigotes is injected
intradermal^ into the nose, ears or foot pads and the inoculation site is
biopsied 7-10 days later to obtain samples for culture or, at a later date, for
histological examination (Manson-Bahr 1987).
Identification of Leishmania species. Isoenzyme analysis remains the
principle method of typing because it is simple to use, reproducible and well
established. It is the standard against which newer methods, such as
monoclonal antibodies and DNA probes, are assessed. An aqueous extract
containing many enzymes is prepared from promastigotes cultured from the
lesion. This extract is analysed by electrophoresis during which the banding
pattern, identified by staining for a single enzyme such as glucose-6-
dehydrogenase or malic dehydrogenase, is compared with that of a known
reference strain. Several such zymogrammes, each stained for a different
enzyme, are required to identify a given species (Kreutzer & Christensen
1980, Kreutzer et al 1987, Evans 1989). These reference strains are
maintained at several WHO international leishmania reference centres such
as that at the London School of Hygiene and Tropical Medicine.
DNA buoyant density has also been used to distinguish between leishmanial
strains. This method is based on the observation that the equilibrium buoyant
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densities vary with the guanine and cytosine content of the DNA coupled with
theoretical estimates of DNA homologies as revealed by their buoyant
densities - for example a buoyant density difference of 0.001 g/ml suggests
significant differences in 10-25% of their genes. Buoyant densities range
from 1.716 - 1.720g/ml for nuclear DNA (nDNA) and 1.688 - 1.707g/ml for
kinetoplast DNA (kDNA). The kDNA therefore varies more than the nDNA
between species (Janovy 1987). These methods have now been superseded
by advances in recombinant DNA technology.
Monoclonal antibodies have been developed which are able to distinguish
between different species of leishmanial promastigotes but probes are not yet
available for the specific identification of amastigotes. Monoclonal antibodies
have the advantage of speed and the available panel is increasing but it still
lacks the sensitivity and specificity of isoenzyme analysis (McMahon-Pratt &
David 1981, Hanham 1991).
DNA probes for kDNA are being developed which can identify the species of
cultured promastigotes, and in some cases, tissue amastigotes (Barker et al
1986, Wirth & McMahon-Pratt 1982, Lopez et al 1988). The early techniques
used radio-labelling which limited their application to research laboratories.
Alternative markers, such as biotin and digoxigenin, are currently under
assessment, but in general they appear less sensitive. Chemiluminescent,
rather than colourimetric, markers may improve sensitivity (Wilson 1991).
Most recently the polymerase chain reaction has been utilised to detect
species specific DNA sequences for Lbb and this holds great promise for the
future (de Bruijn & Barker 1992).
Serological methods. Techniques such as the enzyme-linked
immunosorbent assay (ELISA) and the indirect fluorescent antibody test
(IFAT) have been widely used in the diagnosis and management of visceral
leishmaniasis. However, in cutaneous disease, the antibody titres are much
lower and in Old World disease serology is not useful in diagnosis (WHO
1990). More encouraging results have been reported in New World disease
with both IFAT (Pappas et al 1983) and ELISA (Guimaraes et al 1990)
although both groups reported a false positive rate of 5%. In a group of
British soldiers who contracted CL in Belize, an ELISA test was insufficiently
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sensitive and specific to be of use (Evans, personal communication).
Western blotting can detect leishmanial antigens in the serum of patients with
multi-lesional disease and future developments in this area can be expected
(Bogdan et al 1990). Walton (1980) speculates, that in those who do have a
significant antibody titre and in whom the diagnosis is proven, if the high titre
persists then that is indicative of a persisting infection. It may, therefore, be
an indication for re-treatment.
Leishmanin (Montenegro) skin test. This detects delayed-type
hypersensitivity and is analogous to the tuberculin and lepromin tests. A
suspension containing 106 promastigotes/ml in 0.5% phenol-saline is used;
0.1ml is injected intradermal^ into the forearm. An equal volume of 0.5%
phenol saline is injected into a second adjacent site as a control to detect
sensitivity to the diluent. An indurated nodule with surrounding erythema
develops and the reaction is read at 48-72 hours. An area of induration
measuring 5mm or more is positive (Manson-Bahr 1987). Unfortunately,
because standardised test antigens are not available, the reagents are
produced in the laboratories of tropical disease centres and vary in their
sensitivity and specificity (Weigle et al 1991). The test becomes positive once
the lesions begin to crust (Even-Paz & Sagher 1961, Mauel & Behin 1987) and
it remains so indefinitely. It is therefore unable to distinguish between past and
present infection. Its main use is in epidemiological studies because in
endemic areas up to 9% of healthy controls are positive, presumably from past,
often asymptomatic, infection (Weigle et all 1991). Its value in repeated
assessment of the same individual, for example, before and after exposure is
not known for each reagent; the test itself sensitise the individual and give a
false positive reaction. It is, however, a useful supplementary test in visitors
returning with a suspicious lesion.
1.2.6 Treatment
There is no single optimal treatment for all forms of CL. Indeed, even
neglecting economic factors, the natural diversity of the parasites, together with
the wide spectrum of clinical disease that they produce, means one is unlikely
to evolve in the forseeable future. The situation is further complicated by the
46
self-healing nature of CL. Although this has been appreciated for many years
in Old World disease it has only been recognised relatively recently that over
half the lesions due to Lmm heal spontaneously within 4 months (Herwaldt et al
1992). Adequately controlled therapeutic trials are therefore essential to
assess the efficacy of any new treatment. Unfortunately the literature abounds
with reports of 'effective' treatments based on case reports and uncontrolled,
small, series which makes it difficult to assess their efficacy. Selection of the
most appropriate therapy can be very difficult. It has become increasingly
apparent that each endemic area must establish its own optimum treatment
regimen based on efficacy and toxicity, without neglecting the practical
difficulties of administration and cost.
Fortunately there are some guiding principles. Lesions due to different species
vary in both their severity and response to treatment - New World disease tends
to be more severe and longer lasting than Old World disease. Most Old World
lesions will heal spontaneously within a few months or at most two years,
therefore active treatment is not mandatory. Indeed, for patients living in
endemic areas, it may not be appropriate because spontaneous healing is
associated with the development of protective immunity. However, patients
with lesions on cosmetically or functionally important sites, such as the face or
hands, those with associated lymphangitis and those with multiple or more
complicated lesions, are best given active treatment. Local treatment is
appropriate for early non-inflamed lesions and systemic therapy for those with
multiple or more complicated lesions. An exception to these rules are those
lesions caused by L.aethiopica which is relatively resistant to antimony and for
which local treatments have not been validated. The WHO recommends that
they are left to heal spontaneously unless they occur in the nasopharyngeal
area, in which case systemic pentamidine should be used (WHO 1990).
In New World disease the first crucial step is to decide whether or not one of
the L.braziliensis complex could be the infecting species because, until further
information is available, all such cases must be considered capable of causing
mucocutaneous disease and therefore adequate systemic therapy is
mandatory. Hence, if the patient contracted CL in any area in which
L.braziliensis occurs (i.e. Belize, Brazil, Colombia, Costa Rica, French Guiana,
Honduras, Surinam, Panama, Venezuela, the western slopes of the Andes and
the Argentinian highlands (Lainson & Shaw 1987)), the parasite must be
isolated and identified before any alternative to optimal systemic therapy is
considered. If the disease were contracted in other areas, or if L.mexicana
complex (except L.m.amazonensis) is isolated, then alternatives, including
topical or no therapy at all, may be considered. The WHO recommends that
cases due to L.m.amazonensis are treated in the same way as those due to
Lbb because a high proportion develop DCL (WHO1990).
Table 1.5

































The literature is full of alternative therapies (table 1.5), some are of proven
efficacy (eg pentavalent antimony and pentamidine), some are promising
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anecdotally or in small series (eg ketoconazole) and others are under
investigation (eg paromomycin ointment). It is not feasible to describe each
one in this thesis so I refer to several recent reviews (Bryceson 1987, Berman
1988, Mukherjee et al 1990, Olliaro & Bryceson 1993) and I shall consider
pentavalent antimonials and aminosidine (paromomycin) in detail.
Pentavalent antimonials
Pentavalent antimonials remain the mainstay of effective systemic therapy for
all forms of leishmaniasis. Many different preparations have been developed
over the years (table 1.6) and these vary in their antimony composition (as can
Table 1.6
Overview of pentavalent antimonials
Pentavalent antimonials are derived from stibonic (antimonic)acid
and fall into 2 groups:
(1) Derivatives of benzene (or para-aminophenyl) stibonic acid.
Polymerised 4-aminobenzene stibonic acid=stianilic acid.
Salts of stibanilic acid=stibonates.
(a) Sodium salts of stibanilic acid = Stibamine and Stibosan.
(b) Acetyl derivative of stibamine = Stibacetyn, Stibenyl.
(c) Diethylamine derivative of stibacetin = ethyl stibamine =
Neostibosan
(d) Urea salt of stibanilic acid = urea stibamine = Urea
Stibosol, Stiburea.
(e) Nitrogen glucoside of Stibamine = Neostam.
(2) Derivatives of stibonic acid in which antimony is joined through
oxygen atoms to the carbon chain(s) of glucose.
(a) Sodium stibogluconate = sodium antimony(l) gluconate* =
Pentostam, Solustibosan, Solyusurmin, Stibanate,
Dibanate, Stibek.
(b) N-methyl glucamine antimoniate = meglumine
antimoniate = Glucantime, Prostib.
*A preparation of sodium antimony(l) gluconate containing trivalent antimony
was in use for a short time in the late 1930s.
(From Bryceson 1987)
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different sources of the same compound). Urea stibamine, Stibosan and
Neostibosan became available in the 1920s. Pentostam was first manufactured
between 1935 and 1945 and the concentrated solution (100mg antimony/ml)
became available and was first used in 1945 (Berman 1988).
Two preparations are widely available commercially: sodium stibogluconate
(PentostamR, Wellcome, UK), which contains 100mg antimony/ml and is
primarily used in English speaking countries, and meglumine antimoniate
(GlucantimeR, Rhone Poulenc, France), which contains 85mg antimony/ml and
is principally used in French and Spanish speaking countries. Although their
efficacy has been well established their precise structure and mode of action
are not well defined. A commonly drawn structure for Pentostam shows 2
molecules of gluconate complexed via oxygen atoms to 2 molecules of
antimony with 3 sodium atoms balancing the 3 negative charges on the rest of
the molecule (figure 1.7). In reality it is likely to be a more complex macro-
Figure 1.7
Sodium stibogluconate (PentostamR) (James et al 1985)
CH2OH CH2OH
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molecular structure because the molecular weight for that structure is 746
daltons and the osmolarity of a solution of 100 mg of Sb/ml would be 1644
mOsmol. In fact the osmolarity of Pentostam is approximately 800 mOsmol
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and it consists of numerous moieties with molecular weights of 100-4000
daltons. Clinical formulations of sodium stibogluconate may, therefore, be
described as 'an unknown number of uncharacterised complexes of antimony
with carbohydrates derived from gluconic acid" (Berman 1988). It would not be
surprising if different sources differed in their composition in important respects,
indeed the production of PentostamR has been described as 'cookery rather
than chemistry' (Marsden 1985). In fact the osmolarity of PentostamR varies
from batch to batch and if it is over lOOOmOsmol then it is clinically ineffective
(Berman & Grogl 1988). The situation may be further complicated, at least for
GlucantimeR, because there is a variable amount (10-18%) of (toxic) trivalent
antimony present (Franco 1992).
These compounds probably have a number of modes of action on leishmanial
amastigotes which include inhibition of bioenergetics by (1) the inhibition of
glycolytic enzymes resulting in a decrease in ATP and GTP (and a consequent
increase in ADP and GDP) but they do not affect the citric acid cycle or the
hexosemonophosphate shunt, and, (2) the inhibition of fatty acid oxidation
(Berman 1988). More speculatively, it may act as an immunomodulator
whereby it in some way injures the amastigote, thereby exposing different
antigens which trigger CD4 dependant destruction. In HIV infection where
there are few functional CD4 cells sodium stibogluconate is ineffective or only
effective at very high doses (Peters et al 1990, Magill personal communication).
It cannot be absorbed orally and therefore parenteral administration (im or iv) is
necessary. It is rapidly excreted, largely unchanged, by the kidney - 80% of a
single dose is eliminated within 6 hours (Dollery 1991). Whilst this avoids acute
toxicity, about 5% is excreted as trivalent antimony, which has a much longer
half-life, and may account for the observed cumulative toxicity which increases
in proportion to the dose and duration of therapy (Bryceson 1987).
Efficacy. The efficacy of pentavalent antimonials in CL has been established
beyond doubt provided they are given in adequate doses and for an adequate
length of time (table 1.8). Sodium stibogluconate and meglumine antimoniate
are of similar efficacy provided their differing concentrations of antimony are
taken into account. Only CL and DCL due to L.aethiopica are consistently
unresponsive (Bryceson 1987). Although there is more extensive data
Table1.8Efficacyofpentav l ntntimonialsicu aneouleishm i sis. CountryDrug:doseF equency (mg)TotalSb^Curerat(°/ mg/kg
Toxicity
Iran (1950) Mexico (1953) Chad (1958) France (1958) Biskra (1959) Brazil (1968) Panama (1973) Panama (1974) Panama (1974)
G:16-36/kgodx10
240-4804/4(100)
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available for its action against visceral leishmaniasis (VL) those results cannot
be extrapolated to CL because pentavalent antimonials are preferentially
concentrated in the liver and spleen with relatively little reaching the skin.
Furthermore, immune responses are less efficient at the cooler temperatures of
the skin. This can be illustrated, crudely, by the observation that 40 days
treatment cures all patients with VL in Bihar, but 120 days treatment is
necessary to cure patients with post kala-azar leishmaniasis (Olliaro &
Bryceson 1993).
Therapeutic regimens. These were developed without access to
pharmacokinetic data and with caution resulting from the high toxicity
associated with the parent trivalent antimonials. This resulted in the concepts
of single daily doses (when bd or tds would be more logical) and of short
courses of therapy lasting 6-10 days with repeat courses only after a gap.
Indeed, this was still the recommendation in the manufacturer's data sheet for
pentostam until recently (Anonymous 1989). This type of regimen has been
abandoned by many clinicians in recent years because there is no evidence to
support them and, indeed, they may encourage the development of resistant
strains (Bryceson 1987). The optimum dosage has not been determined in Old
World CL. In New World CL it has been shown that 20 days treatment with
sodium stibogluconate 20mg/kg/day is more efficacious, and may be no more
toxic, than 10mg/kg/day for L.panamensis (Ballou et al 1987). The higher-dose
regimen will cure virtually all lesions due to L.panamensis in Panama and
L.braziliensis in Guatemala (Herwaldt & Berman 1992). The WHO
recommends that when pentavalent antimony is used to treat CL a dose of 10-
20mg/kg/day should be given at least until the lesion has healed (WHO 1990).
These recent studies indicate that this recommendation should probably be
amended in 2 ways. First, 20mg/kg/day (sodium stibogluconate) does not
appear significantly more toxic, yet it is more effective, than 10mg/kg/day.
Therefore, unless 10mg/kg/day has been reported to be as effective as
20mg/kg/day for an endemic region (none so far) CL should be treated with
(sodium stibogluconate) 20mg/kg/day. Second, both re-epithelialisation of
lesions and elimination of parasites continues after antimony therapy has
stopped. Treatment until complete clinical and parasitological cure has been
achieved therefore constitutes considerable overtreatment. A more logical
approach would be to give antimony for a predetermined number of days and
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then examine the patient 4-6 weeks later to see if complete clinical and
parasitological cure has occurred. Current data suggests that treatment should
last 20 days. If cure rates of >95% without relapse are observed for a given
area a trial of a lower daily dose or of a shorter duration of antimony treatment
could be undertaken (Berman 1988).
The development of antimony resistance has been well documented in visceral
leishmanisasis and innate resistance is well recognised for L.aethiopica and,
more recently, for L.mexicana (Bryceson 1987, Olliaro & Bryceson 1993).
Parasites causing New World CL and MCL show a wide range of susceptibility
to antimonials in vitro. Some isolates from patients unresponsive to antimony
are fully resistant and strains of Lmm and Lbb from patients who relapse are
10-17 times less susceptible than before treatment. The development of
resistance has been linked to discontinuous drug exposure or inadequate
dosage. Tests to assess resistance and predict the clinical response to
antimony therapy are now under development (Grogl et al 1989, Grogl et al
1992).
Toxicity of the pentavalent antimonials has been, and remains, the subject of
intense debate, partly because of the undoubted toxicity of their parent trivalent
compounds. Whilst reviewing the available literature Bryceson (1987)
concluded that:
'sodium stibogluconate and meglumine antimoniate
are amongst the safest drugs in current medical use.
They have been used for 40 years, in all races and in
most countries in the world, in hundreds of thousands
of patients with all forms of leishmaniasis, often
malnourished and desperately ill; yet only two deaths
have been attributed to their use 1
However they have a poor reputation because the trivalent antimonials
invariably produced cardiac toxicity and reports of ECG abnormalities during
sodium stibogluconate therapy appeared relatively early on in the literature
(Dempsey 1965, Kaplan et al 1978). A study of 22 British soldiers with CL
treated with sodium stibogluconate (10 mg/kg/day) failed to find any changes in
blood pressure, heart rate, left ventricular function or heart rhythm, although
serial ECGs showed a reversible decrease in T-wave amplitude (Henderson &
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Jolliffe 1985). A study of 65 patients with visceral leishmaniasis treated with
sodium stibogluconate (doses ranged from 10-60 mg/kg/day) serial ECGs
showed changes in 54% of the treatment courses. Furthermore, the proportion
of patients with T-wave changes increased with both the daily dose of antimony
and the duration of treatment. There was an essentially linear correlation
between the proportion of patients with any new ECG abnormality and
cumulative dose of antimony administered. The abnormalities observed were
T-wave flattening, T-wave inversion and prolongation of the QTc interval - the
QTc changes were seen in 13 patients all of which had been treated with more
than 20 mg/kg/day for more than 30 days. These ECG changes were always
transient in that they were not present on follow-up. In the few patients who
remained in the hospital for initial follow-up, the ECG changes resolved over 1-
3 weeks. Three patients died during treatment: all showed QTc prolongation,
ST concavity and T-wave inversion. One patient was presumed to have
developed a fatal ventricular arrhythmia and the other two had severe measles
infections (Chulay et al 1985). Similar ECG changes have been observed with
meglumine antimoniate (Antezana et al 1992). It appears that sodium
stibogluconate, in standard doses of up to 20mg/kg/day for 20 days, whilst
associated with ECG changes is rarely associated with clinical cardiotoxicity
(Ballou et al 1987, Dollery 1991) although further studies are needed.
A further cause for concern is the transient increase in liver aminotransferase
levels which have been reported during treatment of both visceral (Chulay et al
1983) and cutaneous disease and which may be dose related (Oster et al 1985,
Ballou et al 1987). Although these abnormalities settle within 6 weeks of
stopping therapy their significance is unknown. A transient fall in the white
blood cell count has also been noted during the first few days of therapy but this
recovers despite further treatment (Ballou et al 1987). Impairment of renal
function during therapy has also been reported ((Viega et al 1983).
Patients frequently complain of loss of appetite, muscle pains and joint stiffness
during treatment (table 1.9); these symptoms usually start during the second or
third week and may be dose-related. They settle rapidly after the treatment is
stopped. Joint effusions can occur during prolonged high dose therapy (Ballou
et al 1987, Castro et al 1990). Thrombophlebitis at the site of injection is
common.
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Local infiltration of the lesions with either sodium stibogluconate (Kellum 1986)
or meglumine antimoniate (Barrios et al 1986, Harms et al 1991) is an
alternative to systemic administration for L.tropica, at least, provided there are
only a few lesions. However, technique is important and several injections are
usually required (WHO 1990).
Aminosidine
Aminosidine is an aminoglycoside antibiotic produced by Streptomyces
chrestomyceticus (Arcamone et al 1959). Its chemical structure is identical is to
both paromomycin (which is produced by another streptomyces species)
(Schillings & Schaffner 1961) and monomycin (Reynolds 1993). Like other
aminoglycoside antibiotics, aminosidine is poorly absorbed from the
gastrointestinal tract. Intramuscular administration leads to prompt and
complete absorption with peak levels obtained after one hour of 20 and 40mg/L
with doses of 0.5 and 1.0g respectively. Intravenous administration of the same
doses given in saline or 5% dextrose, over 100 minutes, yields a similar profile.
There is relatively little protein binding and it is excreted unchanged through the
kidneys. Its pharmacokinetic behaviour fits a multi-compartment model with a
dominant elimination half-life of approximately 2.3 hours followed by a slower
elimination half-life of about 40 hours (Kahlmetir 1979, Scott et al 1992).
Efficacy. Its anti-leishmanial properties were first reported in the 1960's.
Subsequent studies have confirmed these early findings in vitro using hamster
peritoneal macrophages (Mattock & Peters 1975a,b) and in vivo using Balb/c
mouse skin lesions (Neal 1968). When compared with sodium stibogluconate it
was 6-times more active against L.mexicana and 600-times more active against
L.major. Furthermore it was fully active against antimony resistant strains of
L.donovani. It is difficult to interpret in vitro and in vivo experiments, as the
assays used and the strain of a given leishmania subspecies affect the result,
but it appears that New World cutaneous parasites, particularly Lbb, are less
sensitive than Old World and visceral parasites (Neal 1987). There is
potentiation between aminosidine and antimonials in vitro against L.mexicana
but this effect is less marked in vivo. The mode of action of aminosidine
against leishmania is not known (Berman 1991).
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Aminosidine, as monomycin, has been used extensively in Russia to treat CL;
when 5000 lU/kg i.m. was given t.d.s. parasites could not be detected after a
mean of 6.9 days and the sores healed in a mean of 13.5 days (Akovbyan &
Mukhamedov 1969, Er|hov 1978). Toxicity was not reported but it may not
have been looked for systematically (Bryceson 1987). More recently,
aminosidine has been assessed for treating VL in 4 open studies (table 1: 9)
which indicate that it may be an effective first-line alternative to pentavalent
antimony for the treatment of naive and unresponsive VL. The apparent
increase in efficacy of aminosidine when it was combined with sodium
stibogluconate noted in the Kenyan study was tested under appalling field
conditions in the epidemic of VL in Southern Sudan where it was found that
combined therapy could reduce the duration of treatment from 30 to 17 days
(Seaman et al 1993). The efficacy of systemic aminosidine for CL and MCL
has yet to be established, although 1 of 2 patients with Old World CL and 1 of 2
with MCL which were resistant to antimony have been successfully treated
(Scott et al 1992).
Toxicity. Aminosidine, like all aminoglycosides, is associated with
nephrotoxicity and ototoxcity (Ito et al 1968). Toxicity is associated with high
plasma concentrations, impaired renal function and concomitant exposure to
other nephrotoxic agents (Burkle 1981). Therapeutic doses administered to
patients with normal renal and otological function are unlikely to produce toxic
reactions, even during prolonged courses of treatment (Donno & Rimoldi 1974).
No clinical or biochemical toxicity was reported in either the Indian or the
Kenyan study which is perhaps surprising in view of the well documented
elevations in liver enzymes reported during treatment with sodium
stibogluconate for CL. The London study was the most closely monitored and
patients received higher doses for a longer time; reversible renal impairment
occurred in 2 patients and high frequency deafness occurred in one of these
patients and another. In the first 3 studies aminosidine was well tolerated and
the patients preferred it to the antimonials.
Aminosidine ointment. An ointment containing aminosidine has been
pioneered by the group led by Joseph El-On in Jerusalem. Animal studies
using Balb/c mice led to the development of a preparation containing 15%
aminosidine and 15% methyl benzethonium chloride (MBCL) in white soft
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paraffin. Uncontrolled studies in man suggested it would heal lesions due to
L.major when applied twice daily for 10 days (El-On et al 1985, El-On et al
1986) and also that it may be effective for lesions due to L.aethiopica
(Weinrauch et al 1987) and Lmm (El-On et al 1988). A double blind, placebo-
controlled, cross-over trial has recently confirmed its efficacy in L.major
infections: 77% of patients given active treatment were cured within 10 days
compared to 27% in the placebo group (El-On et al 1992). Although the Israeli
group reported inflammation (due to the MBCL), other workers have found this
to be so severe that treatment could not be continued. When less irritant
preparations, containing less MBCL, were used they were less effective (El-Safi
et al 1990). A preparation containing urea is currently in Phase 2 to 3 trials in
Iran and Tunisia via the WHO. Preliminary evaluation suggests that new
formulations may be needed to improve penetration into the lesion (Olliaro &
Bryceson 1993).
In conclusion, treatment of CL is unsatisfactory. A safe, cheap and either single
dose or oral preparation is needed but none is available. The pentavalent
antimonials remain the mainstay of therapy but the optimal dose regimen for
each geographical area has not been worked out and further assessment of
their toxicity is required. Parenteral aminosidine may be effective and safer
and, therefore, it should be evaluated in controlled clinical trials.
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1.3 Cutaneous Leishmaniasis and the British Army in Belize
1.3.1 The history and role of the British garrison
Belize is a country the size of Wales lying on the east coast of Central America.
It has a population of 150,000, half of which are under 19 years old. Its main
product is sugar. The earliest European settlers were British buccaneers who
began arriving in the mid-17^ Century making use of the many sheltered
anchorages to launch raids on Spanish shipping. Spain mounted repeated
attacks against the British settlers but in 1763 granted them rights to fell log
wood and eventually recognised British sovereignty in the Treaty of Amiens of
1802. As British Honduras the area had been governed by British
administrators from 1786. It became subject to British law in 1840 and was
designated a Crown Colony in 1862. The importance of the colony for Britain
(which had trading interests all along the Caribbean coast) was primarily
economic. It had the best deep-water port facilities in the region, and in the




Guatemala gained independence from Spain in 1821 and began to lay claim to
Belize (as did Mexico for a time). In 1859 a treaty was concluded between
Britain and Guatemala under which Guatemala recognised the colony's
boundaries in exchange for a British undertaking to construct a road from
Guatemala City to the Caribbean coast. The commercial importance of British
Honduras declined markedly with the completion of the Panama railway in
1855, which moved the focus of Central American trade to the Pacific
seaboard. Guatemala did not actively pursue Britain's failure to build the road
until it abrogated the treaty in 1945, claiming that Britain had failed to fulfil its
obligations (Brooks 1983, Goetz 1991).
The colony was granted internal self-government in 1964, it was renamed
Belize in 1973, and granted full independence on 21st September 1981. As a
result of the moves towards independence Guatemala renewed its claim to the
territory. Since then Anglo-Guatemalan talks on this issue have repeatedly
broken down. At the time of independence Belize had a very rudimentary army
- the Belizian Defence Force numbering only 500 soldiers; consequently the
British government agreed to provide a defensive garrison to deter the large
Guatemalan forces across the border. The formal mission of the British Forces
is four-fold: (1) to provide assistance to the Belize Defence force in the defence
of Belize against any external aggression, (2) to assist the Belizian Defence
Force with training, (3) to keep track of what is going on in the area, (4) to
provide assistance to the civil power in disaster relief and in the maintenance of
emergency services. The garrison consists of approximately 1800 troops and
airmen, mostly on 6 month, unaccompanied tours of duty, from many different
parts of the Army and the Royal Air Force; many undertake jungle training
during their tour (Fursden 1988).
1.3.2 The cutaneous leishmaniasis problem
The deployment of troops to Belize in the late 1970's in preparation for
independence was soon followed by the appearance of cases of CL; from
1977-1990 a total of 319 soldiers contracted it during or immediately after their
tour of duty (figure 1.1 i). The US army has had a similar experience in
Panama
62
(Takafuji et al 1980); from 1977-1984 the Walter Reed Medical Center in
Washington DC treated 70 cases from that theatre (Ballou et al 1987). This is
not surprising. As described earlier, New World leishmaniasis is essentially a
zoonosis maintained by forest rodents. Most cases are occupational and are
related to the length of time the non-immune worker spends in the forest in
contact with potentially infected sandflies. The incidence is very variable and
this is probably related to the presence of "hot-spots" - some units are
unfortunate enough to select one of these areas for training.
Figure 1.11: Incidence of CL in British troops from Belize
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The first cases of CL caused some difficulties in diagnosis and it took time to
develop expertise in diagnosis and management. The large number of cases in
1979 (coupled with a headline in the Sun newspaper: "British Troops Beaten
Back By Jungle Flies') prompted a concerted public health programme within
the Army but also involving the RAF and the Royal Navy. All suspected cases
were sent back to the Dermatology Department of the Cambridge Military
Hospital in Aldershot where expertise was concentrated. Soldiers and their
regimental medical officers were briefed about CL prior to departure and they
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were issued with a 'Leishmaniasis Warning Card1 upon their return to show to
any medical attendant consulted within 2 years. This resembled a credit card
and recommended referral to Aldershot if CL was considered a possibility.
Preventative measures such as impregnation of mosquito nets with permethrin
were also introduced.
However, the very nature of their task means that the troops continue to be
bitten and CL has become a major health problem for the British Army. This is
likely to continue as long as troops remain in Belize.
Figure 1.12: British troops training in Belize.
64
Chapter 2
A Retrospective Study of Belizian Cutaneous
Leishmaniasis in British Troops From 1978 to mid-
1990.







2.1 Aims of the Investigation
To determine the clinical features of cutaneous leishmaniasis in British troops
returning from Belize.
To determine the diagnostic criteria used.
To determine the relative frequency of cases caused by Lmm and Lbb.
To identify any clinical differences between lesions due to Lmm and those due to
Lbb.
To identify the types, efficacy and toxicity of therapies used.
2.2 Introduction
In the 12 years from 1978 until mid-1990 over 300 soldiers were treated for CL in
the Dermatology Department of the Cambridge Military Hospital, Aldershot, the
central referral hospital for all cases of CL in the British Armed Forces. The data
from this large series of patients had never been systematically analysed. Before
any further studies could be contemplated, it was, therefore, necessary to
determine which of the many clinical impressions formed over the years could be
substantiated, thereby defining our knowledge of Belizian CL and its management.
As knowledge of CL increased so management changed. The most important
discovery was the isolation of Lbb, with its potential complication of espundia, in
some of the returning soldiers (Evans et al 1984). Until that time all cases of
Belizian CL had been assumed to be due to Lmm following the classical work by
Lainson and Strangeways-Dixon (1963). Lesions due to Lmm and Lbb were
thought to be clinically identical. Numerous therapeutic modalities had been used
on an ad-hoc basis but sodium stibogluconate had been found to be the most
useful. Initially short, low-dose courses were used but later longer courses at a
higher daily dose had been adopted and found more efficacious.
66
2.3 Methods
A clinical diagnosis of CL had been made in 306 servicemen between 1978 and
mid-1990 following a tour of duty in Belize. Their hospital case notes were
scrutinised and the following data extracted: age; dates of Belize tour; date lesion
first noticed; number, size and site of the lesions; the results of histological
examination of the lesions; culture and isoenzyme typing of the parasite. Detailed
records were made of the treatment given including dates, drug, dose, duration,
side-effects, and the haematological and biochemical parameters used in
monitoring treatment. Resolution of the ulcers, an objective end point that could be
assesssed easily and reliably by all physicians, was the standard criterion for cure.
Patients were closely supervised by army dermatologists to ensure that cure was
attained and maintained for at least 3 months. Thereafter patients were usually
followed-up by their regimental medical officer and re-referred if they relapsed.
For the purposes of this thesis, detailed analysis was restricted to the 187 cases in
which the clinical diagnosis was confirmed by demonstration of the parasite by
culture and/or histological identification of Leishman-Donovan (LD) bodies. In
general a single lesion had been sampled and other, clinically similar, lesions were
assumed to be of the same aetiology. A comparison of the clinical features was
made between those cases in which Lmm and those in which Lbb had been
identified.
During the early part of the 12 year period covered by this study the main treatment
strategy consisted of an initial 10 day course of intravenous (iv) sodium
stibogluconate (PentostamR) 600-800mg daily. If the ulcers were not healing
satisfactorily this was either continued, or repeated after a break, as recommended
by the manufacturer (Anonymous 1989). Because many patients required
repeated courses a higher dose regimen was subsequently adopted . This
consisted of an initial 14 day course of iv sodium stibogluconate 600mg twice daily.
Again, if the ulcers were not healing satisfactorily, this was either continued or
repeated after a break. The success of these strategies was compared.
Haematological and biochemical monitoring parameters prior to treatment, at the
end of treatment, and 2 weeks after cessation of treatment, were available for 2
cohorts, one treated with 600mg daily iv for 10 days to a total of 6g (36 cases) and
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a second treated with 600mg twice daily iv for 14days to a total of 16.8g (24
cases).
Statistical analysis. Pre-treatment lesion size and duration in all the cases, and
in the Lmm and Lbb subgroups, were statistically evaluated using an unpaired t-
test. Differences in the haematological and biochemical parameters before, during
and after treatment, were evaluated using a paired t-test.
2.4 Results
A clinical diagnosis of CL was made in 306 otherwise healthy male soldiers, mean
age 23 years (sd 3.9), who had acquired their infection whilst on active service in
Belize. Confirmation of the diagnosis by demonstration of the parasite was made
in 187 cases (61%): a positive culture was obtained in 117 cases, and LD bodies
were identified in a further 70 cases. Of the 117 culture-positive cases the species
was identified in 107: 77 were due to Lbb, 29 to Lmm, and in one case both Lbb
and Lmm were identified from a single lesion (figure 2:1). Lesions started as small
inflammatory papules which gradually enlarged and ulcerated. The ulcer was often
covered with an adherent crust (figure 2.2) which subsequently separated to
expose a necrotic ulcer base which was frequently secondarily infected with either
staphylococci aureus or B-haemolytic streptococci. The fully developed lesion
consisted of a painless ulcer with a necrotic base and an indurated violaceous
margin (figure 2.3).
A total of 283 lesions were identified in the 187 parasitologically confirmed cases: a
solitary lesion was present in 71%, two lesions in 16%, three lesions in 8% and
four lesions in 4%. One soldier had five lesions and another had 12 lesions.
Cases due to Lmm and Lbb had similar numbers of lesions and most occurred on
exposed body sites with the head, neck, wrists and hands accounting for 51% of
lesions. Lesions due to Lmm were more common on the head and neck than those
due to Lbb (figure 2.4). The mean diameter (longest axis) of all ulcers was 14.4
mm (sd 9.3), lesions on the head and neck being smaller than those elsewhere at
presentation. The lesions due to Lbb were significantly (p<0.01) larger (mean
diameter 17 mm) than those due to Lmm (mean diameter 12.3 mm), despite the
observation that Lbb lesions had been present for a significantly (p<0.05) shorter
Figure2:1: Thediagnosticbreakdownof306casesutan ousleis maniasi . 306casesof clinically diagnosedCL119clinicaldiag osison y (39%)(parasitenotdemonstrated)
.excluded from analysis
187parasite (61%)demonstrated
117Culturepositive (LDbodiesin71) Culturenegative (ornotavailable)LDbodiesse n






Figure 2.2: Early lesion of cutaneous leishmaniasis from Belize with adherent
crust.
Figure 2.3: Later lesion in which crust has separated to form an ulcer.
Figure 2.4: Site of ulcers in cases due to Lmm (top) and Lbb (bottom)
Each spot represents 1% of lesions.
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time (mean 8.8 weeks) than Lmm lesions (mean 12.5 weeks). Most soldiers
presented either during their Belize tour of duty, or within 4 months of their return.
One soldier presented 11 months after his return. The data for these analyses are
shown in appendix 1.1. These clinical parameters were very similar in the 187
parasitologically proven cases to the whole group of 306 cases in which a clinical
diagnosis of CL had been made (appendix 1.2).
Treatment started after a mean interval of 9.9 weeks (sd 6.7) had elapsed after the
lesion was first noticed. Sodium stibogluconate was the mainstay of treatment.
The ulcers of 166 soldiers healed with sodium stibogluconate alone, although there
was a wide range in the total dose required (mean 13.1 g, sd 7.2). During the early
part of the study 101 patients were treated with a low (600-800mg) daily dose
regime. Clinical side-effects were recorded in only one case - that soldier reported
aching muscles after receiving 800mg daily for 11 days. The higher dose regime
(600 mg twice daily) which was subsequently adopted was associated with greater
morbidity; of the 72 soldiers who received this regime 3 became nauseated and
anorexic, 11 developed myalgia, 2 developed chest pain (which was associated
with tender costal cartilages), 2 reported non-specific malaise and 2 developed
thrombophlebitis at the site of the indwelling iv cannula, associated with pyrexia.
One soldier developed cheiropompholyx, although that resolved with appropriate
treatment whilst sodium stibogluconate was continued. One soldier developed an
acute aseptic arthritis of his knee 2 days after completing a course of 16.8g and
another developed severe hip pain, accompanied by a serum creatine kinase level
of 25,290 IU/I, 14 days after receiving 23.4g sodium stibogluconate. Both
problems gradually resolved over the following 4 months without specific therapy.
Sequential haematological and biochemical monitoring parameters, assessed prior
to treatment, at the end of treatment and 2 weeks after treatment, were available
for 2 cohorts. Although laboratory data were available for other soldiers they had
not been collected systematically and, therefore, their analyses could have been
misleading. The first cohort received the 'standard' low-dose regimen consisting of
600mg/day to a total of 6g (36 soldiers) and the other received the 'standard' high-
dose regimen consisting of 600mg twice daily to a total of 16.8g (24 soldiers). A
mild, although significant (P<0.05), leukopenia was noted at the end of treatment in
both groups, but there was no change in the haemoglobin level. The serum urea
did not rise during treatment. Serum aminotransferase levels (alanine
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aminotransferase (ALT) and aspartate aminotransferase (AST)) were both
elevated at the end of treatment but had almost returned to pre-treatment levels 2
weeks later. These changes were more marked in the group which received the
high-dose regimen. The serum glutamyl transferase (GGT) was only elevated in
the high-dose group at the end of treatment and it had also returned to normal 2
weeks later. The alkaline phosphatase (ALK P) level was elevated in the high-
dose group at the end of treatment and in both groups 2 weeks later. A transient
fall in serum creatine kinase at the end of treatment was noted in both groups.
There was no significant rise in lactate dehydrogenase . These changes are
summarised in table 2.1 and the detailed results are given in appendix 1.3. The
clinical features of the soldiers given the low and high dose regimens are shown in
table 2.2.
Table 2:1




White cell count N I N
Alkaline phosphatase N N T
Gamma glutamyl transferase N N N
Alanine aminotransferase N T T
Aspartate aminotransferase N T N
Creatine kinase N I N
High-dose regimen
Pre-Rx Post-Rx Recovery
White cell count N I N
Alkaline phosphatase N T T
Gamma glutamyl transferase N T T
Alanine aminotransferase N T T
Aspartate aminotransferase N T T
Creatine kinase N i N
Changes are indicated at the end of treatment and 2 weeks after treatment
stopped (recovery).









Number of patients 101 72
Mean number of lesions 1.54 1.47
Mean duration of lesions prior 9.2 (sd 6.9) 8.8 (sd 4.4)
to treatment (weeks)
Mean lesion size
(longest axis of ulcer, mm) 15.9*(sd 9.9) 12.3 9 (sd 7.7)
Lesion site
Head and neck 39 (25%) 28 (26%)
Trunk 26 (17%) 16(15%)
Arms 16 (10%) 14(13%)
Hands/wrists 42 (27%) 25 (24%)
Legs 31 (20%) 20 (19%)




Lmm and Lbb 0 1
Not available 42 35
* significant difference P<0.05
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The low daily dose sodium stibogluconate regime (600-800mg daily) was initiated
in 101 soldiers. Treatment was given for 10 days in the first instance after which it
was either continued or repeated after a break. This initial 10 day course cured 49
(49%) of those soldiers and, ultimately, the ulcers of 94 (93%) healed on this
regimen. In the remaining 7 cases treatment with sodium stibogluconate was
stopped and alternative treatments given because of dissatisfaction with their
clinical progress. The ulcers of 90% of soldiers treated with this low-dose regimen
had healed after a cumulative dose of 24g (ie 40 days treatment).
The high daily dose sodium stibogluconate regimen, (600mg twice daily) was
initiated in 72 soldiers. Treatment was given for 14 days in the first instance, after
which it was either continued, or repeated after a break. The initial 14 day course
cured 46 (63.9%) of these soldiers, and ultimately the ulcers of all these soldiers
healed with this regimen. The ulcers of 90% of soldiers treated with this regimen
had healed after a cumulative dose of 24g sodium stibogluconate (ie 20 days
treatment).
Fourteen soldiers were initially given treatments other than sodium stibogluconate.
Seven were treated with ketoconazole 800mg daily for 28 days following which the
ulcers of 5 had healed - the remaining 2 healed after a course of 7g sodium
stibogluconate. Three soldiers, all with infections due to Lbb, were given a one
month course of rifampicin 150mg combined with isoniazid 150mg twice daily; one
healed but the other 2 required further treatment with 7g sodium stibogluconate.
Three soldiers with ulcers caused by Lmm were treated by local excision. One
soldier with an ulcer due to Lbb was successfully treated with pentamidine 4mg/kg
iv on alternate days for 3 weeks; pentamidine had been chosen because during
treatment for CL, type unknown, with sodium stibogluconate several years earlier
he had developed an exfoliative dermatitis; when he was subsequently
rechallenged with a small dose of sodium stibogluconate he developed
cheiropompholyx.
As described above 7 soldiers (6 due to Lmm and 1 culture negative) in whom the
low-dose regimen had been started were subsequently given alternative treatment
because of dissatisfaction with their progress. Sodium stibogluconate was stopped
after various doses: 6g, 12g, 12g, 12g, 18g, 20g and 21.5g. The alternative
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treatments included pentamidine, ketoconazole, itraconazole and paromomycin
ointment. All ultimately healed.
The lesions recurred in 7 soldiers following initially successful treatment. In 6
soldiers this occurred between 4 and 7 months after healing and in the remaining
soldier after 19 months. Six were successfully re-treated with sodium
stibogluconate and in the remaining case the lesion was excised. Mucocutaneous
leishmaniasis has not, as yet, developed in any British soldier following service in
Belize.
2.5 Discussion
There are few reports which document the clinical features of New World CL, the
largest is that of Llanos-Cuentas in which the lesions of 182 cases with active
disease (predominantly due to Lbb) are described (Lainson & Strangeways-Dixon
1963, Llan os-Cuentas et al 1984, Ballou et al 1987, Jones et al 1987, Walton
1987). One further problem is that interpretation of data from many of these
studies is difficult because the diagnosis has not been confirmed by demonstration
of the parasite in all cases. In this study, although a clinical diagnosis was made in
306 cases, analysis was restricted to the 187 cases in which the parasite was
demonstrated. In each case a single lesion had been biopsied and it was assumed
that other, clinically similar, lesions in the same soldier were of the same aetiology.
Seventy-one percent of cases presented with a solitary lesion, usually on the
exposed extremities, which is similar to other reports. However, in this study a
greater proportion of lesions occurred on the hands and wrists compared with the
legs. This may be attributable to the fact that natives work in the jungle with bare
legs whereas soldiers wear boots and long trousers. A higher proportion of lesions
due to Lmm occurred on the head and neck. This has been attributed to the biting
habits of Lutzomyia olmeca olmeca, the vector of Lmm, which tends to bite at head
level (Walton 1987). The vector of Lbb in Belize has not yet been established.
Interestingly, this predominance of head and neck lesions was also noted 20 years
ago by Lainson and Strangeways-Dixon (1963), at which time all lesions in Belize
were thought to be caused by Lmm. The average diameter of lesions at
presentation was smaller than reported in other studies; this is probably the result
of earlier presentation.
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Diagnosis may be difficult. In the early stages the lesion resembles an insect bite
and later, the presence of secondary infection, may lead to further diagnostic
difficulty. Demonstration of the parasite is crucial to confirm the diagnosis.
Histological identification of the parasite by staining with Giemsa, and culture,
followed by isoenzyme typing, were the main methods employed. However,
parasitological confirmation was only obtained in 61% of these cases. There is a
need for more sensitive diagnostic tests - at present most centres rely on a battery
of different diagnostic methods including histology, culture, impression smears and
serology (Bergeret al 1987, Manson-Bahr 1987).
Lbb was isolated from 77 cases, Lmm from a further 29, and in one additional case
both Lbb and Lmm were identified from a single lesion. As it is more difficult to
culture Lbb compared with Lmm (which grows readily) (Manson-Bahr 1987), it is
likely that Lbb is the most prevalent of CL which requires treatment in Belize. It is
therefore imperative that all such cases receive effective systemic therapy to
prevent the late development of espundia (Bryceson 1987). The identification of
Lmm from a single lesion would not appear to remove this obligation. Lesions due
to Lbb and Lmm cannot be differentiated by their clinical features, although there is
an indication that those due to Lmm grow more slowly.
This study confirms the relative safety and efficacy of sodium stibogluconate which
has an unjustifiably poor reputation because of the toxicity of the earlier trivalent
antimonials (Bryceson 1987). The manufacturer of sodium stibogluconate
(PentostamR) has, until recently, recommended a 10 day course of 600mg iv daily
which may be repeated after a 10 day rest (Anonymous 1989). A single such
course cured 48.5% of our cases, with minimal side effects. A higher dose
regimen was subsequently introduced because of dissatisfaction with the high
proportion of soldiers requiring further courses of treatment, coupled with increased
confidence in the safety profile of the drug. This regimen consisted of an initial 14
day course of 600mg iv twice daily which was either continued, or repeated after a
break, if the ulcers were not healing satisfactorily. The initial 14 day course cured
63.9% of cases, and all those treated with this regimen healed with sodium
stibogluconate alone. It was notable that in both the low and high-dose regimens
90% of cases were cured when 24g of sodium stibogluconate had been
administered. This supports the principle that the efficacy of antimonials depends
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upon the total dose that can be administered within a given period of time
(Bryceson 1987). It is not possible to determine whether the 7 soldiers withdrawn
from the low dose regimen would have ultimately healed if sodium stibogluconate
had been continued, or whether there was true resistance to antimony at that dose.
It may be significant that 6 of these 7 soldiers had lesions due to Lmm. The
development of antimony resistance is a cause for concern and it has been linked
to inadequate initial daily doses and treatment duration (Bryceson 1987).
The high-dose regimen was associated with greater morbidity, particularly
arthralgia; this has been observed by others (Marsden et al 1985). The fall in white
blood cell count and rise in aminotransferase and alkaline phosphatase levels,
which are objective evidence of toxicity, although a feature of both regimens, were
of greater magnitude in those who had received the higher daily dose. Higher
dose regimens have been developed by others (Ballou et al 1987, Oster et al
1985) but significant dose-dependant toxicity has not been reported. There was
considerable individual variation in these biochemical and haematological changes,
which usually developed in the absence of symptoms, and which were reversible
after treatment stopped. It is unlikely, however, that factors other than the therapy
caused these changes because patients were confined to hospital during
treatment. It was reassuring that the serum urea did not rise during treatment as
renal tubular dysfunction has been reported during therapy (Veiga et al 1983). The
only cardiac effect noted in a group of 22 of these soldiers who had received the
low-dose regimen was a reversible flattening of the T-wave (Henderson & Jolliffe
1985). Data was not available to study the cardiac effects of the high-dose
regimen but these effects have been reported to be dose-related by others
studying sodium stibogluconate therapy in visceral leishmaniasis (Chulay et al
1985).
These results indicate that sodium stibogluconate 600 mg iv twice daily for 14
days, with an option to extend or repeat the course if necessary, is an appropriate
regimen for the treatment of Belizian CL and it can be expected to cure all cases.
The initial 14-day course cured 63.9% of these cases and, if extended to 20 days a
cure rate of 90% would be anticipated. The higher dose regimen is associated with
greater morbidity, but the development of drug resistance is less likely to become a
clinical problem if higher dose regimens are given in the first instance for a
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reasonable period of time. Other types of treatment have been tried on an ad-hoc
basis, but none has been found as useful and none formally evaluated.
All these soldiers were followed up for at least 3 months by army dermatologists
after which follow up was continued by their regimental medical officer. It is
unlikely that relapses would have gone unnoticed. No cases of mucocutaneous
leishmaniasis have occurred. In the light of the pattern of relapses observed it
would seem appropriate to keep patients with Belizian CL under review for at least
2 years.
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2.6 Summary: A retrospective study of cutaneous leishmaniasis in British troops
from Belize from 1978 to mid-1990
1. The medical records of 306 British soldiers in whom a clinical diagnosis of CL
had been made following a tour of duty in Belize were analysed. The diagnosis
had been confirmed by demonstration of the parasite in 187 (61%) of cases;
leishmania were cultured in 117 cases and L-D bodies were identified in a further
70 cases. In the remaining cases only a clinical diagnosis had been made and,
although the clinical features of this group did not differ significantly from those in
which the parasite was demonstrated, these cases were eliminated from further
analysis.
2. Lbb was identified by isoenzyme analysis in 78 cases and Lmm in a further 29
cases. In one case both Lbb and Lmm were identified from a single lesion.
3. Seventy-one percent of patients had a single lesion which usually occurred on
the exposed extremities. Lesions due to Lmm were more common on the head and
neck.
4. The mean diameter of the ulcers was 14.4mm and lesions had been present for
a mean of 9.9 weeks before treatment started. Those due to Lbb were larger yet
they had been present for a shorter time than those due to Lmm, indicating faster
growth. There were no other distinguishing features between them.
5. Treatment with sodium stibogluconate was effective. Two regimens were used
consisting of either 600-800mg daily given initially for 10 days, or 600 mg bd given
initially for 14 days. Of those allocated to the lower dose regimen 48.5% were
cured after the initial 10 day course and ultimately the ulcers of 93% healed
following more prolonged treatment at that dose. Of those allocated to the higher
dose regimen 63.9% were cured after the initial 14 day course and ultimately the
ulcers of all these soldiers healed after more prolonged treatment at that dose. In
both regimens 90% of patients were cured when a total of 24g of sodium
stibogluconate had been given.
6. Soldiers did not tolerate the higher dose regimen as well as the low dose
treatment - reports of myalgia, anorexia and malaise were more frequent in those
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who received the higher dose. A transient leucopenia and a rise in serum
aminotransferases was noted during treatment. These changes were dose
dependent but appeared to be settling 2 weeks after treatment.
7. No cases of mucocutaneous leishmaniasis were detected.
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CHAPTER 3
Hepatotoxicity of sodium stibogluconate
therapy.







3.1 Aims of the Investigation
To determine whether hepatocellular damage occurs during sodium
stibogluconate therapy.
To assess the effect of sodium stibogluconate therapy on hepatic metabolic
capacity.
3.2 Introduction
Sodium stibogluconate is the mainstay of treatment for most forms of
leishmaniasis. In recent years higher doses have been administered and
courses have lasted longer in order to achieve greater efficacy. A rise in
serum aminotransferases, ALT and AST, have been noted during treatment
for cutaneous disease. The results of the retrospective study described in
chapter 2, and those of Ballou et al (1987), indicate that these changes may
be dose-related. Increased serum aminotransferase levels indicate
hepatocellular damage but there is little correlation between their absolute
level and the degree of damage (Hayes & Bouchier 1989). It is therefore
important, particularly with the higher doses now in vogue, to determine
whether significant hepatocellular damage occurs during sodium
stibogluconate therapy and whether it is reversible after therapy has been
stopped.
Glutathione S-transferase B1 (GST, EC 2.5.1.18) has been shown to be a
very sensitive index of hepatocellular damage. Indeed, marked elevations
may be observed when other indices of liver damage remain normal (Bass et
al 1978, Beckett etal 1985a, Beckett etai 1985b, Beckett & Kelletetal
1985, Beckett & Hayes 1993). Furthermore, unlike aminotransferase levels,
plasma GST levels correlate with the histological changes observed in
patients with chronic liver disease (Sherman et al 1983).
The predominant GST isoenzymes found in human liver are cationic and
comprise at least 2 distinct subunits, Bi and B2 ( Stockman et al 1985).
These basic isoenzymes, like all basic cytosolic GST, are dimeric and the B1
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and B2 subunits combine to form dimers. Measurement of either of these
subunits is a more sensitive index of hepatocellular damage than serum
aminotransferase activity (Beckett et al 1985b, Beckett & Hayes 1987). This
greater sensitivity may be related to their intra-hepatic distribution. The
aminotransferases, GGT, and ALK P are predominantly localised to the
periportal hepatocytes and provide satisfactory markers of damage to this
zone of the liver, they are poor indicators of alcohol and drug-related liver
damage that may occur in centrilobular hepatocytes; frank centrilobular
necrosis may occur without any abnormalities being evident in the plasma
aminotransferases (Rappaport 1980). In contrast, GST Bi is found in very
high concentrations in hepatic cytosol and it is distributed evenly throughout
the entire liver lobule (Redick et al 1982, Hiley et al 1989). A further
advantage of GST over aminotransferases is its very short half-life in plasma
(less than 1 hour); it is therefore able to detect when hepatocellular damage
stops with more precision (Adachi et al 1980, Beckett & Hayes 1987, Beckett
& Hayes 1993). Assay of plasma GST has been used to detect
hepatocellular damage in a variety of diseases and also following toxic
damage due to alcohol, halothane and paracetamol (Beckett et al 1985a,
Hussey et al 1986, Beckett & Hayes 1987, Howie et al 1989, Hayes et al
1990).
Although aminotransferases and GST will detect hepatocellular damage, it is
more important, clinically, to determine whether or not the metabolic capacity
of the liver is impaired. The large metabolic reserve of the liver, particularly in
fit young men, means that the commonly measured parameters of hepatic
synthetic capacity, such as the prothrombin time and serum albumin, do not
become abnormal until the damage is extensive (Preisig 1986). This problem
has been solved by the development of clearance tests, analogous to the
creatinine and inulin clearance tests used to assess renal function (Preisig
1986, Hayes & Bouchier 1989, Mclntyre & Rosalki 1991). Hepatic clearance
depends upon 2 major factors: (a) hepatic blood flow (Q) and, (b) extraction
during passage through the liver (E):











The tracer used must be excreted only by the liver.
Tracers can be divided into 2 types: (a) flow dependent tracers - those in
which clearance varies with hepatic blood flow (i.e. E approaches unity) and,
(b) capacity limited - those in which clearance is independent of hepatic blood
flow (i.e. E is small). Capacity limited tracers are required to assess
metabolic capacity. Caffeine is an ideal tracer: it is readily available, it is well
absorbed orally, in the doses required it is completely innocuous, it is solely
metabolised in the liver (by cytochrome P450IA2) and it has a low extraction
(E) ratio. It has been shown that the clearance rate of caffeine from the
blood, following oral administration, directly reflects the amount of functioning
liver tissue. Furthermore, there is no overlap in clearance rates between
healthy subjects and patients with cirrhosis (Hayes & Bouchier 1989, Kalow &
Tang 1993, Preisig 1986, Renneret al 1984).
In this study hepatocellular damage and metabolic capacity were
prospectively assessed in patients treated for CL with either sodium
stibogluconate or aminosidine.
3.3 Methods
Thirteen consecutive British soldiers enrolled into the prospective,
randomised trial comparing the efficacy of sodium stibogluconate with
aminosidine for the treatment of Belizian CL (fully described in chapter 5)
entered this study. Each soldier gave his informed consent. Treatment with
either sodium stibogluconate 20 mg/kg/day (PentostamR, Wellcome,UK) or
aminosidine 14 mg/kg/day (max 1 g/day) (Gabbromicina, Farmitalia Carlo
Erba, Italy). Both drugs were given for 20 days by iv infusion: sodium
stibogluconate was given undiluted at 1 ml/minute whereas aminosidine was
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diluted in 400 ml N saline and given over 3 to 4 hours. Routine clinical and
laboratory monitoring was performed as described in chapter 5. Ulcers were
considered to have clinically healed when they had re-epithelialised and the
scar was flat and non-indurated.
Routine liver function tests (bilirubin, AST, ALT, GGT, ALK P and albumin)
were measured using an automatic analyser (BM/Hitachi 747, Boehringer
Mannheim, Mannheim, Germany) and plasma glutathione S-transferase Bi
(GST, E.C.2.5.1.18) was measured by radioimmunoassay (Hayes et al 1983).
The caffeine clearance test was performed according to the method described
by Setchell et al (1987): subjects were fasted overnight, a single dose of
225mg caffeine was administered in a cup of decaffeinated coffee which was
consumed over 5 minutes. Blood samples were taken at 0, 60, 90, 120 and
180 minutes and the caffeine level measured by high performance liquid
chromatography using an Altex 320 (Anachem, Luton, UK). All tests were
performed before treatment, at the end of treatment and 6 weeks after
treatment had stopped.
Five of these soldiers had been treated with sodium stibogluconate, 6 with
aminosidine and 2 soldiers were first treated with aminosidine and then,
because of their poor response, with sodium stibogluconate after a 6 week
break. The clinical features of these soldiers at the start of treatment and
their response to treatment are shown in table 3:1.
Statistical analysis. Changes in ALT, GST and caffeine clearance before
and at the end of treatment, and also before and 6 weeks after treatment
were analysed by a Wilcoxon matched-pairs test.
3.4 Results
The variations in the activity of ALT, the concentration of GST and the
caffeine clearances for each individual within each treatment group are shown
in figures 3:1, 3:2 and 3:3 respectively; the data can be found in appendix 2:1.
Sodium stibogluconate therapy was associated with a significant rise in ALT
(p<0.05) and GST (p<0.05) and a non-significant fall in caffeine clearance in
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Table 3:1







Mean age (years) 23.6 (sd 3.3) 25.0 (sd 2.7)
Mean weight (kg) 72.0 (sd 5.9) 72.2 (sd 6.5)
Mean number of lesions 1.3 (sd 0.8) 1.3 (sd 0.7)
Mean duration (weeks) 16.6 (sd 8.5) 10.6 (sd 4.6)
Mean size#(mm) 16.0 (sd 2.7) 10.6 (sd 4.6)
Site of lesions
Limbs 5 6
Head & neck 3 3
Trunk 0 1
L-D bodies observed 7 8
Positive culture 3 8
Clinically healed 6/7 5/8
*Two of these soldiers had been treated with aminosidine first.
#longest axis
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Figure 3.1: Changes in ALT before treatment, at the end of treatment,
and 6 weeks after treatment stopped for soldiers treated with sodium













Figure 3.2: Changes in GST before treatment, at the end of treatment,
and 6 weeks after treatment stopped for soldiers treated with sodium

















Figure 3.3: Changes in caffeine clearance before treatment, at the end of
treatment, and 6 weeks after treatment stopped for soldiers treated with












































every case. Log ALT correlated with log GST (r=0.87, n=40). The
prothrombin time and serum albumin did not change. Six weeks after
treatment stopped the ALT and GST had returned to near pre-treatment
levels in every patient as had the caffeine clearance in all cases except one.
This soldier had the greatest fall in caffeine clearance and his GST had
increased from 1.7 ug/l to 10.3 ug/l.
Aminosidine was not associated with a rise in ALT or a fall in caffeine
clearance. In one soldier a small rise in GST was noted and in a further
soldier, who was reported to consume large quantities of alcohol, the ALT and
GST were elevated before treatment, fell during treatment (alcohol was
forbidden during treatment which was supervised in hospital) but rose again
after discharge. Acute alcohol ingestion in heavy drinkers leads to increased
GST levels and their basal levels are often raised (Beckett & Hayes 1993).
3.5 Discussion
An increase in serum aminotransferases, indicative of hepatocellular damage,
has been reported during treatment of CL with sodium stibogluconate in
American soldiers (Ballou et al 1987) and it was also found in the
retrospective study of British soldiers in whom the elevation appeared to be
dose-dependent (chapter 2). The clinical significance of this observation is
not known. It is not possible to separate toxic from therapeutic effects on the
liver in visceral leishmaniasis but this should not be a problem in cutaneous
disease. Nevertheless, a further control group of soldiers with CL who were
treated with aminosidine, which is not known to be hepatotoxic, was
incorporated into this study. GST is a very sensitive and specific indicator of
hepatocellular damage and its short half-life in plasma allows early
recognition of when active cellular damage has ceased (Beckett & Hayes
1993). Treatment with sodium stibogluconate, but not aminosidine, resulted
in significant increases in ALT and GST confirming that sodium
stibogluconate causes hepatocellular damage. The elevation of both ALT and
GST indicate that damage was occurring either in all zones of the liver or that
it was confined to the periportal hepatocytes. The fall in both ALT and GST to
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pre-treatment levels 6 weeks after treatment stopped indicates that damage
had stopped.
The fall in caffeine clearance with sodium stibogluconate indicates that the
metabolic capacity of the liver was reduced. The numbers in this study were
insufficient to reach statistical significance but caffeine clearance fell in every
case. In most cases this appears reversible. Although the fall in clearance
could be accounted for by selective inhibition of cytochrome P-450 1A2, the
principle pathway by which caffeine is metabolised (Kallow & Tang 1993), the
concomitant changes in ALT and GST indicate that hepatocellular injury is the
probable mechanism. These change were not observed in soldiers treated
with aminosidine. Sodium stibogluconate is, therefore, implicated as the
cause.
Hepatotoxicity must therefore be added to the list of complications associated
with sodium stibogluconate therapy. In most cases of CL this will be of limited
clinical significance, but for those with pre-existing liver disease, and possibly
those with visceral disease, alternative therapy should be considered. In all
cases the concurrent use of other potentially hepatotoxic agents should be
avoided. The ALT gives a practical indication of the severity of acute
hepatocellular damage, but it will not detect any cases who sustain
permanent damage. The nature and extent of this hepatotoxicity require
further studies. The number of patients studied was small and not all patients
were studied before treatment, at the end of treatment and 6 weeks after
treatment. A larger study along similar lines would confirm and quantify the
acute toxicity. In addition, however, the caffeine clearance test should also be
repeated 6 months after treatment to determine whether there is a persistent
impairment of metabolic capacity.
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3.6 Summary: Hepatotoxicity of sodium stibogluconate therapy.
1. Sodium stibogluconate causes acute hepatocellular damage in a dose of
20mg/kg/day. The damage stops when treatment stops.
2. The ALT appears to be a reasonable measure of the amount of acute
damage.
3. The available data indicate that there is a fall in the metabolic capacity of
the liver during treatment with sodium stibogluconate.
4. Aminosidine is not hepatotoxic.
Chapter 4
Cardiotoxicity of sodium stibogluconate.
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4.1 Aim of the investigation
To detect and assess the cardiac effects of sodium stibogluconate therapy in
a dose of 20 mg/kg/day for 20 days.
4.2 Introduction
Antimony is cardiotoxic. In dogs it reduces myocardial contractile force
(Bromberger-Barnea & Stephens 1965) and in man the trivalent antimonials
have been associated with hypotension, bradycardia, ventricular tachycardia,
syncope, electrocardiographic (ECG) changes (deformed P-waves, QT
prolongation and T-wave flattening) and occasionally sudden death (Honey
1960, Davis 1961, Somers & Rosanelli 1962, Surawicz 1970, Sapire &
Silverman 1970, Stemmer 1976). Sodium stibogluconate was derived from
the trivalent antimonials as a safer alternative (Anonymous 1961, Stemmer
1976) but T-wave flattening and QTc prolongation during therapy have been
reported (Dempsey 1965, Kaplan et al 1978) and appear dose related
(Chulay et al 1985); similar changes have also been observed during
meglumine antimoniate therapy (Antezana et al 1992). It is not known if these
changes occur in association with dysrhythmias, other markers of myocardial
electrical instability, or changes in cardiac function although a study of 22
British soldiers treated with a 10 day course of sodium stibogluconate (10
mg/kg/day) noted transient ECG changes but no change in either heart
rhythm or echocardiographic parameters (Henderson & Jolliffe 1985).
Current regimes recommend the administration of prolonged high dose
sodium stibogluconate in order to increase efficacy (WHO 1990, Ballou et al
1987, Hepburn et al 1993). As the ECG changes are dose related (Chulay et
al 1985) it was important to determine whether these intensive regimes are
associated with significant deleterious effects on cardiac function.
I therefore performed a comprehensive, non-invasive, cardiac assessment in
12 soldiers before, during and after treatment with sodium stibogluconate (20
mg/kg/day for 20 days). In addition to routine haemodynamic, biochemical
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and electrocardiographic recordings, including 24 hour ambulatory recordings,
detailed assessments of left ventricular function, in both systole and diastole,
were made by systolic time interval analysis. The autonomic nervous system
is deranged in chronic heart failure (Nolan et al 1992), therefore a measure of
cardiac autonomic control was obtained by analysing the heart rate variability
over a 24 hour period (Ewing et al 1984, Ewing 1992).
Systolic Time Interval analysis. This technique relates echocardiographic
measurements of chamber size and blood flow to the cardiac cycle giving
sensitive indices of ventricular performance, thereby permitting detection of
any changes in cardiac function occurring as a result of therapy (Lewis et al
1974, Nishimura et al 1989).
A M-mode echocardiograph (Figure 4.1) gives details of chamber size at
each point in the cardiac cycle together with the duration of each phase. In
addition to these measurements, the fractional shortening and ejection
fraction can be calculated using the formulae:
Fractional = LVDD - LVSD
Shortening LVDD
where: LVSD = left ventricular systolic dimension





where: LVSV = left ventricular systolic volume
LVDV = left ventricular diastolic volume
(these volumes are calculated by cubing the appropriate
dimension)
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Figure 4.1a: Aortic M- mode echo showing the parasternal short axis
view at the level of the papillary muscles showing the cavity size
measurements.
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Figure 4.1b: Aortic M-mode echo showing the parasternal view
at the level of the aortic root (top) and a styalised recording
showing the systolic time intervals (bottom).
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Figure 4.2: Mitral Doppler recording (top) with a styalised representation
(bottom).
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Drug-induced impairment of left ventricular systolic function would be
indicated by a:
-fall in ejection fraction (EF)
-fall in fractional shortening (FS)
-rise in left ventricular cavity dimensions
-fall in left ventricular ejection time (LVET)
-rise in pre-ejection period (PEP)
-rise in the PEP/LVET (C) ratio (corrected for heart rate
by dividing by^cycle length)
A Doppler echocardiograph (figure 4.2) gives information about flow rates at
each phase of the cardiac cycle and this is particularly useful in assessing
diastolic function. There are 4 phases to diastole:
Isovolumic relaxation time (IVRT)
-this is the period when the left ventricle is relaxing but all the
valves are closed (therefore pressure is falling but the volume is
constant).
Rapid early filling phase (E-wave)
-most of left ventricular filling (-70-80%) occurs early in diastole
when a large pressure gradient exists from left atrium to left
ventricle.
Diastasis period
-the point at which left atrial pressure falls to left ventricular
pressure and flow stops.
Late atrial filling (A-wave)
-the atrium contracts and the final 20-30% of left ventricular
filling occurs prior to systole.
Abnormalities of left ventricular diastolic function often precede abnormalities
of systolic function (Bonow et al 1981a, Bonow et al 1981b, Clarkson et al
1994) and may therefore be more sensitive to small drug induced changes in
myocardial performance than measures of global systolic function. The
pressures are relatively low, therefore it is necessary to measure each
parameter during inspiration, expiration and apnoea. Drug-induced
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impairment of diastolic function would be indicated by an increase in stiffness
of the ventricle with consequent:
-increase in the IVRT
-fall in the rate of ventricular filling
4.3 Methods.
Subjects and drug regime. Twelve British soldiers, aged between 20 and
30 years, who had contracted CL during jungle training in Belize were studied.
All the subjects gave informed consent and their characteristics are shown in
table 4.1. None had pre-existing cardiac disease, renal disease, diabetes
mellitus or alcohol abuse. Those receiving concurrent medication were
excluded from this study. All subjects had a history of exposure to the
parasite, a typical skin lesion and in every case it was confirmed by
identification of LD bodies and in 9 cases also by culture. Treatment with
sodium stibogluconate (PentostamR, Wellcome, UK. batch no. A1058A,
manufactured January 1991 and stored at below 25°C) 20 mg/kg/day was
administered by i.v. infusion at 1 ml/min for 20 days.
Blood pressure and biochemical measurements were made before
treatment started (day 0), weekly during treatment (days 7,14), on the last day
of treatment (day 20), 2 weeks after treatment stopped (day 34) and 6 weeks
after treatment stopped (day 62). Blood pressure was measured at rest using
a mercury sphygmomanometer (diastolic phase V). Creatine kinase and
urea-stable lactate dehydrogenase were measured using commercial
photometric assays (Monarch, Allied Instrumentation Laboratory, Warrington
UK).
Electrophysiological measurements. Standard resting ECGs were
recorded using a Minigraph 12 lead recorder (Cardiac Recorders, London,
UK) before treatment weekly during treatment (days 7, 14, & 20) and at 2 and
6 weeks after treatment stopped. The ECGs were inspected and the cardiac
axis determined using standard criteria (Fisch 1992). The ECGs were then
projected onto a screen to produce a magnification of x5. Using the
isoelectric PR and post-T wave segments as the baseline, the height of the R-
wave in Vi and the sum of the heights of the T-waves in V4-V6, together with
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their calibration recordings, were measured directly using a ruler and used as
quantitative measurements of changes in QRS and T wave magnitude.
Twenty-four hour ambulatory ECGs were obtained, during normal ambulatory
activity, from each subject before treatment, on the last day of treatment (day
20) and 6 weeks after treatment stopped (day 62) using a miniature tape
recorder (Tracker, Reynolds Medical Ltd, Hereford. U.K.). Times of going to
bed and getting up were noted by the subjects. The tapes were analysed
using a Pathfinder arrhythmia analyser (Reynolds Medical Ltd, Hereford.
U.K.) at 120 times the original recording speed.
Supraventricular and ventricular ectopic beats were detected due to
differences in their timing and morphology, compared with continuously
updated characteristics of normal sinus beats (Neilson 1975). Each analysis
was monitored throughout by a specialist technician to confirm the ectopic
beats and scrutinise P wave morphology to exclude any episodes of non-
sinus rhythm. Where less than 24 hours of recording was suitable for
analysis the totals were adjusted to the equivalent of 24 hours. Recordings
shorter than 18 hours or with less than 40% of the tape suitable for analysis
were rejected. The mean waking and sleeping heart rates over the 24 hour
period were calculated, and the number of ectopic beats per 24 hours was
counted.
Changes in autonomic activity occur in association with changes in left
ventricular function (Nolan et al 1992) and may be important in the
pathogenesis of ventricular tachyarrhythmias (Verrier & Lown 1975). During
arrhythmia analysis, each normal RR interval was measured, the mean RR
interval calculated, and the 24 hour standard deviation (SD) of RR intervals
was measured as a general index of sympatho-vagal activity (Murray et al
1975, Ewing 1992). A specific measure of parasympathetic activity was
obtained by the NN50 time domain index in which each time the difference
between the RR intervals of consecutive normal beats increased by more
than 50 milliseconds a count was registered. The results were presented as a
total 24 hour count (NN50 count) (Ewing et al 1984, McAreavey et al 1989).
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Assessment of left ventricular function by echocardiography was
performed on ail subjects before treatment, on the last day of treatment (day
20) and 6 weeks after treatment stopped (day 62). All echocardiographic
measurements were obtained by the same operator (Mrs L. Fenn), using
identical equipment on each occasion, in a temperature-controlled laboratory
at 22°C. Following an overnight fast, the patients rested in the standard left
lateral position until their heart rate stabilised. Fleart rate was recorded from a
continuous ECG (lead 2) and respiration with a respiratory probe. High
quality simultaneous recordings of the echocardiogram, ECG,
phonocardiogram and respiration tracing were obtained using an Accuson
128/XP10 scanner (Allison, Mount Vernon, USA). Phonocardiograms were
obtained with a high impedance piezo-electric microphone with a low
frequency filter positioned at the base of the heart. Aortic valve closure was
taken as the start of the first high frequency vibration of the aortic component
of the second heart sound, checked for validity with the aortic echocardiogram
and aortic artefact on the Doppler recording. Two dimensional, M-mode and
Doppler echocardiograms were obtained with a hand-held 3.5 MHz phased
array transducer during quiet respiration. The simultaneous recordings were
printed onto thermal paper at 100 mm/s. Only subjects in whom clear
continuous echos from the septum and posterior wall, and in whom easily
recognisable aortic valve opening and closure were visible were used for the
study. Pulsed Doppler recordings of the mitral inflow velocity profile were
obtained by positioning the sample volume at the level of the mitral leaflet tips
in diastole in the apical four chamber view. Care was taken to obtain a
smooth velocity curve with well defined peaks and minimal spectral
broadening. Recordings were analysed using a sonic pen and a digitising
tablet (Sunnagraphics 0.1mm resolution, grid) interfaced to a Microcomputer
(Sun 3/180 workstation, Sunnagraphics, Connecticut, USA) using the
measurement techniques described below. A minimum of 5 cardiac cycles
were digitised for each subject on each occasion.
Left ventricular systolic function. Left ventricular internal cavity dimensions
were measured at end-systole and end-diastole using standard criteria from
the parasternal short axis view (Sahn et al 1978). The left ventricular ejection
fraction was derived from the measurements of left ventricular cavity size
using the cube formula and fractional shortening (%FS) by calculating the
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difference between left ventricular diastolic and systolic dimensions divided by
the diastolic dimension (Mason & Fortuin 1978, Freigenbaum 1986). The left
ventricular ejection time (LVET) and the total duration of electromechanical
systole were measured from the combined ECGs and aortic echocardiograms
(Hirschfeld et al 1975). The ratio of the pre-ejection period (PEP) to the left
ventricular ejection time (LVET), corrected for heart rate (PEP/LVET(C)),was
calculated as an additional heart rate-independent index of left ventricular
systolic function (Benchimol & Matsuo 1971, Gutgesell et al 1977).
Left ventricular diastolic function. Events during early diastole were
characterised by measurement of the isovolumic relaxation time (IVRT) and
quantitative analysis of the early (E) Doppler velocity profile. Events during
mid to late diastole were quantified by measurement of the diastasis period
(the time interval from the termination of early inflow to the onset of late
inflow) and quantitative analysis of the late (A) Doppler velocity profile. The E
and A waves were quantitatively analysed by measurement of their peak
velocities, acceleration and deceleration gradients, acceleration and
deceleration times, the area under each peak, and the ratio of peak early to
peak late inflow velocities (Nishimura et al 1989, Labovitz & Pearson 1987,
Spirito & Maron 1988). Measurements were made during inspiration,
expiration and inspiratory apnoea.
Statistical analysis was carried out using the statistical package SpSS-PC
(SpSS, Chicago, USA). Analysis of variance was used to test for changes of
the variables over time, a logarithmic transformation was used during testing
of the 'counts'. Linear regression analysis was used to test the fall in the




Number of Patients 12
Mean age (years) 23.7 (sd 3.1)
Mean Weight (kg) 71.7 (sd3.1)
Mean number of lesions 1.25 (sd 0.6)
Mean duration of lesions 21.3 (sd 9.9)
(weeks)
Mean size*(mm) 16.7 (sd 5.0)
Site of lesions:
limbs 11
head & neck 3
trunk 1
LD bodies seen 12/12
Positive culture 9/12 (6 Lbb, 3 Lmm)





The 20 day course of sodium stibogluconate (20 mg/kg/day) healed the ulcers
of 11 of the 12 subjects. All the subjects reported muscle aches and loss of
appetite during treatment but there were no other symptoms or signs, in
particular no subject developed any cardiac symptoms.
Blood pressure and heart rate. There was a fall in the systolic and diastolic
blood pressure (P<0.05) associated with an increase in heart-rate (p<0.05) at
the end of the course of treatment. Blood pressure and heart-rate returned to
pre-treatment levels 6 weeks after treatment stopped (tables 4.2 & 4.3).
Cardiac enzymes. There was no change in either serum levels of creatine
kinase or lactate dehydrogenase during treatment. A significant (P<0.05) rise
in lactate dehydrogenase was noted at both 2 and 6 weeks after the end of
treatment and the soldiers had returned to full physical duties. There was no
change in creatine kinase following treatment in 10 soldiers but in two it rose
to 1497 and 416 IU/L respectively 6 weeks after treatment stopped (table 4.2).
The soldier who had the highest level also had an elevated waking and
sleeping heart rate (95 & 90 beats/min) at that time compared to his baseline
(70 & 51) and post-treatment (83 & 62) rates. His CK remained high at 545
IU/L 14 months after treatment but at that time only 2% was CK-MB indicating
most was derived from skeletal muscle.
Electrocardiography. The cardiac electrical axis and R-wave magnitude did
not change during this study. There was, however, a steady and significant
(P<0.001) decrease in the sum of the heights of the T-waves in V4-6 as
treatment progressed followed by a return to pre-treatment levels 6 weeks
later (table 4.3, figure 4.2).
A complete series of analysable 24 hour recordings was only available for 7
subjects. In 2 cases a pre- treatment recording was not performed, in the
remaining 3 cases one of the series contained less than 18 hours of
analysable recording. There was no significant increase in supraventricular or
ventricular arrhythmias with treatment. Similarly, neither the 24 hour standard
Table4.2:Bloodpressurenbiochemicalanges(m an±s ) Pre-treatmentITreatm tRecoverydavOav7142034d62 BoodPressure (mmHg) Systolic126(3.61)14 7682. 8)1 3( 032.94(3 ) Diastolic84(2.02)78971.68)3( 4584.2. 289) Creatinekin s99(26.8)711 756( 7.4)61 . )05(24 3339 8 (IU/L) Lactatedehydrogenase189(10.5)748.82( .0)2 82421 .2)08(14.9)(IU/L)
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Figure 4.2: The change in the sum of the heights of the T waves
in leads V4 + V5 + V6 during treatment with sodium
stibogluconate.
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deviation of RR intervals nor the NN50 count changed significantly during the
course of this study (table 4.3).
Left ventricular function. There were no significant changes in left
ventricular cavity dimensions or measures of left ventricular systolic function
(table 4.4). Similarly, the indices of early and late left ventricular diastolic
function did not change with treatment (table 4.5).
4.5 Discussion
The pentavalent antimonials, sodium stibogluconate and meglumine
antimoniate, remain the mainstay of treatment for leishmaniasis. Their
precise composition is not known and, indeed, it may vary depending upon
the source and batch (Marsden 1985). They contain moieties of very different
molecular weights (range 100-4000 daltons) and a variable quantity of
trivalent antimony is present (Berman 1988, Marsden 1985). Although
sodium stibogluconate is rapidly excreted, largely unchanged, by the kidney,
5% is excreted as trivalent antimony which has a much longer half-life
(Bryceson 1987). The cardiotoxicity of trivalent antimonials is well established
(Berman 1988). It was, therefore, important to determine whether the sodium
stibogluconate regimen (20 mg/kg/day for 20 days) currently used to treat
American cutaneous leishmaniasis causes cardiac damage.
These results demonstrate that this regime has no measurable effect on left
ventricular systolic or diastolic function in fit young adults. There was no
biochemical evidence of drug induced myocardial injury during therapy.
There was, however, a significant (p<0.05) increase in lactate dehydrogenase
when the soldiers had returned to physical duties after completing treatment.
This remains unexplained. In the larger study reported in chapter 5 a
significant rise in lactate dehydrogenase was not detected. A significant
(p<0.05) increase in creatine kinase 6 weeks after the completion of therapy
was also noted, but this was entirely due to a large elevation in 2 subjects,
one of whom had an elevated heart rate. Although his creatine kinase
remained elevated, most was derived from skeletal muscle which may be
relevant to the myalgia reported during treatment in all subjects. It was not
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possible to identify either of these subjects when the echocardiographic
recordings were examined in a blinded manner by an independent observer
(Dr GR Sutherland).
Treatment is associated with a significant, reversible, fall in blood pressure
and an increase in heart rate. The cause of these changes is not immediately
apparent from our study, but it is likely that they represent a peripheral
vasodilatory effect of the drug, since cardiac function remained normal
throughout the study in all subjects.
There are, however, antimony-induced effects on the heart. Serial ECGs
show a progressive fall in T-wave amplitude during treatment which frequently
progresses to T-wave inversion. It returns to normal soon after treatment
stops. Similar changes, related to the cumulative dose of antimony
administered, have been reported by others (Chulay et al 1985) but this study
confirms that these changes occur during treatment with the currently
recommended regimen. The trivalent antimonials, tartar emetic and sodium
antimonyl tartrate, in therapeutic doses, produce T-wave depression in 60-
99% and prolongation of the QT interval in 9-79% of patients (Berman 1988).
Sodium stibogluconate also produces prolongation of the QTc interval during
treatment but only when doses of over 20 mg/kg/day are used or if treatment
is continued for over 30 days (Chulay et al 1985). The ECG changes
observed by us and others (Chulay et al 1985) are similar to those described
for trivalent antimonials. They are probably due to the accumulation of
trivalent antimony during treatment causing changes in ventricular
repolarisation. Changes in ventricular repolarisation are known to be
associated with an increased risk of ventricular tacharrhythmias (Merx et al
1977) which may be the principle mechanism of sudden death during
antimony therapy. Impaired autonomic function (Kleiger et al 1987) and the
presence of frequent arrhythmias also increase the risk of sudden death
(Multicentre 1983), but neither of these risk factors were present during
treatment with sodium stibogluconate in this study. The isolated changes in
ventricular repolarisation may not increase the risk of sudden death although
a larger study would be need to investigate this relationship in detail.
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In conclusion, the standard treatment regimen for American cutaneous
leishmaniasis (sodium stibogluconate 20 mg/kg/day for 20 days) is not
associated with measurable impairment of cardiac function using
echocardiographic parameters of systolic and diastolic function. The
electrocardiographic changes observed during treatment may be caused by
the accumulation of trivalent antimony but they were not associated with
electrical instability assessed by arrhythmia analysis and heart-rate variability.
However, we cannot exclude more subtle abnormalities or idiosyncratic
reactions.
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4.6 Summary: Cardiotoxicity of sodium stibogluconate.
1. The standard treatment regimen for American cutaneous leishmaniasis
with sodium stibogluconate (20 mg/kg/day for 20 days) is not associated with
measurable impairment of cardiac function using echocardiographic
parameters.
2. There was a progressive fall in T-wave amplitude during treatment. This is
likely to be caused by the accumulation of trivalent antimony causing changes
in ventricular repolarisation. However, the ECG changes were not associated
with electrical instability assessed by arrhythmia analysis and heart-rate
variability. If higher doses of sodium stibogluconate were administered, if the
treatment period were prolonged or if renal function were impaired then
significant toxicity may be anticipated.
3. There was an unexplained increase in lactate dehydrogenase 6 weeks
after treatment when the soldiers had returned to their full physical duties.
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5.1 Aims of the investigation
To compare the efficacy of parenteral aminosidine with that of parenteral
sodium stibogluconate for treatment of Belizian cutaneous
leishmaniasis in British troops.
To compare the adverse effect profile of aminosidine with that of sodium
stibogluconate.
To assess the efficacy of sodium stibogluconate 20 mg/kg/day for 20 days.
5.2 introduction
The treatment for New World CL is unsatisfactory. Sodium stibogluconate is
the mainstay of therapy but there are concerns about both its safety and the
development of resistance. Its efficacy for the treatment of Belizian CL was
confirmed in chapter 2 and it appears to be enhanced if longer courses at a
higher daily dose are administered, albeit at the cost of greater morbidity and
toxicity. Indeed extrapolation of the results indicated that a single 20 day
course of sodium stibogluconate 600mg twice daily would cure 90% of cases;
such a regimen may offer a reasonable balance between efficacy and toxicity.
Although these results are in broad agreement with those obtained for
L.panamensis in Panama (Ballou et al 1987), predictions made from data
collected retrospectively have many inherent flaws and must be formally
tested in a prospective trial. The British Army was unusual in using a fixed
daily dose in preference to a dose adjusted for body weight. The WHO and
the US Defence Department recommend a dose of 20 mg/kg/day for New
World CL (Berman 1988, WHO 1990).
Sodium stibogluconate is a far from ideal agent, but at the present time there
is no highly effective alternative available. Aminosidine, however, has shown
early promise; it has anti-leishmanial activity both in vitro and in vivo, it is an
effective and well tolerated alternative to sodium stibogluconate for visceral
leishmaniasis, when given parenterally, and for CL caused by L.major when
used as an ointment (chapter 1). At the start of this study its efficacy in New
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World CL was unknown and therefore an assessment was needed. Recently
an ointment containing 15% aminosidine and 12% methylbenzethonium
chloride shown to heal experimental lesions in mice caused by Belizian
strains of both Lmm and Lbb (El-On et al 1993). The same ointment healed
74% of lesions in an open, uncontrolled study in Belize. (Weinrauch et al
1993). In my opinion, Belizian CL should be treated systemically because
most cases of CL in that country are due to Lbb which may cause
mucocutaneous disease. Although cases of MCL are not frequently seen in
Belize, a soldier with MCL from the Belizian Defence force, was recently
investigated and treated at the Walter Reed Army Medical Center. He had
never been out of Belize (Magill, personal communication). The efficacy of
systemic aminosidine in American CL was unknown. The objective of this
study was to determine whether or not parenteral aminosidine and optimal
sodium stibogluconate were of similar efficacy and whether or not
aminosidine offered advantages in terms of toxicity and patient tolerance.
This was a preliminary, randomised, open trial conducted entirely by a single
observer. A large, blind trial was planned if the results were encouraging.
5.3 Patients and Methods
The study was open, randomised and prospective. It was carried out at the
army medical facility in Edinburgh and I performed all the clinical
observations, took all the samples and administered almost all the treatments
personally. It was approved by the Army Medical Services Research and
Ethics Committee and all the patients gave their written informed consent
(appendix 4.1). All the patients were British soldiers who had contracted CL
in Belize and whom had not received any anti-leishmanial therapy for at least
3 months. A full medical history was taken and a general physical
examination was performed. Detailed records were made and these included
the age and weight of each soldier, the dates of their tour of duty in Belize,
and the appearance, duration, size and site of each lesion. If more than one
lesion was present then details of each lesion were obtained, but a
representative one was selected as the study lesion and all procedures and
































2 & 6 weeks after treatment
audiogram - before & after treatment
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An elliptical, full thickness, skin biopsy was taken from the indurated edge of
the study lesion: the skin was cleaned with 6% hydrogen peroxide and then
infiltrated with 2% lignocaine (± adrenaline according to the site), the defect
was closed with adhesive strips. Each specimen was divided into 3 parts for
histological examination, impression smear and culture. Impression smears
were prepared by gently pressing the tissue against a clean, dry microscope
slide 4 to 5 times, following which the slide was air dried and then fixed in
95% ethanol for 3 minutes. The slides were then stained with H&E and
examined for the presence of LD bodies. The specimens for culture were
inoculated into "sloppy Evans" media, with added gentamicin, and dispatched
to Dr. D. Evans for incubation. If a culture was established, the isolate was
typed by isoenzyme analysis (Evans 1989). Specimens for histological
examination were formalin-fixed and paraffin-embedded. Sections were
stained with H&E and examined for the presence of LD bodies.
The clinical diagnosis was confirmed by identifying LD bodies histologically
and/or by culture in every case before entry to the study. If necessary, the
diagnostic procedures were repeated.
Soldiers were randomly allocated (using a computer generated random
allocation list supplied by Dr. Drake, Farmitalia Carlo Erba, UK) to receive
either aminosidine 14 mg/kg/day (max 1 g daily) (Gabbromicina, Farmitalia
Carlo Erba, Italy, batch N1004 manufactured Oct 1991) or sodium
stibogluconate 20 mg/kg/day (Pentostam, Wellcome, UK., batch A1058A
manufactured Jan 1991). The sodium stibogluconate was stored in the dark
at below 25°C, and once opened it was stored at 4°C with no bottle used for
more than 10 days. Intravenous treatment with each drug was given for 20
days: the aminosidine was diluted in 400 ml normal saline and infused over 3
to 4 hours, the sodium stibogluconate was given undiluted at 1 ml/minute.
Monitoring. I asked each soldier about his general well being and,
specifically, about muscle pains, appetite and nausea everyday before
treatment was given. A physical examination, including assessment and
measurement of the study lesion, pulse and blood pressure recordings, a full
blood count (haemoglobin, white cell and platelet count) (Sysmex NE8000,
Sysmex, Japan), urea, electrolytes and creatinine, liver function tests (LFTs:
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bilirubin, ALT, AST, GGT, ALK P and albumin) (BM/Hitachi 747, Boehringer
Mannheim, Mannheim, Germany), cardiac enzymes (creatine kinase (CK)
and lactate dehydrogenase (LDH)) (Monarch, Allied Instrumentation
Laboratory, Warrington, UK) urinalysis and an electrocardiogram (Minigraph,
Cardiac Recorders London, UK) were performed before treatment, weekly
during treatment and again 2 weeks and 6 weeks after treatment finished. An
audiogram (CA 850, Amplivox, Kidlington, Oxford, UK) was performed before
and at the end of treatment. A further skin biopsy was taken 6 weeks after
the end of treatment (figure 5.1).
Assessment of cure. Lesions were considered to have clinically healed
when the ulcer had completely re-epithelialised and the scar was flat and non-
indurated. Soldiers were followed up for at least 6 months to ensure that the
lesion did not reactivate. Parasitological cure was defined as an absence of
LD bodies and a negative culture.
Statistical analysis. The difference in cure rates between the 2 treatment
groups was evaluated using a Chi-squared test with Yates correction. The
monitoring parameters were compared at each time point with the pre-
treatment baseline using a paired t-test. The analyses were performed using
the statistical software 'Minitab' (Minitab INC, State College PA, USA)
5.4 Results
Thirty-four soldiers were enrolled into the study: 17 received aminosidine and
17 received sodium stibogluconate. Their characteristics are shown in table
5.1.
Efficacy. A complete clinical cure, assessed 6 weeks after treatment had
stopped, was observed in 10 (59%) given aminosidine and 15 (88%) given
sodium stibogluconate, table 5.2. Sodium stibogluconate was not statistically
more effective (0.5>p>0.1). No lesion that was considered to have clinically
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Table 5.1
Clinical features of the study soldiers.
Aminosidine Sodium Stibogluconate
Number of soldiers 17 17
Age (years) 23.8 (sd 3.6) 23.5 (sd 3.8)
Weight (kg) 72.8 (sd 7.1) 73.3 (sd 6.6)
Number of lesions 1.58 (range1-5) 1.76 (range1-3)
Age of lesion at start
of treatment (weeks) 15.7 (sd 10.3) 10.9a (sd 5.8)
Size of lesion at start
of treatment*3 (mm)
ulcer 18.6 (sd 14.5) 11.8 (sd 5.8)
induration 28.0 (sd 17.9) 25.4 (sd 13.5)
Site of study lesion
head & neck 4 4
trunk 1 1
limbs 12 12





a = excluding one soldier who contracted CL 4 years earlier
b = longest axis
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healed had reactivated during follow up of at least 6 months (mean 11.4, sd
6.1 months) (figure 5.2).
All 7 soldiers whose lesions had not healed with aminosidine were
subsequently successfully treated with sodium stibogluconate. One of the 2
lesions which did not fulfill the criteria for healing with sodium stibogluconate
had re-epithelialized but the scar was indurated at the 6 week assessment;
this soldier did not receive further treatment and his lesion has not reactivated
during follow up of 16 months. Another soldier, treated with aminosidine, had
two large ulcers on his neck, one of which was the study lesion, and a small
papule on his left knee; both the neck lesions healed (and he therefore
counted as a cure) but the papule on his knee enlarged and subsequently
ulcerated. A biopsy was taken from that lesion 4 months later and LD bodies
were identified. He was then given a course of sodium stibogluconate and
the lesion healed.
Leishmania were not cultured nor were LD bodies identified 6 weeks after
treatment had stopped (ie parasitological cure) from 9 of 17 lesions treated
with aminosidine and 10 of 17 lesions treated with sodium stibogluconate
(table 5.2).
Toxicity of aminosidine. Aminosidine was generally well tolerated: only 2
adverse clinical events were recorded. One soldier reported myalgia from
days 14 to 19 of treatment. Another, who had no previous history of skin
problems, developed a widespread itchy papular eruption on day 11 which
was unresponsive to treatment with a topical betamethasone 17-valerate, but
which resolved 14 days after he stopped treatment on day 18 (figure 5.3).
There was no significant change in any of the monitoring parameters with the
exception of a small (<3g/l), but significant (p<0.05), rise in albumin on days
20, 34 and 64 (figure 5.4). In particular there was no significant change in
urea or creatinine and urinalysis was consistently negative. There was no
change in any of the soldiers' audiograms. The data is shown in appendices









Culture negative 4/5 5/7
Parasitological cure3 9/17 10/17
Post-treatment results
LD bodies^ 8/17 7/17
Lbb 4/9 0/7
Lmm 0/3 1/3
a = no LD bodies seen and culture negative.
b = includes both definite LD bodies and basophilic intracellular fragments.
Toxicity of sodium stibogluconate. Sodium stibogluconate was not well
tolerated; all the soldiers reported myalgia which started after 12-17 days of
treatment and persisted until 2-4 days after the course finished. Symptomatic
treatment with indomethacin was only partially effective. Six soldiers reported
loss of appetite and 3 reported headaches. One soldier developed an
erythematous macular rash after 17 days of treatment which resolved 2 days
after treatment stopped (figure 5.5). There was no significant change in
pulse, systolic or diastolic blood pressure, or cardiac enzymes. In 2 soldiers
there was a large rise in creatine kinase 6 weeks after treatment. A
progressive diminution in the T-wave of the ECG was noted as treatment
proceeded but no other abnormality was detected. Significant (p<0.05) falls
occurred in the WBC count at days 7, 14 and 20, and in the platelet count at
days 14 and 20. In one patient the platelet count to 59 x 109/L therefore
treatment was stopped after 19 days. There was no change in either urea or
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Figure 5.2a: Lesion due to Lmm before treatment.
Figure 5.2b: Lesion due to Lmm 6 weeks after treatment with
aminosidine.
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Figure 5.2c: Lesion due to Lmm 1 year after treatment with aminosidine.
Figure 5.3: Rash during aminosidine treatment.
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Figure 5.5: Rash during sodium stibogluconate therapy.
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creatinine, and urinalysis was consistently negative. A rise in
aminotransferases (ALT and AST) occurred during treatment which, although
settling, remained elevated (p<0.05) 6 weeks after treatment. A rise in ALK P
at days 14 and 20 and 2 weeks after treatment stopped and a small (<3g/l),
but significant (p<0.05) fall in serum albumin at the end of treatment and 2
weeks after treatment stopped were also noted. All these parameters had
returned to normal when the soldiers were reviewed 3 months after treatment.
These changes are shown in figure 5.4. The data are shown in appendices
4.3, 4.5 and 4.6.
5.5 Discussion
The literature on cutaneous leishmaniasis contains numerous reports of
'effective' treatments most of which are based on reports of one or two cases
or small, uncontrolled series (Bryceson 1987). Given the self-healing nature
of many of the lesions, including those from the New World (Herwaldt et al
1992), it is mandatory to assess any potential treatment in a controlled clinical
trial. Ideally there should be a placebo group, to assess the rate of
spontaneous healing, and also a group given optimal conventional treatment.
However, in Belize most cases of CL are due to Lbb which may progress to
MCL; this makes the use of a placebo ethically unacceptable. The low rate of
spontaneous remission (approximately 6% of lesions caused by Lbb in
neighbouring Guatemala (Herwaldt et al 1992)) would also make a placebo
group unacceptable to the army, and to the soldiers, many of whom would be
unable to perform their full duties until resolution.
The data from the retrospective study in chapter 2 indicated that a single 20
day course of sodium stibogluconate 600mg bd would cure approximately
90% of cases. It is more usual to use a dose adjusted for body weight and
the current recommendation is to use 20mg/kg/day (Berman 1988, WHO
1990). This has the advantage of avoiding toxicity in smaller soldiers,
although for most it represents a greater daily dose (mean weight 73 kg,
therefore 600mg bd = 16.4 mg/kg/day). A dose of 20mg/kg/day for 20 days
was, therefore, selected in order to aid comparison and because this regimen
had been shown to cure 90% of lesions caused by L.panamensis from
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Panama (Ballou et al 1987). The results confirmed that it would cure 88% of
lesions from Belize. However, there was considerable morbidity, particularly
towards the end of the course of treatment, with all patients reporting muscle
pains and many also suffering nausea during the final 7 days. This was
coupled with falls in the white blood cell and platelet counts, indicative of bone
marrow toxicity, and elevations in the aminotransferase levels, indicative of
hepatocellular damage. The haematological abnormalities returned to normal
after treatment. The hepatotoxicity has been more fully investigated in
chapter 3. Two soldiers developed a rise in creatine kinase 6 weeks after
treatment, by which time they had returned to full physical duties. In one this
remained elevated 14 months after treatment; at that time only 2% was CK-
MB indicating most was der ived from skeletal muscle. In view of the myalgia
exptrienced by the soldiers during treatment further assessment is needf In
the first instance the CK and CK-MB should be measured in a large sample of
soldiers who have been treated with sodium stibogluconate. Those in whom
an abnormality is detected and 2 control groups: (1) those who do not appear
to be affected and, (2) normal soldiers who have not received sodium
stibogluconate should be studied. Assessment should include creatine kinase
levels before and after exercise, electromyography, and a muscle biopsy.
Aminosidine is less efficacious, but better tolerated, than sodium
stibogluconate. Although the difference in efficacy did not reach statistical
significance in this study, this is almost certainly a reflection of the lack of
power of the study rather than the absence of a real difference. A larger
study has just been completed in Colombia and the results are similar -
aminosidine healed 60% of lesions and sodium stibogluconate healed 95% of
lesions. Unfortunately the species of leishmania was not identified and close
monitoring for toxicity was not possible in that study (Berman, personal
communication). Aminosidine appears to be relatively inactive against Lbb -
the most common type of CL in Belize. It is these cases that are of most
importance clinically; not only are they unlikely to heal spontaneously, but
they may cause MCL. However, aminosidine has been shown to be
efficacious in visceral leishmaniasis and it may prove to be of use in other
types of CL. The safety of aminosidine shown by this study, and that in
chapter 3, is encouraging. In this study the aminosidine was administered
intravenously over 3-4 hours. Chunge et al (1990) and Thakur et al (1992),
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administered it intramuscularly. Scott et al (1992), gave it intravenously over
100 minutes (to mimic the pharmacokinetic profile of intramuscular
absorption) but encountered high tone deafness and impairment of renal
function during treatment despite assaying drug levels. I was not able to
assay drug levels and high-tone hearing impairment would have had profound
consequences for a soldier's career. The regimen used in this study was
suggested by Dr. ADM Bryceson and Dr. P. Olliaro who had been involved
with the study reported by Scott et al (1992).
The concept of parasitological cure (ie the absence of LD bodies and a
negative culture following treatment) was of little use because it was difficult
to be confident that intracellular basophilic fragments were not viable
leishmania. A post treatment culture alone, which by definition identifies
viable organisms, was useful but the small numbers in this study preclude
meaningful conclusions. It is possible that leishmania persist in healed
lesions. Cure usually results in life-long protection from the disease which is
mediated by the cell-mediated immune response; this in turn could be
maintained by the continuous antigenic stimulus provided by the persistence
of a few live parasites (Aebischer 1994). A study of recurrent disease caused
by L.braziliensis subspecies in Colombia showed that in 50% of cases
parasites cultured from secondary or tertiary lesions were indistinguishable by
3 independent methods (zymodeme, schizodeme and karyotype analyses)
from the leishmania isolated during the primary infection. Fi|hermore,
secondary lesions caused by the same parasites were usually close to the
site of the original lesion, whereas those caused by different parasites were
usually located elsewhere (Saravia et al 1990). If viable leishmania do persist
this may have important consequences if the patients subsequently become
immunosupressed. Relapse, induced by immunosuppression, after a 'cure'
has been demonstrated in mice (de Rossell et al 1992).
In conclusion, aminosidine is not as efficacious as sodium stibogluconate for
the treatment of CL from Belize, particularly in those cases due to Lbb. It is,
however, safe and well tolerated; if its efficacy in other forms of leishmaniasis
is established then it may have a place in the therapy against those forms of
leishmaniasis. The cure rate attained with a single course of sodium
stibogluconate can be increased to approximately 90% as predicted in the
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retrospective study in chapter 2. However, there is a considerable increase in
toxicity, which, although reversible, may occasionally be serious and require
intervention; careful monitoring is therefore essential.
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5.6 Summary: Aminosidine (paromomycin) versus sodium stibogluconate in
the treatment of cutaneous leishmaniasis from Belize.
1. Aminosidine is less efficacious than optimal sodium stibogluconate for the
treatment of Belizian CL.
2. Aminosidine is relatively inactive against Lbb which is the most important
cause of Belizian CL.
3. Aminosidine is well-tolerated and safe.
4. A single course of sodium stibogluconate 20 mg/kg/day for 20 days will
heal 88% of lesions.
5. This intensive regimen of sodium stibogluconate is associated with more
morbidity and toxicity, particularly thrombocytopenia, leucopenia and
hepatocellular damage, than the previously used low dose regimens. Careful
monitoring during treatment is, therefore, required.
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Chapter 6
The diagnostic Pathology of Belizian Cutaneous
Leishmaniasis.







6.1 Aims of the Investigation.
To describe the pathological changes observed.
To assess the value of impression smears in diagnosis.
To assess the value of routine haematoxylin and eosin (H&E) versus Giemsa
staining of biopsy material.
To assess the value of a post-treatment biopsy in patient management.
To make a preliminary assessment of the value of immuno=3tbcVl€miSt?3 as a
diagnostic aid.
6.2 Introduction
American CL is usually diagnosed clinically on the basis of a typical lesion in
conjunction with an appropriate history of exposure, but, because the
differential diagnosis is extensive and treatment for most patients involves the
relatively toxic pentavalent antimonials, it should be confirmed, ideally by
demonstrating the parasite. Unfortunately, no single test is optimal. It is
therefore usual to perform several, such as histology, impression smears,
culture, serology, and/or a Montenegro test, depending upon the facilities
available locally.
Belizian cutaneous leishmaniasis can be caused by either Lmm or, more
commonly, Lbb. The lesions are clinically indistinguishable and must be
differentiated by culture and isoenzyme analysis (chapter 2). Histological
examination of the lesion is the most widely available method of investigation,
but the number of leishmania present falls with the passage of time and they
are reputed to be particularly scanty in lesions due to Lbb (Gutierrez et al
1991). In the absence of leishmania the histology may resemble that of
syphilis, tuberculosis and sarcoidosis (Lucas & Kirkham 1991), although the
nature of the inflammatory reaction pattern should allow a probable diagnosis
to be reached. Lesions caused by Lmm may heal spontaneously whereas
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those due to Lbb are unlikely to do so (Herwaldt at al 1992), added to which
there is the danger of late mucocutaneous disease. Hence, it is especially in
those patients with Lbb, in whom the diagnosis is most important, that
histological confirmation proves most difficult. The retrospective review
(chapter 2) revealed that LD bodies had been identified in only 141 of 306
cases (46%), although histological examination had not always been
performed. Although culture may be more sensitive than histology (Lucas,
personal communication), it is not so widely available and the delay in
obtaining a definitive result means that treatment is generally started before
the result is available. This is a particular problem for the army because
soldiers are often unable to perform their full duties until their lesion has
healed. A rapid, reliable, diagnostic test would therefore be of great value, as
would a method of improving the sensitivity of histological assessment.
Giemsa staining of biopsy material is reputed to be superior to the routinely
used H&E stain because the parasites are stained red whereas they appear
blue-grey with H&E (McKee 1989). Impression smears have been reported to
be a useful rapid diagnostic test (Berger et al 1987). The value of
immunocytochemistry is disputed (Lucas & Kirkham 1991, Salinas at al 1990).
A further problem is the assessment of cure. In routine clinical practice lesions
are considered to have healed when they have re-epithelialised and the scar
is flat and non-indurated. However, small numbers of viable parasites could
remain and may lead to subsequent reactivation of the lesion. Alternatively,
lesions in which all the parasites have been killed may be slow to re-
epithelialise and further, unnecessary, treatment may be given. It is not known
whether a biopsy taken after treatment assists in patient management.
In order to address these issues, I undertook a collaborative study with a
pathologist, Dr L Biddlestone and we examined the sections together.
6.3 Methods
Patients. British soldiers who had contracted CL whilst on duty in Belize were
treated at the army medical facility in Edinburgh as part of a prospective,
randomised study to assess the efficacy of aminosidine versus sodium
stibogluconate, which is fully described in chapter 5. Skin biopsies were
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taken from the indurated edge of the lesions before treatment and each
specimen was divided into 3 parts for histological examination, impression
smear and culture.
Six weeks after the completion of treatment soldiers were reassessed, lesions
were considered to have healed clinically if the ulcer had completely re-
epithelifized and the scar was flat and non-indurated. A second biopsy was
taken at that visit for histology from every lesion and for culture in 31 of the 34
lesions (the specimens were lost in transit in the remaining 3 cases).
Impression smears were prepared by gently pressing the tissue against a
clean, dry microscope slide 4 to 5 times following which the slide was air dried
and then fixed in 95% ethanol for 3 minutes. The slides were then stained
with H&E and examined for the presence of amastigotes.
Culture. Specimens were inoculated into "sloppy Evans" media, with added
gentamicin, and dispatched for incubation. If a culture was established the
isolate was typed by isoenzyme analysis (Evans 1989).
Histology. The skin biopsies were formalin-fixed, routinely processed, and
paraffin-embedded. Sections were stained with H&E and 11 biopsies were
also stained with Giemsa. Histological assessment included: (1) a semi¬
quantitative assessment of parasite numbers (table 6.1), (2) the extent and
nature of the inflammatory cell infiltrate including granulomas, (3) the
presence or absence of dermal necrosis or fibrosis, (4) assessment of the
epidermal changes, and (5) an attempted classification using (i) the general
histological groupings described by Ridley (1987) and, (ii) a specific
classification developed for Brazilian CL (Ridley et al 1980).
Immunocytochemistry. In a preliminary study, a polyclonal antibody, raised
in rabbits against Lmm promastigotes (kindly gifted by Dr J Alexander,
Glasgow), was used to identify organisms in formalin-fixed sections. A
standard avidin biotin technique was used to stain 4 biopsies from lesions
which were culture positive and which contained easily identifiable LD bodies
on the H&E sections. Three biopsies contained Lmm and one Lbb.
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6.4 Results
Clinical and culture. Thirty-six pre-treatment biopsies from 34 soldiers,
mean age 23.6 (sd 3.6) years, were taken. In 2 cases the same lesion was
sampled twice. The lesions had been present for a mean of 14.6 (sd 8.3)
weeks when the biopsy was taken. All but 2 of the lesions were ulcers (mean
diameter 15 (sd 10) mm), usually with an indurated margin; one was a plaque
and the other a papule surmounted by a crust.
Culture was established from 23 lesions, Lbb was identified in 16 and Lmm in
7. Histologically well formed LD bodies were seen in 16 of the culture positive
specimens (10 Lbb and 6 Lmm) but it was only possible to identify fragments
of basophilic material in the remainder (table 6.1).
A total of 9 lesions failed to heal 6 weeks after treatment; in 6 the ulcer never
re-epithelialized and in the others the scar remained indurated. None of the
25 lesions that healed has reactivated during follow up of at least 4 months
(range 4 - 24 months). Leishmania were cultured from 5 lesions after
treatment (4 Lbb and 1 Lmm); the ulcers persisted in 2, induration was the
only sign in a further 2 and the remaining lesion (due to Lmm) had completely
healed clinically (and it has remained healed for over a year without further
treatment). Eight of the 9 cases which failed to heal were successfully re¬
treated with sodium stibogluconate (in the remaining case the scar was
indurated at the assessment 6 weeks after treatment; this settled without
further treatment). Five were re-biopsied and culture was negative.
Histology. All 36 pre-treatment biopsies had a similar appearance with a
moderate to heavy dermal infiltrate including lymphocytes, plasma cells and
macrophages (figure 6.1). Lymphocytes were the predominant cell type in 21,
plasma cells in 11 and macrophages in 4 biopsies. Granulomatous
inflammation was a prominent feature. In 30 biopsies palisading around foci
of necrosis or degenerate collagen was seen. In 11 biopsies well-formed
epithelioid cell granulomas with giant cells and a rim of lymphocytes were
present (figure 6.2). In 33 biopsies there was a variable degree of dermal
connective tissue change with collagen degeneration, small foci of necrosis or
larger confluent areas of dermal necrosis. The majority of untreated lesions
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exhibited notable epidermal changes with florid epithelial hyperplasia in 35
and epidermal ulceration in 29 biopsies. An acute inflammatory cell infiltrate
accompanied this ulceration and neutrophils were also seen around the areas
of dermal necrosis. Parasites were typically scanty. They were usually found
within the clear cytoplasm of macrophages, often in the superficial part of the
lesion. Obvious parasites were identified in 20 biopsies and were numerous
in 7 biopsies (figure 6.3). In some biopsies parasites with a classical
morphology were not identified, although intracellular basophilic fragments
were present which may have represented degenerate forms. H&E stained
sections were superior to Giemsa stained sections for identification of the
parasites. Histological examination and culture of biopsy material were
complementary techniques for identification of the organisms with LD bodies
definitively identified in 4 culture negative cases (table 6.1).
Table 6.1
Semi-quantitative organism counts in pre-treatment biopsies.
Histological Scores
Culture 0+ 1 + 2+ 3+ 4+ 5+
Lmm 1 2 0 2 2 0 (n=7)
Lbb 6 7 0 2 1 0 (n=16)
Negative 9 3 1 0 0 0 (n=13)
Key: 0+ = no well-defined organisms, fragments only.
1+ = small numbers of LD bodies focally.
2+ = small numbers of LD bodies throughout the lesion.
3+ = moderate/numerous LD bodies focally.
4+= numerous LD bodies in most parts of the lesion
5+ = very numerous LD bodies in all parts of the lesion.
Post-treatment biopsies were taken from the 25 clinically healed lesions 6
weeks after treatment and within 8 weeks of re-epithelialisation. All showed a
marked reduction in the inflammatory response (figure 6.5). The residual
infiltrate consisted of perivascular lymphocytes and 9 of the 25 biopsies
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showed well-formed dermal granulomas which included epithelioid
macrophages and giant cells. In contrast to the pre-treatment biopsies,
dermal necrosis was uncommon and the main change seen in the dermis was
fibrosis. The previously marked epidermal changes had also regressed; in 12
there was no residual abnormality and in the remainder there was only mild
acanthosis. Definite parasites were only very occasionally observed in these
biopsies but intracellular basophilic fragments were frequently present.
Post-treatment biopsies from lesions which had failed to heal after the first
course of treatment showed little change from their pre-treatment
appearance. The moderate to heavy inflammatory infiltrate persisted and in 7
dermal necrosis was still present although fibrosis was also seen. Moderate
numbers of parasites had been identified before treatment in 4 of these
lesions and they were still present in 2; in one the number of parasites
identified in the sections had increased. Biopsies following a second,
successful course of treatment were available in 5 cases. They were
indistinguishable from the lesions which had responded to the first course of
treatment. There were no histological features in the pre-treatment biopsies
of this group of cases to distinguish them from the majority which responded
to the first course of treatment.
Impression smears. Parasites were often difficult to identify in the
histological sections and the smears were even more difficult to interpret
(figure 6.6). In no case were definite parasites identified in the smears when
the histological sections were equivocal.
Immunohistochemistry. Immunocytochemical staining of sections from 3
biopsies from which Lmm had been cultured gave specific, strong staining of
LD bodies with low background staining (figure 6.4). However, in this
preliminary study, only biopsies with readily identifiable parasites were used.
One biopsy, from which Lbb had been cultured, was negative even though
definite organisms were easily seen on the H&E sections.
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Figure 6.1: Pre-treatment biopsy from a lesion caused by Lmm stained
with H&E.
Figure 6.2: Dermal inflammatory infiltrate showing plasma cells and
giant cells. Lesion caused by Lbb.
« t\ • **< :j! ho-'.v>«
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Figure 6.3: Numerous LD bodies in the dermis in a lesion caused by
Lmm.
Figure 6.4: Biopsy shown in figure 6.3 labelled with anti-Lmm polyclonal
antibody and stained by immunoperoxidase.
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Figure 6.5: Lesion caused by Lbb 6 weeks after successsful treatment.
Figure 6.6: Impression smear from a lesion caused by Lmm.
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6.5 Discussion
The pathological changes seen in CL show enormous variation from one
geographical area to another reflecting differences in the endemic species
and, perhaps, the genetic background of the patients. Attempts have been
made to develop a histological classification analogous to the spectrum
developed for leprosy, but the pathological diversity of CL has made the
development of a widely applicable classification very difficult (Ridley 1980,
Ridley & Ridley 1983). Even when a single location has been studied and
descriptive histological classifications developed, the interrelationships
between the histological patterns is not clear and their prognostic value
uncertain. However, some characteristic histological features of New World
lesions due to Lbb and Lmm have been identified (Ridley 1979, Ridley 1980,
Ridley et al 1980, Ridley & Ridley 1983, Gutierrez et al 1991). In general,
there are small numbers of parasites with an inverse correlation between their
detection and the age of the lesion. Destructive changes are seen in both the
dermis and epidermis and these are often extensive and more marked than in
Old World CL. The pre-treatment biopsies in this study showed all of these
features. Parasites were typically scanty with only 7 of 36 biopsies scoring 3+
or more on the semi-quantitative scoring system used. No correlation was
found between the duration of the lesions and the number of parasites seen,
but the number of cases was small and the lesions were all of short duration
(Ridley et al 1980). Dermal necrosis was usually present and it was extensive
in 10 biopsies. Ridley and Ridley (1983) described palisading of
macrophages and granulomatous inflammation around areas of dermal
necrosis in Belizian CL and this was seen frequently in these cases.
Epidermal ulceration and florid hyperplasia were also common.
During histological assessment an attempt was made to classify the
pathological appearances using both classifications described by Ridley
(Ridley et al 1980, Ridley 1987). These classifications were difficult to use
with many individual cases not fitting readily into a single group; this has been
the experience of others (Bittencourt & Barral 1991 ).
Some general principles relating histology to prognosis have been proposed.
The presence of epithelioid and giant cells has been associated with a good
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response to treatment and healing (Ridley 1980, Gutierrez et al 1991). The
prognostic significance of dermal necrosis is unclear. Some studies suggest
that a necrotising reaction either within the granulomas or in the dermal
collagen is associated with the rapid elimination of parasites and a good
prognosis (Ridley 1980), whilst others found that necrosis was associated
with resistance to drug therapy (Gutierrez et al 1991). Nine of the 34 lesions
in this study failed to heal following one course of treatment, and, of these, 7
included areas of dermal necrosis and 2 included epithelioid cell granulomas.
There were no histological features predictive of non-responsive lesions prior
to treatment. However, these patients were participating in a randomised
comparative trial of aminosidine and sodium stibogluconate and, as 7 of the 9
lesions which failed to heal were treated with aminosidine this may reflect a
difference in drug efficacy rather than inherent differences in the lesions. The
results of this trial are reported in chapter 5.
Healed biopsies were characterised by dermal fibrosis with a scanty chronic
inflammatory cell infiltrate together with well formed granulomas in
approximately half the biopsies.
Impression smears were of no additional value to the histological sections. It
has been suggested that they are useful as a rapid diagnostic technique in CL
(Berger et al 1987). However, speed is not critical and, even if it were, rapid
processing techniques would allow examination of fixed paraffin-embedded
tissue on the same working day. In this series, as previously described in
New World CL, parasites were very scanty in many of the histological
sections and in none of these cases were parasites identified in the
impression smears. In these cases the associated inflammatory response,
dermal and epidermal abnormalities (not available in the impression smears),
together with the clinical details, give important additonal clues to the
diagnosis.
Immunoperoxidase techniques using polyclonal antibodies raised against
leishmania have been found useful for demonstrating LD bodies in formalin-
fixed tissue (Sells and Burton 1981). These preliminary results, with an anti-
Lmm antibody, demonstrated specific staining of the LD bodies with minimal
background staining. However the utility of this antibody is limited by the
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absence of cross-reactivity with Lbb. In view of the difficulties in positively
identifying leishmania when organisms are scanty further polyclonals should
be developed. Most useful would be one which cross-reacts with all types,
but a battery of species specific antibodies would also be of great value.
It is important to assess the adequacy of treatment, particularly in cases
caused by Lbb which may cause mucocutaneous disease. The results
indicate that the changes observed histologically following treatment
confirmed the clinical appearances. Basophilic intracellular fragments were
frequently seen in biopsies taken 6 weeks after treatment. Although easily
identified, well-formed LD bodies were very infrequent and, provided the
inflammatory reaction was resolving, these appearances were not
incompatible with healing. No lesion in which this material was seen
reactivated provided healing was clinically complete and the culture negative.
It is probable that these intracellular fragments represent cellular debris or
non-viable leishmania rather than viable parasites; immunocytochemistry may
be of use in resolving this problem. Histological examination of a post-
treatment biopsy is therefore of limited clinical value.
In contrast, culture, which by definition detects viable organisms, is of value
following apparently successful treatment. In one case Lmm was identified in
a completely healed scar and in 2 others Lbb was identified in lesions which
had re-epithelialised but remained indurated. Those in which Lbb was
identified were retreated. Whereas re-epithelialisation is an objective end-
point, which can be easily judged by all physicians, induration is much more
subjective; in one case it was minimal and could have been easily overlooked.
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6.6 Summary: A study of the diagnostic pathology.
1. Histological examination and culture of a biopsy from the lesion are
complementary techniques which provide a parasitological diagnosis in most
cases.
2. Parasites are typically scanty. There is a characteristic dermal infiltrate,
composed of lymphocytes, plasma cells histiocytes and giant cells, which is
frequently associated with necrosis. This is associated with florid epithelial
hyperplasia.
3. The classifications proposed by Ridley were difficult to use.
4. No particular pathological change correlated with prognosis.
5. Giemsa-stained sections provide no advantage over standard H&E stained
sections.
6. Impression smears contribute little to confirming the diagnosis.
7. Immunocytochemistry with specific anti-leishmanial antibodies holds
promise for definitive parasite identification. It is likely to be particularly useful
in cases where parasites are scanty or if intra-cytoplasmic material of
uncertain origin is seen.




Conclusions and Management Guidelines
What have these studies told us about Belizian cutaneous leishmaniasis and
its management? The retrospective case-note review described in chapter 2
showed that most soldiers had a single lesion consisting of an ulcer on the
exposed extremities. The lesions referred for treatment were more often due
to Lbb than Lmm. Ulcers caused by Lbb develop more rapidly and are, on
average, larger than those caused by Lmm. However, it is not possible to
distinguish them by their clinical appearance.
Sodium stibogluconate is an effective treatment. The efficacy of a single
course can be increased from 48.5% to 63.9% by increasing the total dose
administered from 6g (600mg/day for 10 days) to 16.8g (1200 mg/day for 14
days) (chapter 2). Extrapolation of these results indicated that 24g would
cure 90%; the study in chapter 5 showed that 20 mg/kg/day for 20 days
(average total dose 29.2g) cured 88% but with considerable morbidity during
the final 7 days of treatment. This regimen was associated with some toxicity
characterised by falls in the white cell and platelets counts, hepatocellular
damage and impairment of hepatic metabolic capacity (chapters 3 and 5).
There is a progressive fall in ECG T-wave amplitude during treatment, this
was reversible. Cardiac function, assessed by echocardiography, is not
impaired during treatment and there is no evidence of electrical instability
(chapter 4). All patients develop myalgia during treatment and in some there
are marked elevations in creatine kinase which persist for months after
treatment. This should be investigated further to confirm that it is skeletal,
and not cardiac, muscle that is involved and to delineate the nature of
inflammation and its relationship to exercise.
In contrast, aminosidine was well tolerated and safe, but it was less
efficacious than sodium stibogluconate, particularly against Lbb. It is
therefore unlikely to be of value as a treatment for Belizian cutaneous
leishmaniasis (chapter 5).
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It can be difficult to confirm a clinical diagnosis of American cutaneous
leishmaniasis. In the retrospective study this was only achieved in 61% of
cases. However, culture and histological examination of a biopsy from the
edge of a lesion permits a diagnosis in nearly all cases. There are fewer
parasites present in lesions due to Lbb, but the characteristic inflammatory
infiltrate can alert the pathologist to their presence. Preliminary results
indicate that immunohistochemistry may facilitate the positive identification of
scanty parasites in otherwise equivocal sections. A polyclonal which reacts
with all types of leishmania should now be developed. The response to
treatment can be judged clinically 6 weeks after the end of treatment. This
should be supplemented by an attempt to culture the parasite from the lesion.
Viable organisms may be persist in the presence of only minimal induration
which can be difficult to evaluate (chapter 6). Relapses can occur for up to 2
years (chapter 2).
On the basis of these results I propose some management guidelines (figure
7.1). The diagnosis should be confirmed histologically and by culture from a
biopsy taken from the active edge of the lesion.. Sodium stibogluconate
20mg/kg/day iv should be administered for 20 days. The result of treatment
should be assessed 6 weeks after the completion of treatment both clinically -
complete re-epithelialisation with a flat, non-indurated, scar, and by culture of
a biopsy. Treatment may be repeated if the lesion has not healed or if the
post-treatment culture is positive. If a second course of sodium
stibogluconate is ineffective then alternatives, such as ketoconazole or
pentamidine, could be considered.
Treatment should be carefully monitored. A full blood count, urea and
creatinine, liver function tests, creatine kinase and lactate dehydrogenase
should be measured and an ECG performed before treatment, weekly during
treatment and 6 weeks after treatment. Monitoring should contiue thereafter
until the parameters return to normal. Patients should be kept under review








Sodium Stibogluconate (20mg/kg/day for 20 days IV)
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Appendix 1.1:
Data on 187 cases in which parasitologicai confirmation of the diagnosis was
obtained
1.Number of lesions on each soldier
No of lesions All cases Lbb cases Lmm cases
1 133(71%) 57(74%) 19(65.5%)
2 30(16%) 13(16.9%) 6(20.7%)
3 15 (8%) 5 (6.5%) 4(13.8%)
4 7 (3.7%) 1 (1.3%) 0
5 1 (0.5%) 0 0
12 1 (0.5%) 1 (1.3%) 0
187 77 29
2.Site of lesion
All lesions Lbb lesons Lmm lesions
Head & neck
total 73 (25.8%) 23 (20%) 20 (46.5%)
nose 2 (0.7%) 0 1 (2.3%)
cheeks 33 (11.7%) 13 (11.4%) 9 (20.9%)
lip 2 (0.7%) 0 2 (4.7%)
chin 5 (1.8%) 3 (2.6%) 0
ears 11 (3.9%) 6 (5.2%) 2 (4.7%)
eyelid 1 (0.35%) 0 1 (2.3%)
forehead 3 (1.1%) 0 1 (2.3%)
scalp 1 (0.35%) 0 0
neck 15 (5.3%) 1 (0.8%) 4 (9.3%)
Trunk 44 (15.5%) 16 (14%) 8 (18.6%)
Arms 33 (11.7%) 12 (10.5%) 6 (14%)
Hands & wrists 72 (25.4%) 27 (23.7%) 4 (9.3%)
Legs 56 (19.8%) 32 (28%) 5 (11.6%)
Unknown 5 (1.8%) 4 (3.5%) 0
283 lesions 114 lesions 43 lesions
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3. Size of lesions
Site of lesion All cases Lbb cases Lmm cases
Head &neck
total 11.5 (44/73) 14.0 (16/23) 8.2 (13/20)
nose 11.0 (1/2) -- (0/0) 11.0 (1/1)
cheeks 11.0 (19/33) 11.6 (8/13) 8.3 (7/9)
lips 14.0 (1/2) -- (0/0) 14.0 (1/2)
chin 16.0 (5/5) 21.7 (3/3) -- (0/0)
ears 14.4 (5/11) 13.0 (4/6) -- (0/2)
eyelids - (0/1) (0/0) -- (0/0)
forehead 7.5 (2/3) -- (0/0) 5.0 (1/1)
scalp 15.0 (1/1) -- (0/0) -- (0/0)
neck 9.2 (10/15) 14.0 (1/1) 10.3 (3/4)
Trunk 12.0 (34/44) 14.0 (14/16) 12.8 (8/8)
Arms 13.8 (29/33) 17.1 (11/12) 14.0 (6/6)
Hands & wrists 16.1 (52/72) 19.8 (22/27) 16.3 (3/4)
Legs 16.2 (43/56) 17.7 (27/32) 15.0 (5/5)
Unknown 25.0 (1/5) 25.0 (1/4) -- (0/0)
Totals
mean size 14.4mm 17.0mm 12.3mm
sd 9.3 10.3 6.5
% known 71.7% 79.8% 81.4%
Table shows the mean diameter of ulcer in mm (longest axis). (The proportion of
lesions in which the size was known is shown in brackets).
4. Duration of lesion before treatment started (weeks)
All cases Lbb cases Lmm cases
mean 9.9 8.8 12.5









Comparason of clinical features of 187 parasitologically confirmed cases
with all 306 cases in which a clinical diagnosis of CL was made.
1. Number of lesions on each soldier
No of lesions Parasite shown All cases
1 133 (71.0%) 213 (69.6%)
2 30 (16%) 50 (16.3%)
3 15 (8%) 21 (6.7%)
4 7 (3.7%) 10 (3.3%)
5 1 (0.5%) 1 (0.3%)
6 0 6 (1.9%)
8 0 3 (1.0%)
9 0 1 (0.3%)
12 1 (0.5%) 1 (0.3%)
Total 187 306
2.Site of lesions
Parasite shown All cases
Head & neck
total 73 (25.8%) 122 (24.3%)
nose 2 (0.7%) 6 (1.2%)
cheeks 33 (11.7%) 44 (8.8%)
lip 2 (0.7%) 6 (1.2%)
chin 5 (1.8%) 8 (1.6%)
ears 11 (3.9%) 20 (4.0%)
eyelids 1 (0.35%) 10 (2.0%)
forehead 3 (1.1%) 5 (1.0%)
scalp 1 (0.35%) 1 (0.2%)
neck 15 (5.3%) 22 (4.4%)
Trunk 44 (15.5%) 49 (9.8%)
Arms 33 (11.7%) 51 (10.2%)
Hands & wrists 72 (25.4%) 132 (26.2%)
Legs 56 (19.8%) 142 (28.2%)
Unknown 5 (1.8%) 6 (1.1%)
Total 283 lesions 624 lesions
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3. Size of lesions.
Site of lesion Parasite shown All cases
Head & neck
total 11.5 (44/73) 16.3 (69/122)
nose 11.0 (1/2) 11.0 (1/6)
cheek 11.0 (19/33) 14.8 (26/44)
lip 14 0 (1/2) 12.6 (3/6)
chin 16.0 (5/5) 20.6 (8/8)
ear 14.4 (5/11) 13.7 (11/20)
eyelid -- (0/1) 5.0 (1/10)
forehead 7.5 (2/3) 22.5 (3/5)
scalp 15.0 (1/1) 15.0 (1/1)
neck 9.2 (10/15 19.3 (15/22))
Trunk 12.0 (34/44) 17.9 (39/49)
Arms 13.8 (29/33) 17.8 (44/51)
Hands & wrists 16.1 (52/72) 19.2 (87/132)
Legs 16.2 (43/56) 18.3 (73/142)
Unknown 25.0 (1/5) 32.0 (2/6)
Totals
mean size 14.4mm 18.0mm
sd 9.3mm 9.4mm
% known 71.7% 62.5%
(203/283) (314/502)
Table shows the mean diameter of the ulcer in mm (longest axis). (The proportion
of lesions in which the size was known is shown in brackets).
4.Duration of lesion before treatment started (weeks)








Table 1 Haematological and biochemical changes during treatment with
sodium stibogluconate 600mg/day for 10 days (total 6g).
The mean (x), standard error (se) and the number of soldiers in which it was









WBC 4-11 X 6.72 5.90* 7.19
x109/l sd 2.24 1.38 2.28
n 36 35 26
Hb g/l 13.5-18 X 15.6 15.4 15.4
sd 1.24 1.08 1.19
n 36 35 26
Urea 3-6.5 X 4.75 4.35* 4.33*
mmol/l sd 0.90 1.08 0.73
n 36 36 27
ALK P 36-92 X 73.0 74.7 81.7*
IU/I sd 25.7 19.6 31.6
n 36 36 26
GGT 11-54 X 23.8 26.8 28.3
mmol/l sd 26.6 17.9 25.8
n 36 36 26
ALT 6-37 X 21.8 84.6* 31.7*
mmol/ sd 20.0 70.0 37.2
n 36 36 26
AST 10-30 X 24.9 54.3* 29.8
mmol/l sd 17.2 38.0 26.4
n 36 36 26
Creatine 36-188 X 161 107* 141
Kinase sd 81.2 55.5 94.1
IU/I n 21 21 19
LDH 190-340 X 273 197* 264
IU/I sd 108 84 67
n 21 21 19
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Appendix 1.3
Table 2. Haematological and biochemical changes during treatment with
sodium stibogluconate 600mg twice daily for 14 days (total 16.8g).
Abbreviations as for table 1.
Normal Pre- Post- 2 Weeks after
range treatment treatment treatment
WBC 4.5-6.5 X 6.13 5.13* 7.04*
X109/I sd 1.04 1.20 1.38
n 23 23 12
Hb 13-18 X 14.9 14.9 14.9
g/i sd 0.84 0.94 1.39
n 23 23 11
Urea 3.1-6.1 X 4.73 4.58 5.33
mmol/l sd 1.11 1.24 2.17
n 24 24 12
ALK P 75-275 X 167 254* 226
IU/I sd 40 167 84
n 24 24 20
GGT 3-45 X 28.7 53.2* 42.5*
mmol/l sd 14.9 48.7 24.7
n 24 24 20
ALT 4-40 X 25.3 282* 66.6*
mmol/l sd 14.4 382 64.1
n 24 24 20
AST 11-45 X 22.8 * 178* 50.4*
mmol/l sd 9.8 249 50.9
n 24 24 20
Creatine 16-300 X 163 112* 209
Kinase sd 62.6 129 169
IU/I n 22 19 14
LDH 105-195 X 200 213 207
IU/I sd 43.9 73.9 77.2
n 22 19 13
































































































































































































































































































































































Key:GST=glutathioneS-transfersas(IU/L) CCL=affeineclearance(mL/mi ute) GGT=gammaluta yltransfeerase(IU/L) ALT=alanineminotransferase(IU/L) ALP=alkalinephosphatase(IU/L) ALB=albumin(g/L) PT=prothrombintime(seconds)
65 54 65 64 63 64
48 49 48 48 48 47
12 12 13 13 13 12
Appendix3.1 Dopplerechocardiographdata:mitralEw ve. CaseNo.TimRespAreacc lgradD celP kA ltiD c 1.A.C.Rxinsp8.1.62-3 883.10 064 exp8.37.16-4. 28.30.07 apnoea8.0811.35-4.3291.20.1 Postin p6.9946-2.978.40.01 exp7.004 8-3.3667.50. 812 apnoea7.294 53-3.1566.80.01 2.G.S.Rxinsp10.386 2-2.7978 90.01 exp9.197 51-3.238 .30.0716 apnoea9.885. 9-2.817 .30 0.17 Postin p9.6317-4.1682.00.06 exp10.153.08-3.0779.0.21 apnoea11.723.23-3. 187.60.051









































































































































































































































































































































































































































Appendix3.1(continued):Dopplerechocar iographdatamitr lEw ve. CaseNo.TimRespAreacc lgradDe celP kAc lti ccelm 12.R.M.Preinsp7 146.0-3.794.00..05 exp7.505 84-3.7164.60.0914 apnoea6.7356-2.875 .0.0716 Rxinsp9.847.26-2.244.00 07. exp9.925.79-2.8178.20 0.17 apnoea8.256.4-2.388.40.0618 Postin p10.978.19-3.732.30 08 exp9.4461- .428 .0.07.15 apnoea9.007.95-4.358.60.0815 apnoea=rec rdingduringh lins iratoryapnoeae c ltimdeccelera i(s)

























































































































































































































































































































































































































































































































































































































































































































































































































































































1 V l \ 1 J
Exp Apnoea
1 A.C. Rx 0.08 0.07 0.08
Post 0.07 0.06 0.06
2 G.S. Rx 0.09 0.10 0.09
Post 0.09 0.10 0.08
3 S.R. Pre-Rx 0.08 0.07 0.09
Rx 0.05 0.05 0.07
Post 0.08 0.09 0.09
4 M.L. Pre-Rx 0.09 0.08 0.09
Rx 0.09 0.08 0.10
Post 0.08 0.07 0.08
5 D.R. Pre-Rx 0.08 0.07 0.07
Rx 0.07 0.06 0.06
Post 0.07 0.07 0.07
6 J.F. Pre-Rx 0.07 0.07 0.07
Rx 0.08 0.08 0.08
Post 0.06 0.06 0.08
7 A.Y. Pre-Rx 0.07 0.07 0.07
Rx 0.06 0.07 0.07
Post 0.06 0.03 0.03
8 L.J. Pre-Rx 0.06 0.06 0.07
Rx 0.05 0.05 0.04
Post 0.06 0.09 0.05
9 N.S. Pre-Rx 0.06 0.05 0.07
Rx 0.07 0.06 0.06
Post 0.07 0.07 0.06
10 M.B. Pre-Rx 0.06 0.06 0.06
Rx 0.03 0.04 0.03
Post 0.05 0.04 0.04
Appendix 3.3 (continued):
Interventricular relaxation times (IVRT).
IVRT (s)
Patient Time Insp Exp Apnoea
11 D.B. Pre-Rx 0.06 0.07 0.04
Rx 0.04 0.07 0.08
Post 0.06 0.06 0.06
12 R.M. Pre-Rx 0.05 0.05 0.06
Rx 0.07 0.05 0.06
Post no phono - no ivrt
Key: Pre-Rx = before treatment
Rx = at end of treatment
Post = 6 weeks after treatment



















































































































































































































































































Keytoapp ndix3.4:Echocardi graphicdatfa ticM-modre rdin . LVDD=leftventriculardiastolicdiameter(c ) LVSD=leftventricularsys olicdiameter(c ) FS(%)=percentagefractionalshortening EF=ejectionfraction Q-A2=totaldurationfelectromechanicalsystole( ) LVET=leftventricularj ctiontime(s) PEP=durationofthepre-ejecti np riod(s)

































































































































Day 0 (Pre-Rx) 59.4 (7.15) 21.7 (1.55) 18.8 (1.94)
Day 7 61.3 (5.64) 22.4 (1.31) 14.7 (2.48)
Day 14 61.7 (5.69) 22.6 (0.58) 10.4 (1.88)
Day 20 (End-Rx) 61.7 (5.75) 21.2 (1.25) 7.4 (1.98)
Day 34 60.6 (6.71) 20.7 (1.95) 15.9 (0.69)
Day 64 58.0 (6.16) 20.0 (1.07) 18.5 (2.92)
The values shown are:
Heights of R waves measured in mm




An open prospective trial comparing systemic sodium stibogluconate
(Pentostam) with systemic aminosidine (paromomycin) in the treatment of
American Cutaneous Leishmaniasis.
You are being asked to participate in a study to investigate whether a new
treatment for cutaneous leishmaniasis is as effective as the standard
treatment used in the British army. The standard treatment consists of daily
injections of Pentostam for 20 days which cures nearly all ulcers, however,
many patients are unwell whilst having this treatment. The new treatment,
consisting also of daily injections for 20 days, has been reported to be safe
and to cause few problems. Although it is known to work in other forms of
leishmaniasis we do not yet know if it will work in patients with the form that
causes skin ulcers in Belize.
Before any treatment is started background information will be taken relating
to your disease and a sample (under local anaesthetic) will be taken to
identify the organism causing the infection. Your progress will be carefully
assessed by the doctor throughout the treatment and blood tests performed to
check for any ill-effects.
Your participation in this study is requested because the army medical
services are keen to develop a more acceptable cure for your illness,
however, it must be proven to work as well as the standard treatment.
If you enter the trial you will be given either the standard or the new treatment
determined at random. You are free to refuse to participate, either now or
later in during the study, and this will not affect the relationship between you
and your doctor, nor will it deprive you of the possibility of receiving other
treatments for your infection.
All information gained about you and your condition will be treated in the
strictest confidence.
If we find out information about these drugs which might affect your decision
whether or not to take part in the study we will make sure you are informed.
The doctor may stop your participation in the study at any time for safety
reasons.
Patient Written Consent
have read and understood the information sheet for
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Cutaneous leishmaniasis in British troops from Belize
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Summary The medical records of 306 British soldiers in whom a clinical diagnosis of cutaneous leishmaniasis
had been made following a tour of duty in Belize were analysed. Parasitological confirmation of the
diagnosis was established in 187 cases; leishmania were cultured in 117 cases and Leishman-
Donovan bodies were identified histologically in a further 7c cases. Leishmania braziliensis braziliensis
was identified in 78 cases and Leishmania mexicana mexicana in a further 29 cases. Seventy-one per
cent of patients had a single lesion which, in most cases, occurred on the exposed extremities. The
mean diameter of the ulcers was 14-4 mm. Treatment with sodium stibogluconate was effective. Two
regimens were used, consisting of either 600-800 mg daily given initially for 10 days, or 600 mg b.d.
given initially for 14 days. Of those allocated to the lower dose regimen 48-5% were cured after the
initial 10-day course, and ultimately the ulcers of 93% of patients healed following more prolonged
treatment at this dose. Of those allocated to the higher dose regimen 63-9% were cured after the initial
14-day course and ultimately the ulcers of all patients healed after more prolonged treatment at this
dose. A transient leucopenia and a rise in liver enzymes were noted during treatment, and these
changes were dose-dependent. No cases of mucocutaneous leishmaniasis were encountered.
American cutaneous leishmaniasis (CL) is a major
health problem in Central and South America, and is
increasing in incidence.1 It is being encountered more
frequently in temperate zones of the western world as
international tourism to endemic areas increases.
Although leishmaniasis has been recognized since an¬
tiquity, the epidemiology, clinical features and treatment
are poorly described in the literature. In 1978 the British
Army established a permanent garrison of approxi¬
mately 1500 troops in Belize, since when over 300
servicemen have been treated for CL. Initially, all cases of
Belizian CL were assumed to be caused by Leishmania
mexicana mexicana (Lmm) which causes a cutaneous
ulcer, which eventually heals spontaneously. However,
Leishmania braziliensis braziliensis (Lbb) was subse¬
quently identified in many of the cases.2 Although CL
due to Lbb also presents as a cutaneous ulcer, the
destructive mucocutaneous form of the disease ('Espun-
dia') may subsequently develop due to metastatic spread.
The clinical features and treatment of 187 cases of
Belizian CL, in which a parasitologically proven diagno¬
sis was made, are described.
Methods
Patients and methods
All servicemen in whom CL was suspected were referred
to the Dermatology Department of the Cambridge Mili¬
tary Hospital in Aldershot for clinical assessment, inves¬
tigation and treatment. A clinical diagnosis of CL had
been made in 306 servicemen between 1978 and mid-
1990, following a tour of duty in Belize. Their hospital
case notes were scrutinized and the following data
extracted: age; dates of Belize tour; date that the first
lesion was noticed; number, size and site of the lesions;
the results of histological examination of the lesion;
culture and isoenzyme typing2 of the parasite. Detailed
records were made of the treatment given including
dates, drug, dose, duration, side-effects, and the haema-
tological and biochemical parameters used in monitor¬
ing treatment. Resolution of the ulcers, an objective end-
point which could be assessed easily and reliably by all
physicians, was the standard criterion for cure. Patients
were closely supervised by Army dermatologists to
ensure that cure was attained and maintained for at
least 3 months. Thereafter, patients were usually fol-
Iowed-up by their regimental medical officer, and re-
referred if relapse occurred.
For the purposes of this study, analysis was limited to
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Figure 1. (a) Sites of lesions in cases due to
Lbb (• = 1% of lesions; total 114 lesions in
77 cases), (b) Sites of lesions in cases due to
Lmm (• = 1% of lesions; total 43 lesions in
29 cases).
the 187 cases in which the clinical diagnosis was
confirmed by demonstration of the parasite by culture
and/or histological identification of Leishman-Donovan
(LD) bodies. A comparison of the clinical features was
made between those cases in which Lbb was identified
and those in which Lmm was identified. During the early
part of the 12-year period covered by this study the main
treatment strategy consisted of an initial 10-day course
of intravenous sodium stibogluconate (Pentostam®)
600-800 mg daily. If the ulcers were not healing
satisfactorily this was either continued or repeated after
a break, as recommended by the manufacturer.3
Because patients required repeated courses a higher dose
regimen was subsequently adopted. This consisted of an
initial 14-day course of intravenous sodium stibogluco¬
nate 600 mg twice daily. Again, if the ulcers were not
healing satisfactorily, this was either continued or
repeated after a break. The success of these strategies
was compared. Haematological and biochemical para¬
meters prior to treatment, at the end of treatment, and 2
weeks after cessation of treatment, were available for 2
cohorts: one treated with 600 mg i.v. daily to a total of 6
g (36 cases) and a second treated with 600 mg i.v. twice
daily to a total of 16-8 g (24 cases). Cases were followed
up for at least 3 months after clinical cure.
Statistical analysis
Pretreatment lesion size and duration in the total patient
group, the Lmm and Lbb subgroups, and between the
two treatment strategies, were statistically evaluated
using an unpaired t-test. Differences in haematological
and biochemical parameters before, during and after
treatment, were evaluated using a paired t-test.
Results
A clinical diagnosis of CL was made in 306 otherwise
healthy male soldiers, mean age 23 years, who had
acquired their infection whilst on active service in Belize.
Confirmation of the diagnosis by demonstration of the
parasite was made in 18 7 cases (61%): a positive culture
was obtained in 117 cases, and LD bodies were identified
in a further 70 cases. Of the 117 culture-positive cases
the species was identified in 107: 77 were due to Lbb, 29
to Lmm, and in one case both Lbb and Lmm were
identified from a single lesion. Lesions started as small
inflammatory papules which gradually enlarged anc|
then ulcerated. The ulcer was often covered by ail
adherent crust which subsequently separated to expt^B
a necrotic ulcer base which was frequently second^^B
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Table 1. Features of the low- and high-dose
regimen cohorts Low-dose regimen High-dose regimen
Number of patients 101 72
Mean number of lesions 1-54 1-47
Mean duration of lesions prior to treatment (weeks) 9-16 (SD 6-9) 8-84 (SD 4-43)
Mean lesion size (longest axis of ulcer, mm) 15-89* (SD9-94) 12-3* (SD 7-74)
Lesion site
Head and neck 39 (25)1 28 (26)
Trunk 26(17) 16(15)
Arms 16 (10) 14(13)
Hands/wrists 42 (27) 25 (24)
Legs 31 (20) 20(19)




Lmm and Lbb 0 1
Not available 42 35
* Significant difference P<0 05.
t Numbers in parentheses are percentages.
infected with either Staphylococcus aureus or /f-haemo-
lytic streptococci. The fully developed lesion consisted of
a painless ulcer with a necrotic base and an indurated
violaceous margin. A total of 283 lesions were identified
in the 187 parasitologically confirmed cases: a solitary
lesion was present in 71%, two lesions in 16%, three
lesions in 8% and four lesions in 4%. One soldier had live
lesions and another had 12 lesions. Cases due to Lmm
and Lbb had similar numbers of lesions, and most
occurred on exposed body sites, with the head, neck,
wrists and hands accounting for 51% of lesions. Lesions
due to Lmm were more common on the head and neck
than those due to Lbb (Fig. 1). The mean diameter
(longest axis) of all ulcers was 14-4 mm (SD 9-3), lesions
on the head and neck being smaller than those else¬
where, at presentation. The lesions due to Lbb were
significantly (P<0-01) larger (mean diameter 17 mm)
than those due to Lmm (mean diameter 12-3 mm),
despite the observation that Lbb lesions had been present
for a significantly (PcO-05) shorter time (mean 8-8
weeks) than Lmm lesions (mean 12-5 weeks). Most
patients presented either during their Belize tour of duty,
orwithin 4 months of their return. One patient presented
11 months after his return.
Treatment started after a mean interval of 9-9 weeks
(SD 6-7) had elapsed after the first lesion was noticed.
Sodium stibogluconate was the mainstay of treatment.
[The ulcers of 166 soldiers healed with sodium stiboglu¬
conate alone, although there was a wide range in the
Ifcil dose required (mean 13-1 g, SD 7-2). During the
early part of the study 101 patients were treated with a
low (600-800 mg) daily dose regimen. In only one case
were clinical side-effects recorded—the patient reported
aching muscles after receiving 800 mg daily for 11 days.
The higher dose regimen (600 mg twice daily) which
was subsequently adopted was associated with greater
morbidity: of the 72 patients who received this regimen
three became nauseated and anorexic, 11 developed
myalgia, two developed chest pain (which was asso¬
ciated with tender costal cartilages), two reported non¬
specific malaise and two developed thrombophlebitis at
the site of the indwelling i.v. cannula, associated with
pyrexia. One patient developed cheiropompholyx,
although this resolved with appropriate treatment,
despite continuing sodium stibogluconate. One patient
developed an acute aseptic arthritis of his knee 2 days
after completing a course of 16-8 g stibogluconate, and
another developed severe hip pain, accompanied by a
creatine kinase of 25,290 IU/1, 14 days after receiving
23-4 g sodium stibogluconate. Both problems gradually
resolved over the following 4 months without specific
therapy.
Sequential haematological and biochemical monitor¬
ing parameters, assessed prior to treatment, at the end of
treatment, and 2 weeks after treatment was stopped,
were available for two cohorts. Although laboratory
data was available for other patients, it was not collected
systematically and, therefore, its analysis could have
been misleading. The first cohort received the standard
low-dose regimen consisting of 600 mg/day to a total of
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Table 2. Haematological and biochemical changes during treatment with sodium stibogluconate
Low-dose regimen High-dose regimen
Pretreatment Post-treatment Convalescent Pretreatment Post-treatment Convalescent
White cell count N 1 N N 1 N
Alkaline phosphatase N N t N T
Gamma glutamyl transferase N N N N T T
Alanine aminotransferase N T t N t T
Aspartate aminotransferase N t N N T t
Creatine kinase N
-
N N 1 N
Changes are indicated at the end of treatment and 2 weeks after treatment was stopped.
N. within normal range, arrows indicate signiticant variation (P<0-05) from the pretreatment value.
6 g (36 patients) and the other received the standard
high-dose regimen consisting of 600 mg twice daily to a
total of 16-8 g (24 patients). The characteristics of these
two groups are compared in Table 1. A mild, although
significant (P< 0-05), leucopenia was noted at the end of
treatment in both groups, but there was no change in
the haemoglobin level. The serum urea did not rise
during treatment. Serum transaminase levels (alanine
aminotransferase and aspartate aminotransferase) were
both elevated at the end of treatment, but had almost
returned to their pretreatment levels 2 weeks later. This
change was much more marked in the group which
received the high-dose regimen. The serum glutamyl
transferase was only elevated in the high-dose group at
the end of treatment, and had also almost returned to
normal 2 weeks later. The alkaline phosphatase level
was elevated in the high-dose group at the end of
treatment, and in both groups 2 weeks later. A transient
fall in serum creatine kinase at the end of treatment was
noted in both groups. There was no significant elevation
in the level of lactate dehydrogenase. These changes are
summarized in Table 2.
The low daily dose sodium stibogluconate regimen
(600-800 mg daily) was initiated in 101 soldiers.
Treatment was given for 10 days in the first instance,
after which it was either continued, or repeated after a
break. This initial 10-day course cured 49 (49%) of these
patients, and ultimately the ulcers of 94 (93%) healed on
this low-dose regimen. In seven of these patients treat¬
ment with sodium stibogluconate was stopped, and they
were given alternative treatment because of dissatisfac¬
tion with their clinical progress. The ulcers of 90% of
patients treated with this low-dose regimen had healed
after a cumulative dose of 24 g (i.e. 40 days' treatment).
The higher dose sodium stibogluconate regimen (600
mg twice daily) was initiated in 72 soldiers. Treatment
was given for 14 days in the first instance, after which it
was either continued, or repeated after a break. The
initial 14-day course cured 46 (63-9%) of these patients,
and ultimately the ulcers of all these patients healed on
this regimen. The ulcers of 90% of patients treated with
this regimen had clinically healed after a cumulative
dose of 24 g sodium stibogluconate (i.e. 20 days'
treatment).
Seven patients relapsed following healing of their
lesions. In six cases this occurred after an interval of
between 4 and 7 months, and in the seventh case after
19 months. Six were successfully re-treated with sodium
stibogluconate, and in the remaining case the lesion was
excised. Mucocutaneous leishmaniasis has not, as yet,
developed in any British soldier following service in
Belize.
Discussion
There are few reports which document the clinical
features of American cutaneous leishmaniasis,1,4"6 but
that of Llanos Cuentas et al.h describes the lesions in 182
cases with active disease. One of the problems with
interpretation of data from previous studies is that the
diagnosis was not confirmed by demonstration of the
parasite in all cases. In this study, although a clinical
diagnosis of CL was made in 306 cases, analysis was
restricted to the 187 cases in which the parasite was
demonstrated. In each patient a single lesion was
biopsied, and it was assumed that other, clinically
similar lesions in the same person, were of the same
aetiology. Our observation that over 70% of cases
presented with a solitary lesion, normally on the exposed
extremities, is similar to other reports. However, in this
study a greater proportion of lesions occurred on the!
hands and wrists compared with the legs. This may b^
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attributable to natives working in jungle areas with bare
legs, whereas British troops wore jungle boots and long
trousers. Also, a higher proportion of lesions due to Lmm
occurred on the head and neck—this has been attributed
to the biting habits of Lutzomyia olmeca olmeca, the vector
of Lmm which tends to bite at head level.1 The vector of
Lbb in Belize has not yet been established. The average
diameter of lesions at presentation was smaller than
reported in other studies, which is probably the result of
earlier presentation. Medical officers and troops receive
instruction about CL prior to a Belize tour of duty, and
are given a 'Leishmaniasis warning card', resembling a
credit card, upon their return, to show to any medical
attendant they consult during the following 2 years.
Referral for assessment to the Military Hospital in
Aldershot is recommended.
Diagnosis may be difficult. In the early stages the
lesion resembles an insect bite, and later the presence of
secondary infection may lead to further diagnostic
difficulty. Demonstration of the parasite is crucial to
confirm the clinical diagnosis. Histological identification
of the parasite by Giemsa staining, and culture, followed
by typing, were the main methods employed. However,
parasitological confirmation of the diagnosis was
obtained in only 61% of cases. There is a need for more
sensitive diagnostic tests—at present most centres rely
on a battery of different diagnostic methods consisting of
histology, culture, touch smears' and serology.8
Lbb was identified from 77 cases, Lmm from a further
29, and in one additional case both were identified from
a single lesion. As it is more difficult to culture Lbb than
Lmm, which grows readily,8 it is likely that Lbb is the
most prevalent type of CL in Belize. It is therefore
imperative that all such cases should receive effective
systemic therapy to prevent the subsequent develop¬
ment ofmetastatic mucocutaneous disease.9 The identi¬
fication of Lmm from a single lesion does not remove this
obligation. Lesions due to Lbb and Lmm cannot be
differentiated by their clinical features, although there is
an indication that those due to Lmm grow more slowly.
This study confirms the relative safety and efficacy of
pentavalent antimony compounds, which have an
unjustifiably poor reputation because of the toxicity of
the earlier trivalent antimony compounds.9 The manu¬
facturer of sodium stibogluconate recommends a 10-day
course of 600 mg i.v. daily, which may be repeated after
a 10-day interval.3 A single course cured 48-5% of our
cases, with minimal side-effects. A higher dose regimen
was subsequently introduced because of dissatisfaction
with the high proportion of patients requiring further
Bourses of treatment, coupled with increased confidence
in the safety profile of sodium stibogluconate. This
regimen consisted of an initial 14-day course of sodium
stibogluconate 600 mg i.v. b.d. which was either
continued, or repeated after a break, if ulcer healing was
not satisfactory. This initial course cured 63-9% of cases,
and all those treated with this regimen ultimately healed
with sodium stibogluconate alone. It was notable that in
both the high- and low-dose regimens 90% of patients
were cured when 24 g of sodium stibogluconate had
been administered. It is not possible to determine
whether the seven patients withdrawn from the low-
dose regimen would have ultimately healed if sodium
stibogluconate had been continued, or whether there
was true resistance to antimony at that dose. It may be
significant that six of these seven patients had Lmm
infections. The development of antimony resistance is a
cause for concern, and has been linked to inadequate
initial daily doses and treatment durations.9
The higher dose regimen was associated with greater
clinical morbidity. The fall in white cell count and rise in
both transaminases and alkaline phosphatase levels
which are objective evidence of toxicity, although a
feature of both regimens, were of greater magnitude in
those receiving the higher dose. Higher dose regimens
have been developed by others'10 but dose-dependent
toxicity was not reported. However, there was a large
individual variation apparent in these biochemical and
haematological changes, which were reversible after
cessation of treatment, and usually developed in the
absence of clinical symptoms. It is unlikely, however,
that factors other than the therapy caused these
changes, as patients were confined to hospital during
treatment. The only cardiac effect noted in a group of 22
of these patients, who had received the low-dose regi¬
men, was a reversible flattening of T-wave amplitude.11
We did not study the cardiac effects of the higher dose
regimen, but they have been reported to be dose-related
by others studying stibogluconate therapy in visceral
leishmaniasis.12
In our experience sodium stibogluconate 600 mg i.v.
twice daily for 14 days, with an option to extend or
repeat the course if necessary, is an appropriate regimen
for the treatment ofAmerican CL and can be expected to
cure all cases. The initial 14-day course cured 63-9% of
cases, and if extended to 20 days a cure rate of 90%
would be anticipated. This higher dose regimen is
associated with greater morbidity, but the development
of drug resistance is less likely to become a clinical
problem if higher dose regimens are given in the first
instance for a reasonable period of time. Other types of
treatment have been tried on an ad hoc basis, but none
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has been found as useful, and none formally evaluated.
All our cases were followed up for at least 3 months by
Army dermatologists. All were servicemen who were
then followed up by their regimental medical officer, and
it is unlikely that any relapses would have escaped our
notice. No cases of mucocutaneous leishmaniasis have
occurred. In the light of the pattern of relapse we have
observed, it would seem appropriate to keep patients
with CL under review for at least 2 years.
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Short Report
Thrombocytopenia complicating
sodium stibogluconate therapy for
cutaneous leishmaniasis
N. C. Hepburn University Department of Dermatology,
The Royal Infirmary, Edinburgh, EH3 9YW, UK
Sodium stibogluconate is the mainstay of therapy for
American cutaneous leishmaniasis. Patients frequently
report anorexia, malaise and myalgia during therapy. A
transient leucopenia, a rise in serum transaminase levels
(Ballou et al., 1987; Hepburn et al., 1993) and electro¬
cardiographic abnormalities (Chulay el al., 1985) have
also been reported and these appear to be dose related.
Thrombocytopenia has not been reported.
gluconate therapy for cutaneous leishmaniasis.
A 24 years old British soldier contracted cutaneous
leishmaniasis during 6 months duty in Belize. He
resented 4 months after his return to the UK with a pa-
tle surmounted by a crust measuring 1 cm in diameter
on his left forearm. The crust had separated on several
occasions but always reformed. The diagnosis was con¬
firmed by finding amastigotes in a biopsy; culture was
negative.
Once haematological and biochemical baseline values
had been established, treatment was started with sodium
stibogluconate (Pentostam®, Wellcome, UK) 20 mg/kg/d
(1-7 g daily). His platelet count progressively fell during
treatment, which was stopped after 19 d. His platelet
count reached a nadir of 36 x 109/L 4 d after his last dose
and did not begin to recover until 8 d after his treatment
ended (see Figure). His white blood cell count fell from
5-8xl09 to 3-1x109/L 3 d after treatment had been
stopped. There was no change in his haemoglobin con¬
centration.
Sodium stibogluconate is now used at higher doses in
courses of longer duration than were common a few years
ago. This change has led to better cure rates at the cost of
greater morbidity (Hepburn et al., 1993). Transient leu¬
copenia during the first week of treatment is well do¬
cumented (Ballou et al., 1987; Hepburn et al., 1993)
but, although I have noted a fall in the platelet count
during therapy in other patients, the absolute count has
remained within the normal range. This patient de¬
veloped severe thrombocytopenia yet he was asympto¬
matic and haemostatic. The case illustrates the import¬
ance of weekly platelet counts so that sodium
stibogluconate can be stopped before haemorrhagic com¬
plications ensue.
References
Ballou, W. R., McClain, J. B., Gordon, D. M., Shanks, G. D.,
Andujar, J., Berman, J. D. & Chulay, J. D. (1987). Safety
and efficacy of high dose sodium stibogluconate therapy of
American cutaneous leishmaniasis. Lancet, ii, 13-16.
Chulay, J. D., Spencer, H. C. & Mugambi, M. (1985). Electro¬
cardiographic changes during treatment of leishmaniasis
with pentavalent antimony (sodium stibogluconate). Ameri¬
canJournal of TropicalMedicine and Hygiene, 34, 702-709.
Hepburn, N. C., Tidman, M. J. & Hunter, J. A. A. (1993). Cu¬
taneous leishmaniasis in British troops from Belize. British
Journal ofDermatology, 128, 63-68.
Received 4 May 1993; accepted for publication 19 May
1993
692
Transactions of the Royal Society of Tropical Medicine and Hygiene (1993) 87 , 692-696
yS T cells in the peripheral blood of individuals from an area of holoendemic
Plasmodium falciparum transmission
Martin Goodier1, Maria Krause-Jauer1, Ambaliou Sanni2, Achille Massougbodji3, Benoit-Christophe Sadeler3,
Graham H. Mitchell4, Manuel Modolell1, Klaus Eichmann1 and Jean Langhorne1* lMax-Planck-Institut fiir
Immunbiologie, Stubeweg 51, D-7800 Freiburg, Germany; 2Department de Biochimie et Biologie Cellulaire, Faculte des
Sciences et Techniques, Universite Nationale du Benin, Cotonou, Benin; iDepartment de Parasitologic, Faculte des Sciences de
la Sante, Universite Nationale du Benin, Cotonou, Benin; 4Department of Immunology, United Medical and Dental Schools,
Guy's Hospital Medical School, London, SE1 9RT, UK
Abstract
y6 T cells bearing Vy9 T cell receptors from unexposed Caucasian donors make large responses to Plasmodium
falciparum in vitro. This finding, together with observations of others showing high levels of Vy9+ T cells in the
blood of infected non-immune individuals, led us to hypothesize that the response of these cells might contribute
to the pathology ofP. falciparum malaria. Acquisition of immunity to disease in people naturally exposed to infec¬
tion may therefore be due in part to down-regulation or alteration of the function of y6 T cells. Supporting this
view, and in contrast to infection in non-immune individuals, Vy9+ T cells are not elevated in peripheral blood of
children or adults living in an endemic area despite constant exposure to P. falciparum. After in vitro stimulation
with P. falciparum, however, the expansion ofVy9+ cells from the African donors is of similar magnitude to that
observed for non-exposed Europeans. Thus, although these cells are not elevated in peripheral blood, they are
still able to respond to P. falciparum antigens. In adult European donors the major y6 T cell population in periph¬
eral blood is Vy9+ (approximately 70% of all yb cells), whereas in the majority of adult Africans V614 Vy9~ T
cells predominated (approximately 70% of total y6 cells).
Introduction
y6 T cells bearing Vy9 T cell receptors collected from
donors not previously exposed to malaria, mount rapid
responses to antigens of Plasmodium falciparum in vitro
(Goerlich et al., 1991; Behr & Dubois, 1992;
Goodier et al., 1992). In addition, in individuals acutely
infected with P. falciparum, the proportion of these cells
is increased in the peripheral blood (Ho et al., 1990;
Roussilhon et al., 1990; Chang et al., 1992). Upon ac¬
tivation, cells of the y6 T cell lineage can produce a var¬
iety of lymphokines such as interleukin 2, interferon y
(IFN-y), and tumour necrosis factors a and P (TNF-a
and TNF-p) (Cron et al., 1989; Christmas & Meager,
1990; Biassoni et al., 1991; Morita et al., 1991; Fol¬
lows et al., 1992), some ofwhich are responsible for the
activation of macrophages with subsequent induction of
inflammatory processes. Since these cells from non-ex-
posed individuals respond at a high frequency and have
been found in increased numbers of the peripheral blood
of infected non-immune individuals, we have hypo¬
thesized that the activation of these cells may contribute
to the fever and pathology associated with P. falciparum
malaria (langhorne et al., 1992). In endemic areas of
P. falciparum, individuals are exposed constantly to the
parasite and therefore y6 T cells could be continuously
stimulated. However, it is well established that in these
areas severe complications of malaria decrease with age,
and older individuals with parasitaemia show little evi¬
dence of pathological complications. This generally oc¬
curs before acquisition of immunity to infection
(McGregor & Wilson, 1988; Playfair et al., 1990).
Therefore, if yS T cells play a role in pathology, they
must either no longer respond to P. falciparum or have
an altered response pattern in older immune individuals.
This may then be reflected in a lack of elevation of circu¬
lating y6 T cells and/or an inability of Vy9+ cells to re¬
spond to P. falciparum in vitro. In order to test this hypo¬
thesis, we determined whether y6 T cells were elevated
in the peripheral blood of children and adults living in an
area of holoendemic P. falciparum. The proportions of
the subsets of peripheral blood yS T cells were moni¬
tored before and after stimulation in vitro with erythro¬
cytes infected with P. falciparum.
Materials and Methods
Subjects
Blood was taken from 18 adults (>20 years old), and
Author for correspondence.
from 17 children (<10 years old) living in and around
Cotonou, Benin, West Africa, during 1990. In this re¬
gion malaria is holoendemic with maximal transmission
during the 2 rainy seasons (hountondji et al., 1989).
Thin and thick Giemsa-stained blood films were exam¬
ined for parasites at the time of sampling.
Preparation, freezing and recovery ofperipheral blood mono¬
nuclear cells
Peripheral blood mononuclear cells (PBMC) were pre¬
pared by centrifugation over Ficoll-Hypaque® (Pharma¬
cia, Freiburg, Germany), according to standard proce¬
dures. Supernatants were then taken from the gradients
and reserved frozen as 'plasma' for subsequent antibody
determinations. Mononuclear cells were removed and
washed twice in phosphate-buffered saline (PBS) before
freezing at 5xl0°/mL in RPMI 1640 medium, 10% di¬
methyl sulphoxide and 20% foetal calf serum at — 80°C
overnight and thereafter in liquid nitrogen. For re¬
covery, cells were transferred to a large volume of warm
medium, centrifuged, and washed twice in fresh medium
before counting. More than 50% of the frozen cells were
normally recovered. Freezing and thawing of PBMC did
not alter the distribution of the different subsets of cells.
The expression of the surface molecules a|3, Vy9+ and
V61-TCR, CD4, CD8, CD45RO, CD45RA, CD14 and
CD20 (see section on flow cytometric analysis) on frozen
and thawed PBMC measured before or after in vitro
stimulation with P. falciparum was not significantly dif¬
ferent from that on freshly isolated PBMC from the same
donors.
Cell culture and proliferation assays
Cells were cultured at 5x10 /mL in 96-well plates in
RPMI 1640 medium with 15% pooled human group A
serum for 6 d in the presence of 1 x 104 parasites/well of
cultured P. falciparum, strain K1 (origin in Thailand,
kindly provided by H. Matille, Hoffman-La Roche,
Basel, Switzerland) or an equivalent number of control
uninfected erythrocytes (Goodier et al., 1992). For flow
cytometric analysis, viable PBMC were isolated after 6 d
of culture by Ficoll-Hypaque® centrifugation.
Flow cytometric analysis
The following monoclonal and polyclonal antibodie
were used. Unlabelled antibodies: BMA031, anti-
TCR (mouse immunoglobulin (Ig) G2b, kindly provi
by R. Kurrle, Behring, Marburg, Germany); OK
anti-CD 14 (mouse IgG2b, American type tissue cul
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The management of American cutaneous leishmaniasis
NC Hepburn
University Department ofDermatology, The Royal Infirmary, Edinburgh, UK
American cutaneous leishmaniasis is a major world health
problem which is encountered more frequently in the
Western world. The clinical features, diagnosis and treat¬
ment are described. Sodium stibogluconate is the mainstay
of therapy, and should be administered in a dose of
20 mg/kg per day for 28 days. It is associated with
leucopenia, elevation in the serum transaminases and ECG
T-wave changes. However, the drug appears safe in clinical
practice. (/ Dermatol Treat (1992) 3: 95-98)
Introduction
The leishmaniases are major protozoal diseases affecting
approximately 12 million people worldwide.1 They are
transmitted by the bite of an infected sandfly, and
produce three principle clinical syndromes: visceral leish¬
maniasis (VL), cutaneous leishmaniasis (CL) and
mucocutaneous leishmaniasis (MCL). The form of leish¬
maniasis which develops is determined principally by the
species of the infecting parasite (Figure 1). This review is
limited to American ('NewWorld') CL, a disease which is
rapidly increasing in incidence.2 It is caused by either the
Leishmania mexicana complex, which causes a simple
cutaneous ulcer, or the L. braziliensis complex which also
causes a cutaneous ulcer initially but may progress to the
destructive mucocutaneous form ('Espundia') by meta¬
static spread. MCL may develop shortly after the ulcer,
but its appearance may be delayed for over 20 years.2
In 1978 the British army established a permanent
garrison of approximately 1500 troops in Belize. Most
soldiers are on 6-month tours of duty and undertake
jungle training during which they are exposed to the bites
of Lutzomyia sandflies. Between 1978 and mid 1990, 306
soldiers were treated for CL following a tour of duty in
Belize. Prior to 1982 all reported cases of Belizian CL
were due to the L. mexicana complex. However, the
L. braziliensis complex, with its associated risk of late
MCL, has subsequently been identified in many of the
returning soldiers.3
Clinical features
The lesion starts as a small inflammatory papule which
gradually enlarges and ulcerates. An adherent crust
initially covers the ulcer but this separates to expose a
necrotic base which is frequently secondarily infected
kvith either Staphylococcus aureus or B-haemolytic strep-
.spondence: Dr NC Hepburn, University Department of
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tococci. The fully developed lesion consists of a painless
ulcer with a necrotic base and an indurated violaceous
margin (Figure 2). Most lesions occur on exposed body
sites (Figure 3). In an analysis of 187 parasitologically-
proven cases from Belize the mean diameter of the ulcers
was 14.4 mm (SD 9.3) after an average duration of 9.9
weeks (SD 6.7), and a single lesion was present in 71% of
cases with only 1% having more than four lesions.
Infected insect bites are the most common problem in
differential diagnosis but these are usually more
numerous. Other differential diagnoses include infected
traumatic ulcers, mycobacterial or fungal infections,
tropical ulcers and neoplastic ulcers. It is not possible to
distinguish between lesions caused by the L. braziliensis
complex and the L. mexicana complex on the basis of the
clinical picture.
Diagnosis
The diagnosis of CL requires a high index of suspicion in
patients presenting with an ulcer and an appropriate
travel history. Demonstration of the parasite represents
the diagnostic gold standard and this must always be
attempted. A biopsy from the active edge of the ulcer
encompassing the full thickness of the dermis should be
divided into three parts. First, an impression smear
should be prepared in which the fresh biopsy is pressed
against the surface of a microscope slide two or three
times. This is fixed with methyl alcohol for 3 min and then
stained using the Giemsa technique.4 Leishman-Donovan
(LD) bodies, which represent the leishmania amastigotes,
appear as round to oval bodies of 2-6 pm in length, and
are most easily identified in the intracellular space.5
The second part of the biopsy should be processed in
paraffin and examined after staining with Giemsa and
haematoxylin and eosin. In early lesions it is usually easy
to identify the characteristic LD bodies. However, after a
few months their numbers decrease and a granulomatous
infiltrate develops.6 The final part of the biopsy should be
used to culture the organism. This requires complex
media and some expertise involving the use of a modified
NNN medium with antibiotics to prevent bacterial
overgrowth. Once the organism has been cultured the
infecting species can be identified by isoenzyme electro¬
phoresis. All these techniques are clearly described in a
handbook by Evans.4 In practice the Department of
Medical Parasitology at the London School of Hygiene
and Tropical Medicine operates an excellent leishmania
identification service.
The Montenegro leishmanin skin test, which resembles
the tuberculin test, is a useful supplementary diagnostic
procedure in which 0.1 ml of a suspension containing 105
promastigotes in 0.5% phenol saline is injected intrader-
mally into the forearm. An equal amount of 0.5% phenol
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Figure 1 Principle types of leishmaniasis.
saline alone is injected into a second, adjacent, site as a
control to determine sensitivity to the diluent.7 A delayed
hypersensitivity reaction develops, consisting of an
indurated nodule with surrounding erythema. This reac¬
tion is read at 48-72 h. A positive result is represented by
an area of induration measuring more than 5 mm in
diameter which can be graded: grade 1, 5-6 mm; grade 2,
6-8 mm; grade 3, > 8 mm; and grade 4, with blistering.8
Unfortunately, standardized test antigens are not
available. The reagents are produced in the laboratories
of tropical disease centres and vary in their sensitivity and
specificity.9 More than 90% of patients with CL give a
positive reaction,5 but so do up to 9% of healthy controls
in endemic areas.9 We have not found serological diag¬
nostic procedures sufficiently specific to help in diagnosis.
Treatment
The literature on the treatment ofAmerican CL is fraught
with contradiction, misconceptions and anecdotal
reports of alternative therapies. The first crucial step in
management is to decide whether or not one of the L.
braziliensis complex may be the infecting organism
because, until further information is available, all such
cases must be considered capable of causing MCL, and
therefore adequate systemic treatment is mandatory. If
the patient is thought to have contracted the disease in
any of the areas in which the L. braziliensis complex
occurs (i.e. Belize, Honduras, Costa Rica, Panama,
Venezuela, Colombia, Suriname, French Guiana, Brazil,
the Western slopes of the Peruvian Andes and the
Argentinian Highlands),10 the parasite must be isolated
and identified before any alternative to optimal systemic
treatment can be considered. If the disease was contracted
in other areas, or if the disease is shown to be due to the L.
mexicana complex, alternatives, including topical treat¬
ment or no treatment at all, may be considered.
Pentavalent antimony remains the mainstay ofeffective
systemic treatment for CL. These compounds have been
widely used since the 1940s, yet have an unjustifiably poor
reputation which appears to stem from their toxic
predecessors, the trivalent antimony compounds. In our
hands, and those of others, these compounds have been
remarkably safe."12 In the UK, and now in the US,13 the
treatment ofchoice is sodium stibogluconate (Pentostam)
given by slow intravenous injection. The optimal treat¬
donovani > Systemic disease
tropica, L. major, L. aethiopica > Localized disease
mexicana complex > Localized disease
braziliensis complex > Localized disease and
metastatic mucocutaneous
disease
ment regimen has not yet been determined, but the
manufacturer's recommendation of 600 mg daily for 10
days (total dose 6 g), followed by a 10-day rest period
after which further courses may be administered14 is
suboptimal. We have found this regimen cures only
48.5% of cases after the first course, although it is
associated with little morbidity.
There has therefore been a move to higher dose
regimens. In the British army we changed to 600 mg twice
daily for 14 days with an option to continue, or repeat the
course after a break, if necessary. The initial 14-day course
cured 63.9% of cases, and all 72 patients started on this
regimen eventually healed without any other antileish-
manial therapy, although one case required a total of
51 g. We have recently extended our initial course to 20
days which we expect will cure at least 90% of patients
first time. The British army is unusual in using a
fixed-daily dose regimen. This is acceptable because all of
our patients have been well nourished adult males.
However, because the majority of cases occur in the
developing world, most authorities recommend a dose
adjusted for body weight, and the current World Health
Organization recommendation is to give 20 mg/kg per
day for 28 days.1
These higher dose regimens are associated with more
morbidity including anorexia, myalgia, arthralgia, chest
wall pain and general malaise. However, these symptoms
resolve spontaneously when treatment is stopped. There
is usually a marked rise in the serum transaminases and a
mild leucopenia during treatment, but these laboratory
parameters do not correlate with subjective complaints of
malaise and revert to normal when treatment stops.
Non-specific T-wave changes have been documented
during treatment, but no objective evidence ofcardiotoxi-
city has been found by us, and in general this drug appears
to have little cardiotoxicity.11,15 In a retrospective survey
of 289 British soldiers treated with sodium stiboglu¬
conate, in only one case was it necessary to stop treatment
because of toxicity - this patient developed an erythroder-
mic reaction. It is our practice to monitor the white blood
cell count, urea, creatinine, liver function tests and to.
perform an ECG prior to treatment and then at weekl*
intervals during treatment. Tests with abnormal resuM
are then repeated at appropriate intervals until tl^B
return to normal. Mtk
An alternative pentavalent antimony, commonly
in Latin America, is meglumine antimoniate (Gh^^H
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Figure 2a,b Cutaneous leishmaniasis of the hand.
ime). It is similar in efficacy and toxicity to sodium
fcibogluconate, but contains a lower concentration of
fctimony (85 mg/ml compared to 100 mg/ml) so larger
fcimes are required. Both preparations may be admini-
^L'l as slow intravenous infusions or intramuscularly-
^Kigh the volumes involved (600 mg = 6 ml) make the^^Kute uncomfortable.
parasitologically confirmed CL (• = 1% lesions).
Since adopting the higher dose regimen of sodium
stibogluconate, we have found second-line treatments
unnecessary. A preliminary trial of ketoconazole 400 mg
twice daily for 28 days cured all eight patients,16 but,
subsequent experience was less encouraging. In patients
sensitive or resistant to sodium stibogluconate, ampho¬
tericin B or pentamidine are suitable alternatives.17
Amphotericin B in a dose of 1 mg/kg body weight is given
as an intravenous infusion in 5% dextrose over 4 h on
alternate days for 2 months. Pentamidine, in a dose of
4 mg/kg body weight, is given by intramuscular injection
on alternate days for 5 weeks in the first instance.' The
persistent forms of CL, such as diffuse CL, are not well
understood and these patients should be referred to
specialist centres for full assessment.
CL due to the L. mexicana complex is not associated
with MCL and therefore may be managed in a similar
manner to Old World CL. Active treatment is not
absolutely necessary as most lesions will heal spon¬
taneously, albeit with scarring, within 12 to 18 months.2
However, because of functional and cosmetic considera¬
tions, we treat all our cases. If the lesion is small it may be
removed by local excision or currettage. Alternatively,
early non-inflamed lesions can be infiltrated with 1 - 3 ml
sodium stibogluconate. Infiltration must be thorough and
produce complete blanching of the lesion base, and may
be repeated once or twice if necessary at intervals of 1 - 2
days.17 Paromomycin ointment is an exciting recent
development as it can be used on an out-patient basis.
Unfortunately, many patients find the present formula-
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tion too irritant.18 Cryotherapy, Grenz rays and local heat
are also used in some centres.1 It is our policy to treat all
cases ofCL from Belize with systemic sodium stibogluco¬
nate in the first instance as the delay in waiting for culture
and typing results would cause more morbidity than a
timely course of systemic sodium stibogluconate.
In a retrospective study of 187 parasitologically proven
cases of CL in British soldiers, seven relapsed after a
clinical cure. In six cases this occurred after an interval of
4-7 months and in the seventh case after 19 months.
Patients should be followed up for 2 years following
clinical cure, and relapses should be investigated and
treated in the same way as primary lesions in the first
instance.
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CUTANEOUS LEISHMANIASIS
Part I: Clinical Features
N. C. Hepburn, Department of Dermatology, Royal Infirmary of Edinburgh
The leishmaniases are ancient afflictions of man which are now recognised to be
much more prevalent than had been considered likely 10 years ago. The World
Health Organisation estimates that 12 million people worldwide are infected and
that 350 million are exposed to infection.1 In the Old World leishmaniasis
extends from the Mediterranean, through the Middle East to India, the southern
countries of the former Soviet Union, China, and down into Africa. In the New
World it is to be found from South America to southern Texas.
The British army has a long association with this disease. In 1885
Cunningham (1843—1914), a doctor in the Indian Medical Service first described
the leishmanial amastigote from a case of Delhi boil and the disease is named
after Lieutenant-General Sir William Boog Leishman (1865—1926) who described
the same parasites from the viscera of a fatal case of kala-azar. More recently,
army dermatologists have been treating a steady stream of soldiers who have
developed the cutaneous form of the disease during jungle training in Belize. The
principle types of leishmaniasis are detailed in Table 1, but this paper concentrates
on the actue cutaneous forms of the disease. Aspects of the epidemiology and
prevention will be presented in Part II.
PATHOGENESIS AND PATHOLOGY
The leishmaniases are due to a protozoa which is transmitted by the bite of an
infected female sandlfy, generally Phlebotomus in the Old World and Lutzomyia
or Psychodopygus in the New World (Fig 1). The inoculated promastigotes
activate complement and thereby attract monocytes/macrophages to the area.
Mature promastigotes (bearing surface antigens of 116kdaltons) bind C3 and then
attach to C3b receptors on the macrophage and are phagocytosed whilst imma- *
ture promastigotes are destroyed by complement mediated cytotoxicity. Once
inside the macrophage, the promastigotes lose their flagellae and become amasti-
gotes which multiply repeatedly by binary fission. Infected macrophages then
burst, releasing their amastigotes which in turn infect other macrophages. The
subsequent fate of the amastigotes depends upon parasite and host factors which
are poorly understood. Viscerotrophic species, such as L. donovani, tend to
migrate throughout the reticulo-endothelial system, whereas dermotrophic species,
such as L. major, usually remain close to the inoculation site. Any spread of
dermotrophic species tends to be late and only to adjacent skin (producing
satellite lesions) or to lymphatics and regional lymph nodes. It is possible that
dermotrophic species migrate as far as viscerotrophic species but are unable to
survive in the internal milieu—for example L. donovani amastigotes are able to
tolerate higher temperatures and resist complement mediated cytotoxicity. These
phenotypic distinctions are not absolute. L. braziliensis is able to migrate to the




Principal types of leishmaniasis
Type Cause Effect










































The life cycle of leishmania.
reactivating to cause the destructive mucocutaneous form of the disease
'Espundia'; there is at least one report of L. tropica causing visceral leishmaniasis2
and in post-kala-azar dermal leishmaniasis (PKDL) the viscerotrophic parasite
becomes dermotrophic as a consequence of treatment.
The interaction between the patient's cell mediated immune response and the
amastigotes is complex and results in a range of clinical and pathological changes.
In all forms of leishmaniasis, however, the presence of amastigotes within the cells
of the mononuclear phagocytic system remains the hallmark of the disease,
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although at times they may be difficult to detect. Infected macrophages measure
20-30 /tm in diameter whereas amastigotes, known as Leishman—Donovan (LD
bodies), are round to oval structures measuring only 2—5 /im. They are sur¬
rounded by a plasma membrane and contain both a relatively large, deeply
basophilic, nucleus and a smaller, densely staining, rod-shaped kinetoplast of
extranuclear DNA (from the base of the flagellum which is lost in the conversion
from promatigote to amastigote). Although haematoxylin and eosin can demon¬
strate amastigotes, a Giemsa stain that stains the kinetoplast bright red is
preferred.3
In early cutaneous lesions, the dermal infiltrate mainly consists of macro¬
phages filled with amastigotes. There are relatively few lymphocytes and plasma
cells. As the lesions develop more lymphocytes and plasma cells appear and the
superficial dermis becomes oedematous. The overlying epidermis becomes hyper-
keratotic and subsequently breaks down to form an ulcer covered with a
coagulum of hyperkeratotic debris, dried exudate, dead cells and a mixture of live
and dead organisms. Over the following months there is a gradual decrease in the
number of amastigotes and macrophages, leaving a granulomatous infiltrate
consisting of lymphocytes, epitheloid cells and multinucleate-giant cells. At this
stage it may be difficult or impossible to detect organisms in Giemsa sections.
Parasite elimination usually follows destruction of the host macrophages, either at
the centre of the circumscribed clusters in the dermis with the release of amasti¬
gotes, or in the subepidermal zone causing liquefaction of the basal layer and
ulceration. Polymorphs are present in the necrotic zone and lymphocytes are
numerous at the periphery. Ultimately, either the patient's immune response is
able to eliminate the infection and effect a spontaneous cure or it fails and a
chronic form of cutaneous leishmaniasis develops. Resolution occurs by
fibrosis.112-3
There are two special non-healing forms of cutaneous leishmaniasis (CL)
which, although rare, are important because they represent two extremes of host
cell-mediated immune (CMI) response to infection with leishmania and have
given insights into the pathogenesis of this disease. Leishmaniasis recidivans
( = lupoid) is characterised by healing with fibrosis in the centre of the lesion but
failure to heal peripherally where there is a granulatomous infiltrate composed of
epitheloid cells, multinucleate giant cells, a variable number of plasma cells but
relatively few lymphocytes. Amastigotes are very scanty. The appearances are
reminiscent of lupus vulgaris both histologically (although there is no caseation)
and clinically (even apple jelly nodules are seen). The lesions usually occur on the
face and develop from an acute lesion after an interval of 12—18 months. There is
a central fibrotic scar surrounded by an active edge containing papules and
nodules. In this type the parasite persists indefinitely despite an exaggerated host
CMI response. It is found mainly in Iran and Iraq. The other extreme is
represented by diffuse cutaneous leishmaniasis (DCL) in which there is a specific
defect in the host CMI reponse to leishmania. Lesions contain a large number of
macrophages full of amastigotes but lymphocytes are scarce. Clinically, the initial
lesion spreads locally and then the disease disseminates to other areas of the body.
There are numerous discrete papules and nodules which coalesce to form plaques
scattered over the whole skin surface but particularly numerous on the face and
the outer aspects of the limbs. DCL is associated with L. aethiopica in the Old




Ridley's classification of the histopathological response in cutaneous leishmaniasis.
GROUP I Diffuse macrophage granuloma formation. Macrophages are full of amastigotes but
do not show signs of activation. Occasional lymphocytes and plasma cells, but no
giant cells. Ulceration is rare.
GROUP II Focal macrophage granuloma formation, with central necrosis, surrounded by
lymphocytes and plasma cells. Initially moderate numbers of organisms are present
in surviving macrophages but later these disappear. Ulceration may occur inde¬
pendently of the necrotic granuloma.
GROUP III The most non-specific group. A mixed inflammatory response consisting mainly of
lymphocytes and plasma cells but with a few macrophages. Amastigotes scanty but
are best seen in the subepidermal zone.
GROUP IV Giant cells of foreign body and Langhans types are present together with a heavy
lymphocytic infiltrate. Scanty or absent amastigotes.
GROUP V Tuberculoid response. Epitheloid cell granulomas with many Langhans giant cells
but small numbers of lymphocytes and plasma cells. No necrosis. No amastigotes.
Adapted from: Ridley DS, Pathology. In: Peters W, Killick-Kendrick R (Eds). The
Leishmaniases in Biology and Medicine, vol. 2. London, Academic Press, 1987, p. 665—702.
These observations prompted Ridley4 to propose a histological spectrum for
cutaneous leishmaniasis, rather analogous to that for leprosy, ranging from aner¬
gic forms of infection with heavily parasitised macrophages to hypersensitive
forms with scanty organisms and a tuberculoid response. There are five groups
arranged in order of descending parasite load and these include the whole
spectum of CL from DCL to recidivans (Table 2). However, whereas in leprosy
there is a straight line spectrum from anergy to hypersensitivity, in individual
cases of CL there are aberrations in which the parasite load is out of step with the
host cell response.
IMMUNOLOGY
The development of longstanding resistance to reinfection is the principal
immunological feature of classical CL. Reinfection amongst residents in regions
for L. tropica is uncommon and experimental infections ih human volunteers
confirm that resistance develops after recovery provided the initial infection runs
its full course. Immunity is not always complete; there are reports of reinfection
occurring five or more years after initial cure or as a result of steroid therapy. In
one case reinfection by the same L. major type followed spontaneous healing of
the original lesion although there were fewer parasites and the lesion healed more
rapidly than the primary infection.5
It is the cell-mediated immune response that provides resistance to infection
with leishmania.6 Although antibodies to leishmania can be detected in the
majority of patients with CL, they are not protective even when present in high
titre.3 The CMI response can be demonstrated clinically by the leishmanin skin
test which is a delayed-type hypersensitivity reaction to the inoculation of a
suspension of phenolised promastogotes (see diagnosis). Patients usually become
leishmanin positive within a few weeks of infection and once positive remain so
for decades. The significance of this long-lasting skin reactivity is unclear. It may
represent genuinely long-lived immunological memory or it may be explained by
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Table 3
Cutaneous manifestations of leishmaniasis
Acute disease Chronic disease Miscellaneous
Old World CL non-healing acute sore Leishmanioma
wet/rural sore mucocutaneous leishmaniasis Post Kala-Azar
dry/urban sore Leishmaniasis recidivans leishmaniasis
diffuse cutaneous leishmaniasis
New World (American) CL
the existence of an occult infection in recovered individuals. Nonetheless, this
delayed hypersensitivity reaction does not represent a measure of resistance to
reinfection. The reaction generally becomes positive early in the course of the
disease whereas the lesion heals many months later. Reinoculation of an indivi¬
dual with both an active sore and a positive skin test leads to the development of
a typical ulcer that develops to the same stage as the original sore and they then
heal together.5
Leishmania infection in mice has been extensively studied as a model for a
disease that is solely dependent on the CMI response for resolution. It was
initially established that CD4+ T cells played an important role in the host's
resistance to infection but, more recently, functional subsets of T cells known as
TH-1 and TH-2 have been identified on the basis of their cytokine secretion
profile. TH-1 cells, which are thought to mediate CMI, secrete IFN-a and IL-2
and are associated with resistance to infection. TH-2 cells, which are thought to
be helper cells for specific antibody production, secrete IL-4 and IL-5 and are
associated with susceptibility to infection.7 These observations were followed up
by blocking IFN-a and IL-2 with monoclonal antibodies (mAbs) in infected
mice: strains of mice genetically resistant to infection with Leishmania treated
with anti-IFN-a mAb developed progressive infections whilst treatment of sus¬
ceptible strains with anti-IL-4 mAb attenuated the disease in all these mice and
resulted in complete resolution of lesions in 85 per cent with the establishment of
protective immunity. These findings opened the door for clinical trials of
immunotherapy using human recombinant cytokines. In a controlled study,
intralesional treatment with recombinant IFN-a produced a reduction in size of
12 out of 13 lesions due to L. braziliensis guyanesis after 3 weeks and some lesions
were free of parasites. Similarly 9 out of 13 lesions due to L. tropica resolved
completely with 4—8 weeks of treatment. Resolution was associated with
Langerhan's cell hyperplasia, expression of HLA-DR by keratinocytes and
increased numbers of IL-2+ T cells indicating that the therapy with r-IFN-a
promotes healing of CL by enhancing the CMI response.8,9
clinical features
The clinical features of CL tend to differ between different regions of the world
reflecting differences in the species of the parasite, the sandfly vector and the
genetic, immunological and cultural background of the patients.1 The cutaneous
manifestations of leishmaniasis are classified in Table 3. The lesions develop where
the infected sandfly bites and are therefore usually on the exposed parts of the
body. A cluster of lesions may occur and this has been attributed to repeated
probings by the sandfly which has difficulty aspirating blood through its
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promastigote-laden proboscis. The incubation period is 1—12 weeks tending to be
shorter with a larger inoculum.3 Although each parasite is classically associated
with a distinctive clinical picture, the features overlap and they cannot be reliably
distinguished on clinical grounds alone.
Old world acute CL (oriental sore). The lesion starts as an erythematous papule,
rather like an insect bite with which it is frequently confused, but it persists and
enlarges to form a painless nodule with a surface crust resembling a volcano. In
some cases there is a larger subcutaneous component which has given rise to the
term 'iceberg nodule'. In most cases the crust separates to expose an ulcer.10
Lesions heal by fibrosis leaving a sharply demarcated, irregular, cribriform scar
which in coloured races is often hyperpigmented and disfiguring. Lesions, par¬
ticularly in cases due to L. major, are often multiple and occasionally over 100
lesions occur in a single patient.3
Oriental sores are often divided into wet and dry types. The wet, rural or
zoonotic, sore is a more inflammatory lesion which is classically associated with
L. major and is usually acquired in rural areas where the infecting organisms are
also rodent parasites and are poorly adapted to man. After an incubation period
of less than two months an erythematous papule develops and two weeks later a
central crust appears which usually falls off revealing a bright red base consisting
of slough alternating with papules of proliferating granulation tissue. The ulcer
enlarges over the following two to three months reaching a diameter of 3—6 cm.
Multiple satellite papules which measure 2—5 mm and do not contain parasites are
much more common in the wet than in the dry type. The lesion heals in three to
twelve months.
The dry, urban or anthroponetic, sore is a more quiescent but indolent lesion.
It is classically associated with L. tropica and is more commonly found in urban
areas where the parasite is better adapted to man. The lesion starts as a brownish
nodule which enlarges to form a plaque measuring 1—2 cm in diameter in about
six months. Ulceration then appears in the centre associated with a closely
adherent crust. Healing may take up to two years.
Lesions due to L. aethiopica are usually single and most commonly occur on
the central part of the face. Satellite papules amalgamate into a large spreading
nodule. Ulceration or crusting is not always a feature. There is relatively little
inflammation and the lesions heal over two to five years. It may progress to
DCL. L. infantum, which generally causes visceral leishmaniasis in children,
usually gives rise to a self-healing sore in adults. Its appearance and evolution are
slow compared to lesions due to L. major1,10,11,12
New World CL. Infection due to either L. mexicana or L. braziliensis complex
produces localised nodulo-ulcerative disease which is similar in many respects to
that seen in Old World disease. The lesion starts as an erythematous papule which
forms a crust then rapidly ulcerates. The ulcer base is necrotic and often secondar¬
ily infected with either Staphylococus aureus or /i-haemolytic Streptococcus. It is
surrounded by an indurated violaceous border. In an analysis of 187 British
soldiers with parasitologically proven cutaneous leishmaniasis contracted in Belize,
most lesions occurred on exposed body sites (Fig 2). Lesions due to L. mexicana
mexicana were more common on the head and neck compared to those due to L.
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Figure 2
Site of lesions in 187 parasitological proven cases of cutaneous leishmaniasis from Belize (courtesy of
J Derm Treat).
braziliensis braziliensis. A single lesion was present in 71 per cent of cases and only
one per cent had more than 4 lesions. The average diameter of the lesions at
diagnosis was 14.4 mm (SD 9.3). It was not possible to distinguish lesions due to
L. mexicana mexicana from those due to L. braziliensis braziliensis on the basis of
their clinical appearance alone.14
Lesions due to L. mexicana complex usually heal spontaneously within six to
eight months although those occurring on the pinna (chiclero's ulcer) often persist
and cause extensive local destruction.12 L. m. amazonensis is associated with DCL.
L. braziliensis complex causes localised disease which may eventually heal sponta¬
neously but it is associated with the destructive mucocutaneous form of the
disease known as 'Espundia'. This usually starts in the nasal mucosa but progressi¬
vely destroys the nose, upper lip, palate, pharynx and larynx leading to death
from secondary infection, starvation or laryngeal obstruction. It has been attri¬
buted to metastatic spread to the nasopharyngeal mucosa and may present within
3 years of the primary lesion but it is often delayed for over 20 years.13
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(Adapted from Kubba et al. 1987).
DIAGNOSIS
This is frequently made on the basis of the clinical appearance of the lesion
together with a history of exposure to infection. However, the differential
diagnosis is extensive (Table 4) and it is therefore important to seek pathological
confirmation, preferably by demonstration of the parasite either morphologically
or by culture. Organisms are most numerous in the active edge of the lesions—
therefore samples should be taken from that area.
Skin biopsy. A wedge or punch biopsy, under local anaesthetic, can be used for
the preparation of impression smears, parasite culture and routine histological
examination. The area should be thoroughly cleaned with 6% hydrogen peroxide
to reduce bacterial contamination prior to biopsy. Amastigotes (L-D bodies) can
be identified in routine H & E sections during the early stages of the disease but
they become less numerous with the passage of time and may be impossible to
find after a few months. The typical granulomatous histology is a much less
specific diagnostic pointer. In these circumstances it may be possible to detect
amastigotes using polyclonal antibodies in conjunction with immunoperoxidase
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staining.15 Monoclonal antibody probes in conjunction with immunofluorescent
.assays are currently being developed16 but are not generally available.
Smear preparations. Can be prepared by pressing a skin biopsy against a glass
slide prior to fixation or by using tissue juice obtained either by aspirating the
edge of the lesion with a 20 gauge needle or by using a slit-skin technique akin
to that used in leprosy. Amastigotes may be detected both intra- and
extracellularly.17 *-
Culture of leishmania is often difficult and involves both art and science.
Whilst some species, such as L. mexicana mexicana, grow readily others, such as L.
braziliensis braziliensis, are more difficult. Essentially the tissue biopsy is placed in
a biphasic blood-agar medium such as a modified NNN to which antibiotics are
added to prevent bacterial overgrowth and incubated at 22°C. Promastigotes may
be identified in as little as seven days although it often takes up to 21 days. The
techniques for culture (and also isoenzyme typing) are clearly described in an
handbook by Evans.18 Animal inoculation is a useful alternative to in vitro
culture, particularly when the parasite load is low or if sterile conditions are
difficult to achieve. The golden hamster is generally the most suitable as it is
sensitive to most strains of leishmania, although the Balb/c mouse is best for L.
major. Homogenised tissue containing amastigotes should be injected intra-
dermally into the nose, ears or footpads and the inoculation site biopsied seven to
ten days later to obtain samples for culture or at a later date for histological
examination.19
Identification of Leishmania species. Isoenzyme analysis remains the method of
choice for typing leishmania because it is simple to use, reproducible and well
established. It represents the standard against which the newer methods, such as
monoclonal antibodies and DNA hybridization probes, are assessed. An aqueous
extract containing many enzymes is prepared from promastigotes cultured from
the lesion. This extract is analysed by electrophoresis during which the banding
pattern, identified by staining for a single enzyme such as glucose 6 phosphate
dehydrogenase or malic dehydrogenase, is compared with that of a known
reference strain of leishmania. Several such zymogrammes, each stained for a
different enzyme, are required to identify a given species.18
DNA hybridization probes for kinetoplast DNA are being developed which
allow identification of cultured promastigotes or amastigotes from lesions. The
technique is very sensitive—identification is possible with as few as 50
organisms—but there are problems with' non-specific labelling. These techniques
are well described in a manual by Barker.20 As these techniques improve and as
more probes become available these methods will probably replace isoenzyme
analysis as the routine diagnostic tool.
Serological diagnosis. Serological methods are widely used in the diagnosis of
visceral leishmaniasis and antibodies are also present in cutaneous disease albeit in
low titre. However, serology has been insufficiently sensitive and specific to be
helpful diagnostically in Old World disease1 and also, in our hands at least, in
New World disease.
Leishmania (Montenegro) skin test. This is a delayed hypersensitivity reaction,
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resembling the tuberculin test, in which 0.1 ml of a suspension containing 105
promastigotes in 0.5 per cent phenol saline is injected intradermally into the
forearm. An equal amount of 0.5 per cent phenol saline alone is injected into a
second, adjacent, site as a control to determine sensitivity to the diluent. An
indurated nodule with surrounding erythema develops and the reaction is read at
48—72 h. An area of induration measuring 5 mm or more in diameter is positive.
Unfortunately, because standardised test antigens are not available the reagents are
produced in the laboratories of tropical disease centres and vary in their sensitivity
and specificity.21 Its diagnostic utility is limited because, although over 90 per
cent of patients with CL give a positive reaction, so do up to 9 per cent of
healthy controls in endemic areas presumably from past, often asymptomatic,
infection.
TREATMENT
The optimal management of CL has not yet been determined. The literature
abounds with reports of 'effective' treatments. However, given the self-healing
nature of most of the lesions together with the distinct lack of controlled
therapeutic trials, selection of the most appropriate therapy, if any, can be
difficult. There are, however, several guiding principles. Lesions due to different
species of leishmania differ in severity and in their response to treatment; in
general New World forms tend to be more severe and longer lasting than Old
World forms.
In the Old World the vast majority of patients have lesions which will heal
spontaneously within a few months or at most two years. Active treatment is
therefore not mandatory—indeed for patients living in endemic areas it may not
be appropriate because spontaneous healing is associated with the development of
protective immunity. However, patients with lesions on cosmetically or function¬
ally important sites, such as the face or hands, those with associated lymphangitis
and those with multiple lesions, are best given active treatment. Local treatment
is appropriate for early non-inflamed lesions and systemic therapy for those with
multiple or more complicated lesions. An exception to this rule are those lesions
due to L. aethiopica which is relatively resistant to antimony and for which local
treatments have not been validated. The WHO recommends that these lesions are
left to heal spontaneously unless they occur in the oronasal area, in which case,
systemic pentamidine should be used.1
In New World disease the first crucial step is to decide whether or not one of
the L. braziliensis complex could be the infecting organism because, until further
information is available, all such cases must be considered capable of causing
mucocutaneous disease and therefore adequate systemic therapy is mandatory.
Hence, if the patient contracted CL in any area in which the L. brazilietisis
complex occurs (i.e. Belize, Honduras, Costa Rica, Panama, Venezuela,
Colombia, Suriname, French Guiana, Brazil, the western slopes of the Peruvian
Andes and the Argentinian Highlands,22 the parasite must be isolated and identi¬
fied before any alternative to optimal systemic treatment can be considered. If the
disease was contracted in other areas, or if the disease is shown to be due to the
L. mexicana complex (except L. tnexicana amazonensis), alternatives, including
topical or no treatment at all, may be considered. The WHO recommends that
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L. mexicana amazonensis is treated in the same way as L. braziliensis complex
lesions because a high proportion develop DCL.
Pentavalent antimonials remain the mainstay of effective systemic treatment
for all forms of leishmaniasis because of their undoubted efficacy and, when
properly used, safety. Two products are available: sodium stibogluconate
(Pentostam; Burroughs-Wellcome, UK) and meglumine antimoniate
(Glucantime; Specia, France). They are similar in both efficacy and toxicity—any
reported differences can be explained by their differing antimony concentrations
(Pentostam: lOOmg/ml; Glucantime: 85mg/ml). Antimonials decrease the avail-
abilty of adenosine triphosphate (ATP) and guanosine triphosphate (GTP)
through inhibition of glycolysis and the citric acid cycle.2 Both drugs must be
administered parenterally, either by slow i.v. or i.m. injection. They are rapidly
excreted, unchanged, by the kidney with a half-life of less than six hours. They
should be administered in a dose of 10-20mg/kg body weight daily in two equal
doses for two to four weeks or until clinical and parasitological cure is achieved.
In the case of lesions due to L. braziliensis complex, the WHO recommends
20mg/kg/day for a minimum of 4 weeks. Serious toxicity is rare although
patients often report malaise, anorexia, myalgia and arthralgia during treatment.
An elevation in serum transaminases, a mild leucopenia and flattening of the T-
waves on the ECG are common during therapy and appear dose related. These
abnormalities settle rapidly when treatment is stopped.
Pentamidine is a second-line drug except in cases due to L. aethiopica. It acts
against leishmania by damaging the kinetoplast DNA-mitochondrial complex. It
must be administered parenterally, either by i.m. or slow i.v. injection in a dose
of 3—4mg/kg body weight once or twice weekly until the lesion resolves.1,2,12
The main adverse effects are hypoglycaemia, myoglobinuria with nephrotoxicity
and cardiotoxicity. It has a narrow therapeutic index and it is therefore generally
preferable to give doses less frequently but for a longer period.23
Ketoconazole has been used in recent years to treat Old World CL although
its efficacy has not been formally evaluated in controlled trials. It is administered
orally in a dose of 600mg daily for 28 days and the lesion should be re-assessed
once a month after treatment.24
Local treatments for CL include physical modalities such as surgical excision,
curettage followed by cautery, cryotherapy and local heat treatment.17 Local
infiltration of lesions with sodium stibogluconate in a dose of 1-3 ml, repeated
once or twice at 1—2 day intervals, is a convenient treatment for early non-
inflamed lesions. Technique is important—infiltration must produce complete
blanching at the base of the lesion.1 An exciting recent development has been the
development of an ointment containing 15 per cent paromomycin and 12 per
cent methyl benzethoniuim chloride in white soft paraffin which is applied twice
daily for 10 days. This regimen has been reported to cure 87 per cent of patients
with Old World disease in 10 to 30 days.25 Unfortunately, this formulation is
very irritant and alternative formulations have been less effective.26
In conclusion, CL remains a major world health problem, but its importance
is now being recognised and research efforts are being directed towards improved
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CUTANEOUS LEISHMANIASIS*
Part II: Historical Aspects, Epidemiology and Prevention
N. C. Hepburn, Department of Dermatology, Royal Infirmary of Edinburgh
HISTORICAL ASPECTS
The leishmaniases are ancient diseases of man. In the Old World, descriptions of
Balkh sore (named after Balkh, a town in the north of Afghanistan near the
Russian border), date back to the first century AD. The disease has been traced
back through the medieval literature of the Middle East by Elgood1 who
speculates that it was carried from Balkh to Baghdad by the invading Mongols in
1215 AD and that it then spread down to the Persian Gulf and, later, back along
the trade routes into the interior of Iran reaching Tehran by 1840. The disease has
many synonyms, mostly derived from place names, such as Dehli boil, Aleppo
boil, Armenian sore, Sart sore and the still commonly used oriental sore.2
In the New World, early records of cutaneous leishmaniasis are more difficult
to identify because other endemic conditions, such as syphilis and blastomycosis,
cause similar lesions. However, mucocutaneous leishmaniasis (espundia) can be
traced back to pre-Columban times through anthropomorphic vessels, huacos,
which have been found amongst the ancient Peruvian Mochica pottery in Inca
tombs (c. 400—900 AD). Some of these figures depict the typical facial lesions as
do terracotta figures from northern Equador. Shortly after the Spanish conquest,
historians such as Pizarro (1517) noted a rare but decimating disease among the
Peruvian Indians which primarily affected the nasal cavities.2 Gade has reviewed
these classical descriptions of the disease which occurred in the same areas as it
does today:
Indians are taken from the highlands to work in the coca fields in the 'Andes of Curzo'
where they get an infection in the nostrils which also makes their nose trunk-like and red,
from which some die.
. . . and the Indians get sick with an incurable disease called 'of the Andes', which is worse
than syphilis... it attacks most commonly the nostrils, lips and uvula of the throat
. . . others get it in the mouth, making a sight one cannot look at without great horror and
fright at such ugliness.3
In addition Spaniards who explored the high Andean valleys, where sandflies
were common, occasionally developed mutilitating lesions of the nares similar to
those depicted on the huacos. This disease was known as 'anti-onccoy' or 'the
disease of the Andes' but only comparatively recently has the name for the long
suspected cause, a small biting fly or uta, being applied to the disease itself.2
Names for the disease in its various forms are also profuse in the New World and
include uta, espundia, mucocutaneous leishmaniasis, ulcera des los chicleros, boton
de Baura, bouba, bay sore, forest yaws, pain bois and leishmaniose tegumentar
americana.
The scientific study of leishmaniasis began with the publication in 1885 in
Scientific Memoirs by Medical Officers of the Army of India by Surgeon-Major
D. D. Cunningham of a description of amastigotes in sections of human skin
*Part I: Clinical features, pathology and treatment is in Proc R Coll Physicans Edinb 1992; 22: 448-59.
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from a patient with Dehli boil.4 He described some 'deeply staining bodies in
certain cells larger than lymphocytes' and attributed these to the spores of a slime
mould. These observations were confirmed six years later by Firth.5
In 1898 Borovsky, a Russian military surgeon studying Sart sore in Tashkent,
described 'small spherical, oval or fungal form corpuscles' measuring 1.5—2.0 /mi
diameter with a nucleus and a 'process running to the periphery'. Unlike
Cunningham, he realised these were protozoa and the cause of the disease.
Unfortunately his observations were published in an obscure Russian journal
'Voenno-Medicinskij-Ziirnal' and the significance of his discovery was not recog¬
nised for many years.6
In 1903 the pace of discovery quickened, Leishman (1865—1926) a British
army pathologist, reported the similarity of degenerating trypanosomes from the
spleen of a laboratory rat which had died after an experimental infection with
African trypanosomes 48 hours earlier to bodies he had observed some three years
previously during a post morten examination of the splenic pulp of a soldier 36
hours after death from a tropical cachexia. The soldier had contracted his illness
during service at Dum-Dum seven miles from Calcutta.7 Leishman concluded
that these organisms had been degenerating trypanosomes. Although incorrect,
this was the first description of a possible causative agent for visceral leishmania¬
sis. Subsequently Donovan, a Captain in the Indian Medical Service at Madras,
described similar organisms in a fresh biopsy from the spleen of a patient with
visceral disease revealing it was a different organism rather than a degenerate
trypanosome.8 Later that year Wright, whilst working in Boston, USA, and
using a greatly improved Romanowsky stain, first accurately described and
photographed the cutaneous Old World parasite obtained from the cheek of a
nine year old girl who had developed the lesion two or three months earlier
whilst in Armenia.9
In 1904 Rogers successfully cultured the visceral parasite by incubating
cultures at 22°C and in 1908 Nicolle cultured the cutaneous organism using a
modification of the rabbit blood nutrient agar medium of Novy and McNeal
known as NNN medium.2
The first report of the New World organism was made in 1909 by
Lindenburg who had been examining ulcers on the face and forearms of railway
workers in Sao Paulo. The clinical features of espundia, a leishmanial infection
involving erosion of the palate, were first described and illustrated by Carini
(1911) whilst working at the Pasteur Institute in Sao Paulo. In the same year
Vianna described parasites present in ulcers contracted in Minas Gerias, Brazil; he
was able to discern a nucleus, kinetoplast and a 'rudimentary flagellum' and
proposed the name Leishmania braziliensis to distinguish it as the cause of
espundia.2 In 1913 an expedition from Harvard investigated and succeeded in
discovering, independently, the cause of uta in Peruvian mountain towns. They
described and illustrated the parasites together with the clinical features including
erosion of the palate. They were also able to culture the organism on blood agar
and reported that it was believed to be transmitted by the genus Phlebotomus.10
The sandfly has been implicated as the vector of cutaneous leishmaniasis as far
back as 1764.11 In 1904 Rogers observed the conversion of amastigotes to
promastigotes in culture12 and subsequently promastigotes were found in sandflies
by Alder and Theodor in 1925.13 In 1921 a volunteer developed a cutaneous
lesion after inoculation with a suspension of caught Phlebotomus14 and then in
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Figure 1
Geographical distribution of cutaneous leishmaniasis.
1931 Shortt was able to transmit L. donovani to hamsters by the bite of
Phlebotomus argentypes.15 It was not until 1941, however, that L. tropica was
transmitted to volunteers by the bite of experimentally infected Phlebotomus
papatasi14 thus confirming the cycle.
EPIDEMIOLOGY
Research during the past decade has revealed that the leishmaniases—both visceral
and cutaneous—are much more prevalent than had been appreciated. In 1990
WHO estimated that 12 million people were affected in over 80 countries and
that 350 million people were at risk of infection.17 More specifically, Ashford et
al.ls estimate that approximately 300,000 cases of cutaneous leishmaniasis occur
each year in 61 countries; they also estimate that 185 million people are at risk of
cutaneous disease. Furthermore, there is good evidence for a dramatic increase in
incidence in the New World.19 The geographical distribution of cutaneous
leishmaniasis is shown in Figure 1. However, it is important to note that more
than half the cases occur in just eight countries: Afghanistan, Algeria, Brazil, Iran,
Iraq, Saudi Arabia, Sudan and Syria.
The cycle of infection. The leishmaniases are complex protozoal infections trans¬
mitted by the bite of an infected female sandfly (Phlebotomus in the Old World,
Lutzomyia or Psychodopygus in the New World). In most cases these infections
exist as zoonoses amongst wild animals and man is only infected as an incidental
host (Figure 2). However, such infections are by no means uncommon in
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Figure 2
The cycle of infection.
endemic areas where up to 9 per cent of the healthy population may have a
positive leishmanin skin test indicative of an earlier, often asymptomatic, in¬
fection.20 The requirements for vector species, reservoir host and environment
tend to be very specific for each leishmanial species, consequently the disease is
often localised to small areas where all three exist together (Table 1).
Vector biology. Sandflies are extremely small, measuring less than 3.5 mm, they
are covered with a sandy yellow or brown coat of hair and have very dark eyes.
The male has prominent terminal organs for grasping the female. These tiny flies
live in dark, damp places and make characteristic little hops when disturbed.
They are able to fly remarkably well and, although the usual radius is only 50 m
from the breeding site, ranges up to 1—2km have been recorded.21,22 Only
females are blood sucking as blood is essential for egg development. They bite
mainly at dusk, their approach is silent, unlike that of most mosquitos, and the
exposed parts are usually attacked. Their minute eggs are laid in cracks and
crevices in dark, moist sites. They hatch in 9—12 days and go through 4 larval
stages followed by a pupal stage before finally developing into a fly. Under
favourable conditions the life-cycle takes about one month but it may be
considerably prolonged under adverse circumstances.21 Temperature is the only
factor that correlates well with sandfly distribution in the world. Although
sandflies are able to survive cold temperatures in diapose (a period of suspended
development accompanied by greatly decreased metabolism), larval development
and adult activity are greatly reduced at temperatures below 20°C. Their distribu¬
tion is therefore largely confined to areas that have at least one month with a
mean temperature of 20°C.23
As sandflies lacerate the skin to feed upon a pool of serosanguinous exudate,
they ingest amastigotes which develop into promastigotes in the gut before
migrating to the salivary glands after seven to ten days, after which time infective
promastigotes can be regurgitated via the proboscis during the next blood meal.
During feeding saliva is introduced into the host and it has recently been
discovered that lysates of the salivary glands from Lutzomyia longipalpis greatly
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injects about 10-100 parasites during a blood meal. However, when a mouse is
inoculated with this number of parasites none survive unless sandfly saliva is also
injected—approximately 105—106 parasites are needed for laboratory infection.24
In addition, if salivary gland lysate is present lesions develop and grow more
rapidly. These lysates have been analysed and a very potent vasodilator, maxadi-
lan, which is similar to the mammalian neuropeptide calcitonin gene related
peptide, has been isolated. This is able to inhibit the production of hydrogen
peroxide by macrophages in response to interferon gamma—the mechanism by
which hosts destroy intracellular parasites.25
The biology of each sandfly species is unique and complex, and it is beyond
the scope of this article to describe each one. However, before a particular species
can be implicated as the vector for a given type of leishmania, it must be
established that the fly bites both man and the reservoir host, that both are
infected in nature with the same type of leishmania, that the fly supports a
flourishing growth of the parasite and it is able to transmit it by biting, and
finally that the geographical distribution of the fly and parasite are similar.17 In
many cases our knowledge is incomplete but the overall picture is summarised in
Table 1.
Reservoir hosts. Leishmania spp are maintained indefinitely within an ecological
system consisting of one or a small number of sandfly vectors and one or a few
vertebrate reservoir hosts. There is usually one primary reservoir host for a given
species within a particular focus but other animals in the same area may become
infected forming secondary hosts (from which leishmania can be transmitted to
other mammals) or incidental hosts (from which leishmania cannot be passed on).
These hosts may not show obvious signs of infection—often there are relatively
few amastigotes in the skin or viscera and the host immune response is minimal.
By way of contrast, dogs, the natural reservoir for L. donovani which causes
visceral disease in man, may eventually be killed by the infection. The parasites
are abundant in both the viscera and the dermis from which they are readily
picked up by the sandfly vectors: thus the site of leishmania in the host does not
necessarily correspond to the site of disease in man. A further example is that of
L.guyanensis which infects the internal organs of the reservoir sloth with minimal
skin involvement but produces cutaneous disease in man.
The identification of reservoir hosts is also difficult. It is based on the
accumulation of evidence to show that the mammal is sufficiently abundant and
long-lived to provide a significant source of food for sandflies, that a considerable
proportion of these mammals are infected, that the infection runs a long course,
that parasites are present in the skin or blood in sufficient numbers to be taken up
by a sandfly, that there is intense host-fly contact and, finally, that the parasites in
the reservoir host are indistinguishable from those in man.17
The leishmaniases can be crudely separated into two groups according to their
reservoir hosts. The zoonotic leishmaniases are those in which the reservoir hosts
are wild animals (e.g. foxes or jackals), commensals (rodents) or domestic animals
(e.g. dogs). Examples of this group are L. m. mexicana and L. major. The anthro-
ponetic leishmaniases are those in which man is the reservoir, for example
L. tropica. However, such distinctions are not absolute. L. tropica infection may
derive from rodents or dogs and man may constitute a secondary reservoir for
L.majorl The principal reservoir hosts are shown in Table 1.
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Factors influencing infection frequency. The transmission of leishmaniasis to man is
dependent upon ecological factors and therefore varies considerably with time
and place. In order for infection to occur man must be exposed to" the bite of an
infected sandfly. In the New World where leishmania are essentially zoonotic and
maintained by forest rodents, the disease is predominantly an occupational one
occurring, for example, during construction projects, forestry and military train¬
ing. In each of these activities, non-immune workers enter the forest where they
may encounter infected sandflies. The chance of any individual becoming infected
is proportional to the length of time spent in the forest—for example during the
construction of the trans-amazonian highway the rate of positive leishmanin skin
tests amongst workers increased progressively with longer exposure times. In
addition, mini-epidemics may occur if workers enter a 'hot-spot' i.e. a well
delimited microfocus where transmission is high as a result of favourable environ¬
mental conditions associated with high densities of both reservoirs and sandflies.
In all affected parts of the world, agricultural development projects can lead
to large numbers of cases because non-immune workers arrive at the same time as
man-made changes to the environment upset the pre-existing zoonotic cycle.
Transmission is further increased if during the hot season workers sleep outside
on terraces without using nets.
Cutaneous leishmaniasis is predominantly a disease of the poor who have
primitive housing and sanitation. The organic debris associated with piles of
bricks and stones constitute potential breeding and resting sites for sandflies.
These people frequently live at the edge of towns close to the natural sylvatic
cycle. A high number of individuals sleeping in one room further attracts
peridomestic anthropophilic sandflies.17
Periodic fluctuations in the number of cases is well recorded. Although
sandflies are present throughout the year in the tropics, each species tends to have
an annual cycle and transmission is greatest towards the end of the cycle when
the maximum number of parous sandflies are present. There are also great year to
year variations, a peak every eight to ten years was noted in a prospective study
from Tres Bracos, Brazil.26
Cutaneous leishmaniasis is also a major problem for the military who, by the
nature of their task, bring in large numbers of non-immune individuals to
endemic areas. The British garrison in Belize has reported 306 cases between 1978
and 1990 and the Walter Reed army medical centre in Washington treated 70
cases from Panama between 1977 and 1984.27 In both cases the soldiers had been
undertaking jungle training. During the war between the Islamic Republic of
Iran and Iraq, thousands of cases occurred amongst soldiers of both sides.17
PREVENTION
Prevention of cutaneous leishmaniasis involves interrupting the cycle of infection
(Figure 2) in at least one place. It is helpful, therefore, to have a comprehensive
understanding of the .ecology of the cycle in that particular region. In the first
instance it is vital to know whether it is anthroponetic or zoonotic. Although
control of the sandfly population is important in both types initially, as the
intensity of transmission decreases it becomes essential to reduce the reservoir of
infection. In anthroponetic leishmaniasis this requires active detection of cases,
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followed by treatment, whereas in zoonotic infections, destruction of the animal
reservoir is appropriate. In addition to these measures, people can take individual
physical precautions against infection and immunisation is a possibility for some.
Vector control. There are two principal approaches to sandfly control—
environmental and chemical. Sandflies require dark, damp conditions, feed on
vegetable matter and are relatively poor fliers. The population can be greatly
reduced by improved sanitation, clearing refuse around buildings, repairing cracks
and crevices, clearing followed by levelling of the ground by rolling for 250
metres around dwellings, covering and repairing stream banks and drains to
eliminate breeding sites. Further measures such as installing fine mesh screens on
doors and windows, good ventilation and sleeping on the first floor of the
building can further reduce the chance of being bitten.
Insecticides are widely used and can give immediate and almost complete
protection indoors even though the sandflies return if spraying is not repeated
regularly. Insecticides with a residual action such as DDT, hexachlorocyclohexane
(HCH) and malathion are most useful. DDT and HCH remain effective for up to
one year, whereas malathion lasts only one to four months. Spraying should be
directed at doorways, windows, stone walls, animal houses and rubbish heaps. If
feasible, spraying for 250 metres around the dwelling is also helpful. Although
these insecticides do not affect the eggs, they kill the emerging sandflies.
During malarial control programmes, in which insecticides were widely used
as in India and the Mediterranean, leishmaniasis was almost eliminated as a
welcome additional benefit. Unfortunately once these programmes stopped, the
leishmania returned. Insecticide resistance has also been reported; for example,
P.papatasi is resistant to DDT in north-east India, and such resistance is likely to
become more widespread. WHO provides a simple test to determine the sensiti¬
vity of flies to insecticides.
In any control programme, it is important to try and quantify the results of
any measures taken. Simple techniques such as quantitative sticky-paper traps or
counting the number of sandflies in a pre-selected room after spraying with a
knock-down insecticide (e.g. pyrethroid) are sufficient.17
Alternative approaches to control which may become available in the future
include the use of biological methods, such as sandfly predators or parasites, and
genetic methods, such as the release into the natural vector population of sandflies
with altered genetic characters (e.g. sterile males).28
Reservoir host control. In the case of anthroponetic infections, active case detec¬
tion followed by treatment is imperative. Such a programme has been dramati¬
cally effective in Azerbaijan where cutaneous leishmaniasis had been endemic for
many years. It was eliminated in just 10 years by active identification followed by
treatment of all affected people (this involved identifying them in hospitals,
dispensaries and even by house to house checking), coupled with spraying of all
microfoci with a residual insecticide. There are three main problems with this
type of programme: (1) good results are obtained initially but as the incidence
falls, enthusiasm wanes and a resurgence can occur, (2) particular attention is
needed to seek out atypical cases (e.g. recidivans in whom the disease lasts a long
time and who may be resistant to the usual treatment) and (3) health
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education must be adequate so that the population understands and are keen to
cooperate.28
Control of the reservoir hosts for zoonotic disease is also difficult. In the Old
World, there have been successes in the USSR where the great gerbil
(Rhombomys opirnus) has been eliminated in some foci by destruction of its
distinctive burrow system by sub-soil ploughing followed by planting. Poisoning
has also been used but it is less specific and re-invasion occurs rapidly unless
prevented by a natural barrier such as a river. Dogs are more difficult to control;
shooting strays helps but it is often unacceptable and poisoning meat with
strychnine may inadvertently destroy other animals and birds. Perhaps hygienic
disposal by burning of remains from slaughter houses and chicken farms, together
with the destruction of stray dogs at rubbish dumps, is a reasonable
compromise.17
Personal protection. This is particularly relevant when non-immune people enter
an endemic region for a relatively short period of time. Simple, but often
neglected, measures include application of an insect repellant (e.g. diethyltolua-
mide which gives up to 8 hours protection) to exposed areas of skin, wearing
long trousers and long sleeved shirts, particularly at dusk, and using a bed-net.
Although sandflies are able to penetrate a mosquito net it can be rendered very
effective by impregnating it with permethrin every three weeks. There is a very
fine mesh sandfly net but it is very uncomfortable to use and is therefore usually
discarded.28
Immunisation. Old World cutaneous leishmaniasis is usually a self-limiting disease
which confers long-lasting immunity if allowed to run its natural course. This
fact has been known to the indiginous populations of endemic areas for centuries
and they have used this knowledge to avoid the disfiguring facial scars of natural
infections in two ways. Firstly, some cover their infants but exposed their
buttocks to the bites of sandflies so that the ensuing lesion occurred on that site;
others inoculated material directly from a cutaneous lesion to the arm or thigh of
the recipient. Clearly in these days of HIV infection, the latter practice has even
less to commend it! When laboratory culture of leishmania became established,
live L. major promastigotes surplanted direct inoculation from lesions and
provided protection against both L. major and L. tropica. All these procedures are
known as leishmanization; in each case lesions were allowed to develop and run
their natural course thereby conferring immunity coupled with a scar on a
cosmetically acceptable site.29 However, in 2 per cent of cases large or persistent
lesions develop which require treatment and there is a small risk of developing
leishmaniasis recidivans; leishmanization cannot, therefore, be recommended.
Although it had been widely practised in the USSR, Israel and Jordan, it has
now largely been abandoned.15
No vaccine against any form of leishmaniasis has, so far, been shown to be
consistently effective. However, Mayrink's group in Brazil have done pioneering
work with a killed promastigote vaccine derived from four strains of leishmania
isolated from cutaneous lesions. This is now being produced commercially and
preliminary results are encouraging.30 A different approach is being taken by
Convit's group in Venezuela who have a particular interest in immunotherapy
with BCG vaccination. They are also attempting to produce a killed promasti-
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gote vaccine but with BCG as an adjuvant.31 The identification of maxadilin in
sandfly saliva and its crucial role in establishing the infection is yet another
avenue which could be explored. If it could be inactivated, then few infections
would ever become established.
CONCLUSION
The leishmaniases are protozoal infections the importance and complexity of
which are only just becoming appreciated. In order to take appropriate steps in
control, a comprehensive understanding of their ecological niche is required.
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Abstract
Sodium stibogluconate is the mainstay of treatment for all forms of leishmaniasis. Therapy is associated with
an increase in serum aminotransferases. In this study liver damage was assessed during treatment of Ameri¬
can cutaneous leishmaniasis with sodium stibogluconate and also in a control group given aminosidine. In
addition to standard liver function tests, acute hepatocellular damage was assessed by measuring plasma glu¬
tathione S-transferase Bi (GST), and hepatic metabolic capacity was assessed by a caffeine clearance (CCL)
test, before, during and after treatment. Thirteen patients were treated; 5 received sodium stibogluconate, 6
received aminosidine and a further 2 patients received aminosidine followed by sodium stibogluconate.
Treatment with sodium stibogluconate was associated with an increase in both alanine aminotransferase
(ALT) and GST and a fall in the CCL, indicating both hepatocellular damage and functional impairment.
Six weeks after treatment had stopped ALT and GST had returned to pre-treatment levels and the CCL re¬
mained depressed in only one patient. Patients given aminosidine did not show any evidence of liver dam¬
age. Sodium stibogluconate is associated with significant hepatocellular damage and hepatic functional
impairment. However, this is rapidly reversible on drug withdrawal. We suggest that liver function is moni¬
tored throughout treatment and that patients with pre-existing liver disease receive alternative treatment.
Introduction
Sodium stibogluconate, a pentavalent antimonial, re¬
mains the mainstay of treatment for both visceral and cu¬
taneous leishmaniasis (WHO, 1990). In recent years
higher doses have been administered and courses have
lasted longer in order to achieve greater efficacy (Bal-
lou et al., 1987; WHO, 1990; Hepburn et al., 1993).
Transient abnormalities of serum aminotransferases have
been recorded during treatment for cutaneous leishma¬
niasis (CL) and these appear to be dose-related (hep¬
burn et al., 1993); however, it is not known whether sig¬
nificant and/or permanent liver damage results from
sodium stibogluconate therapy.
Increased serum aminotransferase levels reflect hepa¬
tocellular damage but there is little correlation between
their absolute level and the degree of damage (hayes &
Bouchier, 1989). Glutathione S-transferase Bi (EC
2.5.1.18; GST) is distributed throughout the liver lobule
whereas aminotransferases are confined to the periportal
cells. Plasma GST levels increase when any zone of the
liver is damaged whilst ALT and aspartate aminotrans¬
ferase (AST) are often normal after centrilobular dam¬
age. GST is a more sensitive marker of acute liver dam¬
age in disease and following paracetamol overdose
(Beckett et al., 1985; Beckett & Hayes, 1993). Al¬
though hepatocellular injury indicates liver damage, it is
more important to determine whether or not hepatic me¬
tabolic capacity is impaired. The liver's large metabolic
capacity, particularly in fit young men, means that stand¬
ard indicators of hepatic synthetic capacity, such as the
prothrombin time or serum albumen, do not become ab¬
normal until damage is extensive (Presig, 1986). The
clearance rate of caffeine from the blood following oral
administration directly reflects the amount of function¬
ing liver tissue. Caffeine is almost exclusively metabo¬
lized in the liver and there is no overlap in clearance rates
between healthy subjects and patients with cirrhosis
(Renner et al., 1984; Presig, 1986; Hayes & Bou¬
chier, 1989; Kalow & Tang, 1993). We report the re¬
sults in a prospective controlled study in which hepato¬
cellular damage and liver function were assessed in
patients treated with sodium stibogluconate for Ameri¬
can CL.
Methods
An open prospective randomized study comparing the
efficacy and toxicity of sodium stibogluconate with ami-
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nosidine for treatment of CL is in progress at the army
hospital in Edinburgh, UK. All the patients are British
soldiers who have contracted CL in Belize. This study
had ethical approval from the Army Medical Services Re¬
search Executive and each soldier gave written informed
consent. In each case a full medical history was obtained
and a physical examination performed and the diagnosis
was confirmed by demonstration of the parasite by histo¬
logy and/or culture. Patients received 20 d treatment
with either sodium stibogluconate (Pentostam , Well¬
come, UK), 20 mg/kg/d, or aminosidine (Gabbro-
micina1', Farmitalia Carlo Erba, Italy), 14 mg/kg/d, maxi¬
mum 1 g/d. Both drugs were given by intravenous
infusion; sodium stibogluconate was given undiluted at 1
mL/min whereas aminosidine was diluted in 400 mL of
normal saline and given over 4 h. Laboratory monitoring
consisting of a full blood count, urea and electrolytes le¬
vels, liver function tests (LFTs), prothrombin time, car¬
diac enzymes and electrocardiography was performed be¬
fore treatment, weekly during treatment, and at intervals
for 6 weeks after treatment. Ulcers were considered to
have healed when they had re-epithelialized and the scar
was flat and non-indurated.
In 13 consecutive patients, in addition to the routine
LFTs which were measured using an automatic analyser
(BM/Hitachi 747®, Boehringer Mannheim, Mannheim,
Germany), plasma GST was measured by radioimmu¬
noassay (hayes et al., 1983) and a caffeine clearance
Table. Clinical features and response to treatment of patients
with American cutaneous leishmaniasis treated with either




No. of patients 7 8
Mean age (years) 23-6 (SD 3-3) 25-0 (SD 2-7)
Mean weight (kg) 72-0 (SD 5-9) 72-2 (SD 6-5)
Lesion
Mean no. 1-3 (SD 0-8) 1-3 (SD 0'7)
Mean duration (weeks) 16-6 (SD 8-5) 10-6 (SD 4-6)





No. with amastigotes 7 8
No. with positive culture 3 8


































Figure. Changes during and after treatment with sodium stibogluconate (a, c, e) or aminosidine (b, d, f) of plasma alanine aminotransferase (ALT; a, b) and
plasma glutathione S-transferase Bi (GST; c, d) levels, and caffeine clearance (e, f), in patients with American cutaneous leishmaniasis.
(CCL) test was performed before treatment, at the end of
treatment, and 6 weeks after treatment had stopped. The
CCL was performed as described by Setchell et al.
(1987). The patients were fasted overnight and allowed
only water to drink. A single dose of 225 mg of caffeine
was administered in a cup of decaffeinated coffee which
was consumed over 5 min. Blood samples were taken at
0, 60, 90, 120 and 180 min and the caffeine level was
measured by high-performance liquid chromatography
using an Altex 320" (Anachem, Luton, UK). Five of
these patients had been treated with sodium stibogluco¬
nate, 6 with aminosidine, and 2 patients had been treated
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first with aminosidine and then, because of their poor re¬
sponse, with sodium stibogluconate after a break of 6
weeks. The clinical features of these patients at the start
of treatment, and their response to treatment, are shown
in the Table. Changes in ALT, GST and CCL before and
at the end of treatment and also before and 6 weeks after
treatment were analysed by a Wilcoxon matched-pairs
test.
Results
The activity of ALT, the concentration of GST, and
the CCLs for each treatment group are shown in the Fig¬
ure. Sodium stibogluconate therapy was associated with
a significant rise in ALT (P<0-05) and GST (P<0-05)
and a non-significant fall in CCL in every patient. Log
ALT correlated with log GST (r=0-87, n=40). The pro¬
thrombin time and serum albumin level did not change.
Six weeks after treatment stopped, ALT and GST levels
had returned to near pre-treatment values in every pa¬
tient, as had the CCL in all patients except one; although
this patient had the greatest fall in CCL, it then in¬
creased, and his GST had increased only from 1-7 pg/1 to
10-3 pg/1.
Aminosidine therapy was not associated with a rise in
ALT or a fall in CCL. In one patient a small rise in GST
was noted and in a further patient, who was reported to
consume large quantities of alcohol, the ALT and GST
were elevated before treatment, fell during treatment (al¬
cohol was forbidden during treatment, which was super-
vized in hospital), but rose again after discharge. Acute
alcohol ingestion in heavy drinkers leads to increased
GST levels and their basal GST levels are often raised
(Beckett & Hayes, 1993).
Discussion
Although increases in serum aminotransferases, indi¬
cative of hepatocellular damage, have been reported dur¬
ing sodium stibogluconate treatment (Ballou et al.,
1987; Hepburn et al., 1993), the clinical significance of
this is not known. It is not possible to separate the toxic
from the therapeutic effects on the liver in visceral leish¬
maniasis, but this should not be a problem in cutaneous
disease. Nevertheless, a further control group of patients
with CL who were treated with aminosidine, which is not
hepatotoxic, was incorporated into this study. GST is a
very sensitive and specific indicator of hepatocellular
damage, and its short half-life in plasma allows early rec¬
ognition of the cessation of active cellular damage (BEC¬
kett & Hayes, 1993). Treatment with sodium stiboglu¬
conate, but not with aminosidine, resulted in significant
increases in ALT and GST, confirming that sodium sti¬
bogluconate causes hepatocellular damage. The elevation
of both ALT and GST indicated that damage was occur¬
ring either in all zones of the liver or that it was confined
to the periportal hepatocytes. The fall in both ALT and
GST to pre-treatment levels 6 weeks after treatment
stopped indicated that the damage had also stopped.
The fall in CCL during treatment with sodium stibo¬
gluconate indicated that hepatic metabolic capacity was
impaired. Although the numbers in this study were in¬
sufficient to achieve statistical significance, CCL fell in
every case. However, this change appeared to be revers¬
ible once treatment had been stopped. Although the fall
in CCL could have been accounted for by selective in¬
hibition of cytochrome P-450 1A2, the principle enzyme
by which caffeine is metabolized (Kalow & Tang,
1993), the concomitant changes in ALT and GST indi¬
cated that hepatocellular injury was the probable mech¬
anism. These changes were not observed in patients
treated with aminosidine, therefore sodium stibogluco¬
nate therapy is clearly implicated as the cause.
Hepatotoxicity must therefore be added to the list of
complications associated with sodium stibogluconate
therapy. In most cases of CL this is of limited clinical sig¬
nificance, but for patients with pre-existing liver disease
or visceral leishmaniasis alternative therapy should be
considered, and in all cases the concurrent use of other
potentially hepatotoxic agents avoided. The ALT level
gives a practical indication of the severity of acute hepa¬
tocellular damage but will not detect any patient who
sustains permanent damage. A less toxic treatment is
needed. Systemic aminosidine has been shown to be as
efficacious as sodium stibogluconate in treating visceral
leishmaniasis in one study (chunge et al., 1990) and it
has been used successfully as an ointment in 'OldWorld'
CL (El-On et al., 1992). It appears to be free of hepa-
toxic effects, but its efficacy in 'New World' CL has yet
to be determined.
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Abstract
The effect of the microfilaricidal drug ivermectin on the antibody response to a detergent extract of adult
Onchocerca volvulus (OvAg) and a number of specific recombinant peptides was examined. Three of the pep¬
tides were combined in a serodiagnostic 'cocktail' and the effect of ivermectin on the diagnostic performance
of this assay was assessed. Immunoglobulin (Ig) Gi serum levels in response to OvAg significantly decreased
following ivermectin treatment. The antibody response to only one recombinant peptide (OvMBP29) was
significantly affected, with IgG levels decreasing following treatment. Levels of total IgE increased following
treatment. No correlation was observed between initial antibody level (or change in antibody level) and any
adverse reaction to treatment. The serodiagnostic 'cocktail' was 100% sensitive before and after the use of
ivermectin. A serodiagnostic assay using specific recombinant peptides can be used to evaluate infection in
the absence of dermal microfilariae in areas where ivermectin is used.
Introduction
The use of ivermectin has revolutionized the treatment
of onchocerciasis. Originally developed as an anti-para¬
sitic drug for use with livestock, the microfilaricidal ac¬
tivity of ivermectin against Onchocerca volvulus infection
in humans was first reported by Aziz et al. (1982a,
1982b). Following extensive human trials, the French
Government first approved the use of ivermectin in 1987
and it is now the drug of choice for onchocerciasis treat¬
ment world-wide.
Diagnosis of O. volvulus currently involves examin¬
ation of skin snips for microfilariae (mf), a technique ren¬
dered ineffective in areas where microfilaricidal ivermec¬
tin is used; furthermore, skin snip diagnosis does not
detect prepatent infections and is insensitive in low level
patent infections (buck, 1974). As an alternative ap¬
proach, a serodiagnostic test was developed employing
recombinant peptides specifically recognized by sera
from persons infected with O. volvulus (see Bradley et
al., 1991, 1993a). Two of these peptides are being con¬
sidered by the World Health Organization (WHO) for
use in a diagnostic assay which could replace, or provide
an additional tool to, the use of skin snip diagnosis
within the Onchocerciasis Control Programme (OCP)
(Ramachandran, 1993). As the OCP has recently intro¬
duced ivermectin treatment as a complementary control
measure to vectoricidal spraying, it is important to assess
any change in the performance of the diagnostic assay
that may result from the use of the drug.
Adverse reactions to ivermectin treatment range from
pruritis to more serious conditions such as hypotension,
although severe reactions such as the latter are rare (De
Sole et al., 1989; Whitworth et al., 1992). As is true
for most of the pathology associated with O. volvulus in¬
fection, the adverse reactions to treatment with the pre¬
vious drug of choice, diethylcarbamazine, and probably
those to ivermectin treatment, are mediated by inappro¬
priate immune responses of the host (Ottesen, 1985). It
is therefore important to assess any influence ivermectin
may have on host immune responses. Steel et al. (1991)
reported changes in antibody responses to an extract of
adult O. volvulus following ivermectin treatment. A more
complete picture may be provided by the examination of
antibody responses to stage- and species-specific recom¬
binant peptides of O. volvulus.
The primary aim of the present study was to examine
the effect of ivermectin treatment on the diagnostic per¬
formance of a 'cocktail' of recombinant peptides, pre¬
viously shown to exhibit high levels of sensitivity and
specificity (Bradley et al., 1993a). The study design
Address for correspondence: Dr Janette E. Bradley, Depart¬
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also enabled the investigation of any association between
changes in antibody levels and the development of ad¬
verse reaction to treatment.
Materials and Methods
Study population
Eighty randomly selected males from the O. volvulus-
endemic region of southern Chiapas in Mexico partici¬
pated in a single 'blind' placebo-controlled trial of iver¬
mectin. All patients were aged between 12 and 60 years
and had the presence of dermal mf confirmed by skin
snip examination. Doses of ivermectin (150-220ug) or
placebo were given 3 times at intervals of 6 months. Pa¬
tients were clinically examined each time and serum
samples were collected before, and 6 months after, the
initial treatment and 6 months after the second treat¬
ment.
Control sera
Non-endemic control sera were obtained from 48 indi¬
viduals living in an area of Venezuela known to be free
from O. volvulus and Wuchereria bancrofti transmission.
Antigens
O. volvulus detergent extract. Aduit female O. volvulus
were dissected from nodules obtained from patients resi¬
dent in the study area. A detergent extract (OvAg) was
prepared as described previously (Trenholme et al.,
1994).
Recombinant proteins. Three recombinant antigens,
OvMBP/10, OvMBP/11 and OvMBP/29, had been pre¬
viously selected for their specificity and sensitivity as di¬
agnostic probes (Bradley et al., 1991, 1993a). They
were over-expressed and purified as described by Brad-
ley et al., (1993a), and are referred to as the diagnostic
'cocktail' when used in combination.
A fourth recombinant peptide, Ovl03, not included in
the diagnostic assay, was over-expressed and purified in
the pGEX-lN plasmid vector, producing a fusion poly¬
peptide with the carboxy terminus of the Schistosoma
japonicum glutathione S-transferase protein (GST)
(Smith etal., 1987; Lustigman etal, 1992b).
OvMBP/10 (corresponding to Ov7; lustigman et al.,
1991) is found in the L3, l4 adult stages of the worm
and Ovl03 is found in the adult female and mf stages
(Lustigman et al., 1992b). Localization studies for
OvMBP/11 and OvMBP/29 are incomplete, although
both are known to be present in adult female worms
(Bradley etal., 1991).
Atatistical evaluation
The frequency distributions of isotype responses to
some recombinant antigens did not permit the use of par-
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Summary
The pentavalent antimonial sodium stibogluconate
is the mainstay of anti-leishmanial therapy. Sodium
stibogluconate is less cardiotoxic than antimony and
the trivalent derivatives, but has been associated
with dose-related electrocardiographic changes. The
effect of the currently-used regimen of sodium sti¬
bogluconate (20 mg/kg/day for 20 days) on cardiac
function is uncertain. We studied 12 soldiers, mean
age 24 years, with proven cutaneous leishmaniasis
treated with this regimen. There were no significant
changes in echocardiographic indices of left ventri¬
cular systolic or diastolic function during treatment.
Indices of myocardial electrical stability (heart-rate
variability and episodes of overt supraventricular
and ventricular arrhythmias) were unchanged, but
there was a reversible decrease in T-wave amplitude
during treatment. Systolic and diastolic blood pres¬
sure fell and the heart rate increased during
treatment.
This regimen of sodium stibogluconate does not
measurably impair left ventricular systolic or dia¬
stolic function. Minor T-wave changes occur during
treatment, but there is no increase in arrhythmia
frequency or change in heart-rate variability. In
most young fit patients, this regimen has no cardiac
side-effects. However, idiosyncratic reactions can¬
not be excluded, and patients with malnutrition,
impaired renal function or pre-existing heart disease
may be more sensitive to any cardiotoxic properties
of sodium stibogluconate.
Introduction
Leishmaniasis is a major world health problem
affecting some 12m people. The pentavalent anti-
monials, sodium stibogluconate and meglumine anti-
moniate, are the mainstay of treatment.1 Antimony
is cardiotoxic. In dogs it reduces myocardial contract¬
ile force2 and in man the trivalent antimonials have
been associated with hypotension, bradycardia, vent¬
ricular tachycardia, syncope, electrocardiographic
(ECG) changes (deformed P waves, QT prolongation
and T-wave flattening) and occasionally sudden
death.3"8 Sodium stibogluconate was developed as a
less cardiotoxic alternative8,9 but ECG abnormalities
(T-wave flattening and QTc prolongation) have been
reported10"13 and appear to be dose-related;12 similar
changes have been observed during meglumine
antimoniate therapy.14 It is not known if these occur
in association with dysrhythmias, other markers of
myocardial electrical instability, or changes in car¬
diac function. Since current regimes recommend the
administration of prolonged high-dose sodium stibo¬
gluconate to increase efficacy,1'15"17 it is important to
determine whether these are associated with signific¬
ant deleterious effects on cardiac function. The aim
of this study was to examine cardiac function in
detail during treatment of cutaneous leishmaniasis
(CL) with the current prolonged high-dose course of
sodium stibogluconate (20 mg/kg/day, without an
upper daily dose limit, for 20 days) using haemo-
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dynamic, biochemical, electrocardiographic and
echocardiographic techniques.
Methods
Patients and drug regimen
Twelve British soldiers, aged between 20 and 30
years, who had contracted CL during jungle training
in Belize, were studied. They formed a subgroup of
patients participating in an open, prospective trial
of sodium stibogluconate vs. aminosidine fully
described elsewhere.18 They all gave informed con¬
sent, and their characteristics are shown in Table 1.
None had a history of cardiac or renal disease,
diabetes mellitus or alcohol abuse. Those receiving
concurrent medication were excluded from the study.
All patients had a history of exposure to the parasite,
a typical skin lesion, and histological evidence of
infection (Leishman-Donovan bodies seen in all 12
patients, positive culture in 9 patients). Treatment
with sodium stibogluconate 20 mg/kg/day without
an upper daily dose limit (Pentostam, Wellcome,
batch no. A1058A, manufactured January 1991 and
stored at below 25 °C) was administered by intraven¬
ous infusion at 1 ml (10mg)/min for 20 consecutive
days.
Blood pressure and biochemical
measurements
These were made before treatment started (day 0),
weekly during treatment (days 7, 14), on the last day
of treatment (day 20), 2 weeks after treatment stopped
(day 34) and 6 weeks after treatment stopped (day
62). Blood pressure was measured at rest using a
mercury sphygmomanometer (diastolic phase V).
Creatine kinase and urea-stable lactate dehydro¬
genase were measured using commercial photo-
Table 1 Characteristics of the patients
Number of patients 12
Mean age (years) 23.7 (SD 3.1)
Mean weight (kg) 71.7 (SD 3.1)
Mean number of lesions 1.25 (SD 0.6)
Mean duration of lesions (weeks) 21.3 (SD 9.9)
Mean size* (mm) 16.7 (SD 5.0)
Site of lesions:
limbs 11
head & neck 3
trunk 1
LD bodies seen 12/12
Positive culture 9/12 (6 Lbb, 3 Lmm)
Lesion healed after treatment 11/12
* Longest axis.
metric assays (Monarch, Allied Instrumentation
Laboratory).
Electrophysiological measurements
Standard resting ECGs were obtained using a
Minigraph 12-lead recorder (Cardiac Recorders)
before treatment, weekly during treatment and at 2
and 6 weeks after treatment. The electrocardiograms
were inspected and the cardiac axis determined
using standard criteria.19 The electrocardiographs
were then projected on to a screen to produce a
magnification of x 5. Using the isoelectric PR and
post-T-wave segments as the baseline, the height of
the R wave in V1 and the sum of the T waves in
V4-V6 were measured directly using a ruler and
used as quantitative measurements of changes in
QRS and T-wave magnitude.
Twenty-four-hour ambulatory electrocardiograms
were obtained from each patient during sedentary
activity before treatment, on the last day of treatment
(day 20) and 6 weeks after treatment stopped (day
62) using a miniature tape recorder (Tracker,
Reynolds Medical). Times of going to bed and getting
up were noted by the patients. The tapes were
analysed using a Pathfinder arrhythmia analyser
(Reynolds Medical) at 120 times the original record¬
ing speed. Supraventricular and ventricular ectopic
beats were detected due to differences in their timing
and morphology, compared with continuously
updated characteristics of normal sinus beats.20 Each
analysis was monitored throughout by a specialist
technician to confirm the ectopic beats and scrutinize
P-wave morphology to exclude any episodes of non-
sinus rhythm. Where <24 h of recording was suit¬
able for analysis, the totals were normalized to the
equivalent of 24 h. Recordings shorter than 18 h, or
with <40% of the tape suitable for analysis were
rejected. The mean waking and sleeping heart rates
over the 24 h period were calculated, and the
number of ectopic beats per 24 h was counted.
Changes in autonomic activity occur in association
with changes in left ventricular function21 and may
be important in the pathogenesis of ventricular
tachyarrhythmias.22 During arrhythmia analysis, each
normal RR interval was measured, the mean RR
interval was calculated, and the 24-h standard devi¬
ation (SD) of RR intervals was measured as a general
index of sympathovagal activity.23,24 A specific meas¬
ure of parasympathetic activity was obtained by the
NNS0 time domain index, in which each time a
normal RR interval exceeded 50 ms, a count was
registered and the results were presented as a total
24-h RR count (NN50 count).25
Assessment of left ventricular function
This was done by echocardiography in all patients
before treatment, on the last day of treatment (day
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20) and 6 weeks after treatment (day 62). All
echocardiographic measurements were obtained by
the same operator (LF), using identical equipment on
each occasion, in a temperature-controlled laborat¬
ory at 22 °C. Following an overnight fast, the patients
rested in the standard left lateral position until their
heart rate stabilized. Heart rate was recorded from a
continuous ECG (lead 2) and respiration with a
respiratory probe. High-quality simultaneous record¬
ings of the echocardiogram, phonocardiogram, elec¬
trocardiogram and respiration tracing were obtained
using an Accuson 128/XP10 scanner (Allison).
Phonocardiograms were obtained with a high-
impedance piezo-electric microphone with a low-
frequency filter, positioned at the base of the heart.
Aortic valve closure was taken as the start of the
first high-frequency vibration of the aortic component
of the second heart sound, checked for validity with
the aortic echocardiogram and the aortic artefact on
the Doppler recording. Two-dimensional, M-mode
and Doppler echocardiograms were obtained with a
hand-held 3.5 MHz phased array transducer during
quiet respiration. Simultaneous recordings were
printed onto thermal paper at 100 mm/s. Clear con¬
tinuous echoes from the septum and posterior wall,
and easily visible recordings of aortic valve opening
and closure were obtained in all patients. Pulsed
Doppler recordings of the mitral inflow velocity
profile were obtained by positioning the sample
volume at the level of the mitral leaflet tips in
diastole in the apical four-chamber view. Care was
taken to obtain a smooth velocity curve with well-
defined peaks and minimal spectral broadening.
Recordings were analysed off-line using a sonic pen
and a digitizing tablet (Sunnagraphics 0.1 mm reso¬
lution grid) interfaced to a microcomputer (Sun 3/180
workstation) using the measurement techniques
described below. At least five cardiac cycles were
digitized for each patient on each occasion.
Left ventricular end systolic and end diastolic
cavity dimensions were measured using standard
criteria from the parasternal long axis view,26 and
the left ventricular ejection fraction was calculated
using the cube formula.27,28 Systolic time intervals
were measured from the simultaneous electrocardio¬
grams and aortic echocardiograms29 and the ratio of
the pre-ejection period to the corrected left ventricu¬
lar ejection time (PEP/LVET(C)) was calculated as an
additional heart-rate-independent index of left ventri¬
cular systolic function.30,31
Abnormalities of left ventricular diastolic function
often precede abnormalities of systolic function32,33
and may therefore be more sensitive to small drug-
induced changes in myocardial performance than
measures of global systolic function. Events during
early diastole were characterized by measurement
of isovolumic relaxation time (IVRT) and quantitative
analysis of the early (E) Doppler velocity profile.
Events during mid to late diastole were quantified
by measurement of the diastasis period (the time
interval from the termination of early inflow to the
onset of late inflow) and quantitative analysis of the
late (A) Doppler velocity profile. The E and A waves
were quantitatively analysed by measurement of their
peak velocities, acceleration and deceleration gradi¬
ents, acceleration and deceleration times, the area
under each peak, and the ratio of peak early to peak
late inflow velocities.34"36 Measurements were made
during inspiration, expiration and inspiratory apnoea.
Statistical analysis
We used the statistical package SpSS-PC. Analysis of
variance was used to test for changes of the variables
over time. A logarithmic transformation was used
before analysis of the NNS0 count, as the data was
not normally distributed. Linear regression analysis
was used to test the fall in the height of the T-waves
on the serial ECG recordings.
Results
The 20-day course of sodium stibogluconate
(20 mg/kg/day) healed the ulcers of 11/12 patients.
All reported muscle aches and loss of appetite during
treatment, but there were no other symptoms or
signs. In particular no patient developed any cardiac
symptoms.
Blood pressure and heart rate
There was a fall in the systolic and diastolic blood
pressure (p < 0.05) associated with an increase in
heart rate (p<0.05) at the end of the course of
treatment. Blood pressure and heart rate returned to
pre-treatment levels 6 weeks after treatment stopped
(Tables 2 and 4).
Cardiac enzymes
There was no change in either creatine kinase or
lactate dehydrogenase during treatment. A small, but
statistically significant (p<0.05) rise in lactate dehy¬
drogenase was noted at both 2 and 6 weeks after
the end of treatment when the soldiers had returned
to full physical duties. There was no change in
creatine kinase following treatment in 10 soldiers,
but in two it rose to 1497 and 416 IU/I, respectively,
6 weeks after treatment stopped (Table 2). The soldier
who had the highest level also had an elevated
waking and sleeping heart rate (95 and 90 beats/min)
at that time compared to his baseline (70 and 51)
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Table 2 Blood pressure and biochemical changes
Pre-treatment Treatment Recovery
Day 0
Day 7 Day 14 Day 20 Day 34 Day 62
Blood pressure (mmHg)
Systolic 126(3.61) 116(4.76) 118* (2.68) 113* (3.03) 121(2.94) 118(3.08)
Diastolic 84 (2.02) 78 (2.97) 81 (2.68) 73* (2.45) 84.7 (2.92) 76 (2.89)
Creatine kinase (IU/I) 99(26.8) 71(21.7) 56(17.4) 61(19.7) 105 (24.3) 233* (119.8)
Lactate dehydrogenase (IU/I) 189(10.5) 174(8.8) 182(10.0) 188(12.8) 248* (21.2) 208* (14.9)
* Significant change (p<0.05) from pre-treatment baseline.
Data are means (SEM).
and post-treatment (83 and 62) rates. His CK
remained high (545 IU/I) 14 months after treatment,
but at that time only 2% was CK-MB, indicating that
most was derived from skeletal muscle. There was
no change in serum potassium, urea or creatinine.
A rise in serum aminotransferases was noted during
treatment, this is well-recognized during treatment
with sodium stibogluconate.15,16,17
Electrocardiography
The cardiac electrical axis and R-wave magnitude
did not change during this study. There was, how¬
ever, a steady and significant (p<0.001) decrease
in the sum of the heights of the T waves in V4-6,
often progressing to T-wave inversion as treatment
progressed, followed by a return to pre-treatment
levels 6 weeks later (Table 3, Figure 1).
A complete series of analysable 24-h recordings
was available for only seven patients. There was no
significant increase in supraventricular or ventricular
arrhythmias with treatment. Similarly, neither the
24-h standard deviation of RR intervals nor the NN50
count changed significantly during the course of this
study (Table 3).
Left ventricular function
There were no significant changes in left ventricular
cavity dimensions or measures of left ventricular
systolic function (Table 4). Similarly, the indices of
early and late left ventricular diastolic function did
not change with treatment (Table 5).
Discussion
The pentavalent antimonials, sodium stibogluconate
and meglumine antimoniate, first manufactured 50
years ago, remain the mainstay of treatment for
Table 3 Electrocardiographic changes
Pre-treatment Treatment Recovery
Day 0
Day 7 Day 14 Day 20 Day 34 Day 62
ECG axis (°) 59.4 (7.15) 61.3 (5.64) 61.7 (5.69) 61.7 (5.75) 60.6 (6.71) 58.0 (6.16)
R-wave height (mm) 21.7 (1.6) 22.4 (1.3) 22.6 (0.58) 21.2 (1.3) 20.7 (2.0) 20.0 (1.1)
T-wave height (mm) 18.8 (2.0) 14.7* (2.5) 10.4* (1.9) 7.4* (2.0) 15.9 (0.7) 18.5 (2.9)
(V4 + V5 + V6)
Heart rate (min"1)
(waking) 69.3 (2.2) NA NA 77.7* (2.2) NA 72.7 (4.0)
(sleeping) 51.9 (1.63) NA NA 65.0* (3.7) NA 57.6 (5.5)
Total supraventricular 3.14 (1.85) NA NA 1.00 (0.68) NA 8.14 (6.36)
ectopic count per 24 h
Total ventricular 5.00 (4.33) NA NA 3.67 (3.08) NA 1.50 (0.72)
ectopic count per 24 h
Standard deviation 198 (11.2) NA NA 158 (15.0) NA 196 (21.1)
RR interval (ms)
NN50 counts per 4.18 (0.048) NA NA 4.01 (0.11) NA 4.06 (0.15)
24 h (log10)
* Significant change from pre-treatment baseline.
Data are means (SEM). NA, not applicable.
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Figure 1. Sum of T-wave heights in leads V4, V5 and V6 during treatment and recovery.
Table 4 Left ventricular systolic function
Pre-treatment Treatment Recovery
Day 0 Day 20 Day 62
LV end diastolic diameter (cm) 5.10 (0.09) 5.28 (0.13) 5.11 (0.07)
LV end systolic diameter (cm) 3.39 (0.11) 3.52 (0.11) 3.55 (0.07)
Ejection fraction (%) 61.5 (2.5) 60.2 (1.6) 57.6 (1.8)
Duration of systole (s) 0.37 (0.006) 0.37 (0.011) 0.39 (0.0056)
LV ejection time (LVET) (s) 0.31 (0.004) 0.32 (0.014) 0.31 (0.0055)
Pre-ejection period (PEP) (s) 0.07 (0.006) 0.08 (0.004) 0.07 (0.002)
Heart rate (rnin-1) 61.3 (3.07) 68.4 (2.89) 58.1 (2.34)
(PEP/LVET) (C) (s_1) 0.24 (0.02) 0.27 (0.02) 0.23 (0.01)
Data are means (SEM).
leishmaniasis. Their precise composition is not
known and, indeed, may vary depending upon the
source and batch.37 They contain moieties of very
different molecular weights (range 100-4000 Da),
and a variable quantity of trivalent antimony is
present.37,38 Although sodium stibogluconate is
rapidly excreted, largely unchanged, by the kidney,
5% is excreted as trivalent antimony, which has a
much longer half-life.39 The cardiotoxicity of trivalent
antimonials is well-established.38 Our studies,16,18
and those of others,15 indicate that a 20-day course
of 20 mg/kg/day, without an upper daily limit, will
heal the ulcers of 90% of patients with CL. Towards
the end of this course, all patients develop myalgia,
and there is usually a rise in serum aminotransfer¬
ases.16,18 A 20-day course has been found to repres¬
ent a reasonable balance between efficacy and
toxicity. In view of the likely accumulation of
cardiotoxic trivalent antimony during treatment, it
was important to determine whether this regimen
causes cardiac damage.
The study population were all young soldiers,
none were malnourished, and none had intercurrent
illnesses, renal or cardiac disease. They were different
from many patients who develop visceral leishmani¬
asis. Abnormalities detected during treatment could
therefore be attributed to sodium stibogluconate, but
these tests may not detect cardiotoxicity exacerbated
by ischaemic or hypertensive heart disease. This
study was too small to detect idiosyncratic reactions,
however, cardiotoxicity associated with trivalent anti¬
monials, and the electrocardiographic changes
observed in other studies, are related to the cumulat¬
ive dose of antimony administered rather than repres¬
enting idiosyncratic reactions.12
The results show that this regime has no measur¬
able effect on left ventricular systolic or diastolic
function. There was no biochemical evidence of
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drug-induced myocardial injury during therapy.
Although a small, but statistically significant, rise in
lactate dehydrogenase was noted when the soldiers
returned to physical duties after treatment, this was
not found when a larger sample of patients was
subsequently studied.18 A significant (p<0.05)
increase in creatine kinase 6 weeks after the comple¬
tion of therapy was also noted, but this was entirely
due to a large elevation in two patients, one of
whom had an elevated heart rate. Although his
creatine kinase remained elevated, most was derived
from skeletal muscle, which may be relevant to the
myalgia reported during treatment in all patients. It
was not possible to identify either of these patients
when the echocardiographic recordings were exam¬
ined in a blinded manner by an independent obser¬
ver. The elevation in lactate dehydrogenase remains
unexplained.
Treatment is associated with a significant, revers¬
ible, fall in blood pressure and an increase in heart
rate. The cause of these changes is not immediately
apparent from our study. Although postural hypoten¬
sion was not looked for, it is likely that they represent
a peripheral vasodilatory effect of the drug, since
cardiac function remained normal throughout the
study in all patients.
Serial electrocardiograms showed a progressive
reversible fall in T-wave amplitude in the lateral
chest leads during treatment, which frequently pro¬
gressed to T-wave inversion. Similar changes, related
to the cumulative dose of antimony administered,
have been demonstrated by others,12 but our study
confirms that these changes occur as treatment
progresses using the currently recommended regi¬
men. The electrocardiographic changes observed in
this and other studies,12 are similar to those induced
by the trivalent antimonials38 and therefore are
probably caused by the accumulation of trivalent
antimony during treatment, causing changes in vent¬
ricular repolarization. Changes in ventricular repolar¬
ization are associated with an increased risk of
ventricular tachyarrhythmias,40 which may be the
principle mechanism of sudden death during anti¬
mony therapy. Impaired autonomic function41 and
the presence of frequent arrhythmias also increase
the risk of sudden death,42 but neither of these risk
factors were present during treatment with sodium
stibogluconate in this study. The isolated changes in
ventricular repolarization demonstrated may not sig¬
nificantly increase the risk of sudden death, although
a larger study would be necessary to investigate this
relationship in detail.
In conclusion, the standard treatment regimen for
American cutaneous leishmaniasis (sodium stiboglu¬
conate 20 mg/kg/day for 20 days) is not associated
with measurable impairment of cardiac function
using echocardiographic parameters of systolic and
diastolic function in fit young men. The electrocar¬
diographic changes observed during treatment may
be caused by the accumulation of trivalent antimony,
but they were not associated with electrical instability
assessed by arrhythmia analysis and heart-rate variab¬
ility. However, patients with pre-existing heart dis¬
ease may be more susceptible to any cardiotoxic
effects of sodium stibogluconate and we cannot
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exclude more subtle abnormalities or idiosyncratic
reactions.
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